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The organocatalytic asymmetric reactions of Mortia-Baylis-Hillman (MBH) 
adducts have been received much attention. The asymmetric allylic substitution 
reactions of MBH carbonates were well studied in the presence of nucleophilic 
catalysts. In this thesis, two types of nucleophiles were used in the asymmetric 
substitution reaction of MBH carbonates. 
Chapter 1 presented a brief summary of organocatalytic asymmetric reactions of 
MBH carbonates. Two types of reactions of MBH adducts were summarized. One 
was the asymmetric allylic substitution reactions while the other was asymmetric [3+2] 
annulation reactions. Several examples were given in both types of reactions.  
In Chapter 2, a highly enantioselective substitution reaction of MBH carbonates 
with nitroalkanes using bifunctional tertiary aminethiourea catalysts was described. 
The different regioselectivity was achieved and the plausible mechanism was 
proposed. The simple manipulation of the product could provide the useful -
alkylidene--butyrolactam. 
In Chapter 3, a highly enantioselective allylic substitution reactions of isatin-
derived MBH carbonates with nitroalkane was described in the presence of Lewis 
base catalyst derived from cinchona alkaloid. The product could transform to 
interesting spiral oxindole structure by simple reducing reaction. The plausible 
mechanism was also discussed. 
In Chapter 4, a highly enantioselective allylic substitution reaction of MBH 
carbonate with an azlactone using phosphine-thiourea catalyst was described. The 
azlactone as a masked formyl anion was used in the allylic substitution reaction. The 
product might transform to useful -alkylidene--butyrolactone. 
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Chapter 1 Introduction 
1.1 Asymmetric Organocatalysis 
1.1.1 The Significance of Chiral Molecules 
Chirality, also called handedness which means an object is not superimposable to 
its mirror image, widely exists in nature. Molecular chirality refers to chiral molecules, 
which are important in synthetic chemistry. Enantiomers are a pair of mirror image 
molecules that are non-superimposable. At the molecular level, nature builds our 
world with only one enantiomer such as amino acid, sugar, nucleic acid and it is the 
basic way that we obtain chiral molecules. A pair of enantiomers shares identical 
chemical and physical properties under the conditions of non-chiral environment. 
Two enantiomers cannot be separated with normal separation method. When the two 
enantiomers exist the same quantity, they are called racemate. Two enantiomers only 
exhibit different properties in chiral environments e.g. human body. For example, D-
aspargine has a sweet taste, whereas natural L-aspargine is bitter. The importance of 
selectively obtaining one enantiomer may be well elaborated by thalidomide tragedy 
which occurred in Europe during the 1950s. Racemic thalidomide was a powerful 
sedative and anti-nausea drug which was typically used to cure morning sickness. 
Unfortunately, it was found that the drug caused birth defects. Further studied showed 
that only (S)-enantiomer was highly effective teratogen, while (R)-enantiomer was 
effective in curing morning sickness without teratogen (Figure 1.1).1 It is important to 
prepare molecules in an enantiomerically pure form, especially in the pharmaceutical 
industry. The significance of chirality in drugs design and development has been well 




of chiral compounds were issued by the Food and Drug Administration in the United 
States.2 Absolute stereochemistry for compounds with chiral centers was required in 
drug development process.  
 
Figure 1.1 Enantiomers of thalidomide 
1.1.2 Asymmetric Catalysis 
There are several methods to obtain a chiral molecule. The most important and 
effective approach is asymmetric catalysis which utilizes a catalytic amount of chiral 
molecules or complexes to generate stoichiometric chiral products. Asymmetric 
catalysis can be classified as enzyme catalysis, transition metal based catalysis and 
organocatalysis.3 Enzymes are Nature’s catalysts and can catalyze numerous 
biotransformations. Although excellent enantioselectivities are often attainable, 
enzymatic reactions are subjected to the availability of enzymes. The narrow scope of 
reactions and limitations of specific stereoisomers are also drawbacks of enzymatic 
catalysis. In addition, the reaction models of enzyme catalyzed transformation are 
often less reliable and predictable.4 
As a complementary method, metal-based catalysis has been widely used in 
organic synthesis in the past few decades. In 2001, the Nobel Prize was awarded to 
Sharpless, Noyori and Knowles for their contributions to the asymmetric catalysis 
mediated by metal complexes. The mechanistic insight of certain well-established 
catalytic systems has been well investigated.5 Metal catalyzed asymmetric reactions 
usually rely on the design of chiral ligands, which affect the stereoselectivity of the 
Chapter 1  
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reaction. Despite the fact that metal catalysis is the most advanced and useful method 
in asymmetric synthesis, approaches involving metals do suffer some key 
disadvantages, such as high cost and toxicity of the metals, sensitivity to air and 
moisture.  
In the past decade, organocatalysis has emerged as an important method in 
synthetic chemistry, complementing enzyme and metal catalysis. Organocatalysis 
employs small organic molecules to function as a catalyst in organic reaction. 
Organocatalysts are often inexpensive, readily available, non-toxic, stable in air and 
moisture, and easily manipulated. Organocatalytic method holds great potential for 
industrial application due to absence of toxic metal.6 Although reactions catalyzed by 
small organic molecules was first reported at the beginning of last century,7 this field 
has been overlooked for a long time. From 1968 to 1997, only a few papers reported 
the asymmetric reaction using organic molecular as catalyst. The Hajos-Parrish-Eder-
Sauer-Wiechert reaction is one of the most important reports during that period, 
which is an intramolecular aldol reaction catalyzed by proline.8 However, it was 
viewed as a unique chemical transformation and the general reaction mode was not 
recognized. In the late 1990s, several research groups did excellent work on 
asymmetric reaction catalyzed by small organic molecules.9 However, the concept of 
“organocatalysis” was established until 2000. Two publications appeared almost 
simultaneously in the literature, making the rebirth of modern organocatalysis; List, 
Barbas and Lerner disclosed enamine catalysis with proline as a catalyst,10 and 
MacMillan and co-workers described their first example on iminium catalysis.11 
Between 1998 and 2008, at least 1,500 manuscripts describing the use of 
organocatalysts in more than 130 discrete reaction types were published.12 




numerous scientists, and some well-known and versatile organocatalysts are 
































































Figure 1.2 Typical and effective chiral organocatalysts 
1.1.3 The Activation Modes of Asymmetric Organocatalysis 
A generic reaction mode provides a reactive species that can participate in many 
different reactions, which benefits the design of new reactions and leads to the 
development of versatile catalysts for a wide range of reactions. According to the 
bonding interactions between catalyst and substrate, organocatalysis can be classified 
as covalent bond catalysis and non-covalent bond catalysis.6 For the covalent bond 
catalysis, the catalytic process might involve covalent bond formation between 
catalyst and substrate, which include enamine catalysis, iminium catalysis, SOMO 
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catalysis and some nucleophilic catalysis such as carbene, DMAP and phosphine.13. 
For example, the enamine catalysis involves a covalent bond formation between the 
catalyst and the substrate to generate an active species. In the non-covalent bond 
catalysis, the weak interactions such as hydrogen-bonds and counter ion pair often 
play an important role in the organic reaction.14 Both reactivity and selectivity of the 
reaction could be influenced by these weak interactions. A few common activation 






































Figure 1.3 Generic activation modes for organocatalysis 
1.2 Organocatalytic Asymmetric Reactions of MBH Adducts  
The Morita-Baylis-Hillman (MBH) carbonates are well studied in asymmetric 
synthesis because they are easily activated by nucleophilic catalysts such as 
triphenylphosphine, DABCO.  
The origin of MoritaBaylisHillman (MBH) reaction can date back to 1968.15 
The MBH reaction is an atom-economic carbon-carbon bond forming reaction 
between the α-position of the activated alkenes (alkynes) and carbon electrophiles 




molecules, which are generally referred to as the MBH adducts. Due to the high 
functionality in the molecules, the MBH adducts have been widely used in many 
types of organic transformations.16 Early work in this field mainly focused on the 
transformations using stoichiometric reagents or non-chiral version reactions. Among 
MBH adducts, MBH acetates and carbonates have received much attention for their 
good reactivity. Recently organocatalytic asymmetric reactions of MBH acetates and 
carbonates have been well explored because of the development of asymmetric 
organocatalysis. The MBH adducts could be activated by a nucleophilic catalyst such 
as a tertiary amine or a phosphine, and function as an electrophile in the reaction.  
The general reaction mechanism17 of allylic substitution reaction of MBH adduct 
is commonly accepted as a tandem SN2’-SN2’ process. The nucleophilic catalyst first 
attacks the MBH adduct in a SN2’ manner, with the concurrent departure of OR group. 
A second SN2’ reaction would occur to afford the allylic substitution product and 
regenerate catalyst when nucleophile is added. In the presence of an extra base or the 
in situ generated base OR, when an electron withdrawing alkene is added, it would 
deprotonate the allylic proton of the intermediate to generate the [3+2] annulation 
product (Scheme 1.1). 















Mechanism for the allylic substitution
























Scheme 1.1 Typical reaction mechanism of two types of reactions of MBH adducts 
1.2.1 Organocatalytic Asymmetric Substitution Reactions of MBH 
Adducts 
The organocatalystic asymmetric allylic substitution reaction has emerged as a 
powerful method in organic synthesis.18 Different types of nucleophiles have been 
examined for metal catalyzed asymmetric allylic substitution reactions, and the 
substrates often have a leaving group at the allylic position or an in-situ generated a 
leaving group at the allylic position. The MoritaBaylisHillman (MBH) acetates and 
carbonates contain a good leaving group at the allylic position and can be applied in 
the allylic substitution reaction. Trost and co-workers have successfully used MBH 
acetate in the palladium-catalyzed asymmetric allylic substitution reactions.19  
For the development of organocatalytic asymmetric allylic substitution via a 




The nucleophilicity of catalyst should be stronger than the nucleophile in the first step, 
but cannot be stronger than the nucleophile in the second step. In 2004, Lu and co-
workers reported the asymmetric allylic substitution reaction of MBH carbonate 
catalyzed by cinchona alkaloids and their derivatives. A pronucleophile was used to 
avoid the competition between two nucleophiles. The tert-butyl carbonyloxy group 
which was chosen as a leaving group can produce a tert-butoxide ion for the in situ 
deprotonation of the nucleophiles. The different nucleophiles were examined in their 
study. Although the enantioselectivity was not ideal and the small amount of tri-
substituted alkene which was formed, the MBH carbonates have drawn much 
attention in the tertiary amine-catalyzed asymmetric allylic substitution reaction after 
this pioneer work (Scheme 1.2).20 
 
Scheme 1.2 Asymmetric allylic amination reaction of MBH carbonates catalyzed by 
-isocupreidine 
In the same year, the phosphine catalyzed allylic substitution reaction of MBH 
acetate has been reported by Krische and co-workers.21 The non-chiral version 
reaction of MBH acetates with phthalimide was explored under the catalysis of 
tertiary phosphine with good regioselectivities and yields. A tandem SN2’-SN2’ 
mechanism was proposed and supported by the deuterium labeling study. Furthermore, 
the proposed mechanism involved the destruction and subsequent reconstruction of a 
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chiral center, suggesting the possibility of realizing a chiral phosphine-catalyzed 
asymmetric substitution reaction of MBH acetates. Indeed, one asymmetric example 
catalyzed by chiral phosphine was given in the same study. To the best of our 
knowledge, this example represented the first example of phosphine catalyzed 
asymmetric allylic substitution reaction of MBH adduct (Scheme 1.3). 
 
Scheme 1.3 Asymmetric allylic amination reaction of MBH acetates catalyzed by 
chiral phosphine 
In 2007, Hou and co-workers also reported asymmetric allylic amination reaction 
of MBH acetate catalyzed by planar chiral monophosphine.22 The planar chiral [2,2] 
paracyclophane monophosphine was synthesized and applied in the asymmetric 
allylic substitution reaction of MBH adducts. The allylic amination reaction of MBH 
acetates with phthalimide gave the products in good yield and up to 71% ee (Scheme 
1.4). Other types of nucleophile were also tested under the optimized condition. The 
yield was low using 4-methylbenzenesulfonamide and para-methoxylphenol. The 
asymmetric allylic alkylation reaction using 2-trimethylsilyloxyl furan only provided 
the product with 36% ee under the same catalytic system. The mono activation of 
catalyst may lead to the low enantioselectivity. These initial screening results inspired 





Scheme 1.4 Asymmetric allylic amination reaction of MBH acetates catalyzed by 
chiral planar phosphine catalyst 
In the same year, Hiemstra’s group developed a new asymmetric allylic addition 
reaction of ethyl ,-cyanophenylacetate to MBH carbonates catalyzed by cinchona 
alkaloid derived tertiary amine catalyst. 23 The reaction gave products with adjacent 
quaternary and tertiary sterecenters. The asymmetric allylic alkylation reaction was 
catalyzed by β-isocupreidine with up to 4:1 distereoselectivity, but the 
enantioselectivity was only moderate to good (Scheme 1.5). The substrate scope was 
quite narrow, and the MBH carbonate with electron-withdrawing group gave poor 
enantioselectivity.  
 
Scheme 1.5 Asymmetric allylic alkylation reaction of MBH carbonates with 
cyanoesters 
The highly enantioselective allylic alkylation reaction of MBH acetates with 2-
trimethylsilyloxyl furan was reported by Shi and co-workers in 2008.24 This is the 
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first successful example of phosphine-catalyzed asymmetric allylic alkylation reaction 
of MBH adducts. The phosphine-amide catalysts were designed and applied in the 
asymmetric allylic alkylation reaction of MBH adducts. The MBH acetates derived 
from methyl vinyl ketone were used in the reaction and the allylic alkylation products 
were obtained with high diastereoselectivity and enantioselectivity (Scheme 1.6). The 
reaction was found to be useful for the production of -butenolides scaffolds which 
widely exist in natural product and pharmaceutical compounds.25 A mechanism was 
proposed to explain the good reacitivity and selectivity. The catalyst contains a 
phosphine which serves to activate electriphiles and an amide bond which functions 
as a hydrogen bond donor. The hydrogen bonding between catalyst and MBH acetate 
played a key role in the enantioselectivity. The addition of water will increase the 
enantioselectivity dramatically without impairing the reactivity. The water may assist 
the Grob-type fragmentation through hydrogen bonding and the formation of a 




















Scheme 1.6 Asymmetric allylic alkylation reaction of MBH acetates catalyzed by 
chiral phosphine catalyst  
Besides phosphine catalysts, tertiary amine catalysts derived from cinchona 




(Figure 1.4). Chen and co-workers have made key contributions to this field. In 2009, 
they reported the allylic aminantion reaction of MBH carbonates with 1,8-
naphthalimide catalyzed by cinchona alkaloid derived  tertiary amine catalysts.27 
After careful screening of the catalysts, (DHQD)2PYR was found to be the best 
catalyst. Under the optimized conditions, a wide range of substrates could be used and 
good yield and satisfactory enantioselectivity were attainable (Scheme 1.7).  
 
Scheme 1.7 Asymmetric allylic amination reaction of MBH carbonates with 1,8-
naphthalimide 
 
Figure 1.4 Tertiary amine catalyst derived from cinchona alkaloid 
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Further work on MBH carbonate was reported by Chen and co-workers. The 
different nucleophile was utilized in the asymmetric allylic substitution reaction of 
MBH carbonates. Indole motif exists widely in natural products. In contrast to the 
nucleophilic alkylation reaction at the C3 position of indole, the N-alkylation 
reactions of indole are very limited.28 Chen et al. developed chemoselective 
asymmetric N-allyic alkylation of indole with MBH carbonates in 2009.29 The NH 
group of indole was expected be depotonated by tert-butyloxide which was generated 
in-situ from MBH carbonates. The N-allylic alkylation products were formed with 
excellent regioselectivities and enantioselectivities in the presence of (DHQD)2PHAL 














Scheme 1.8 Asymmetric N-allylic alkylation of indole with MBH carbonates 
The carbon-oxygen bond formation of asymmetric allylic substitution reaction 
was first studied by Chen and co-workers.30 A specific peroxyl acid was used as 
nucleophile in the allylic substitution reaction of MBH adducts (Scheme 1.9). It was 
found that the best reaction condition is to employ (DHQD)2PHAL in CCl4. The 
reaction products could be easily transformed to MBH products under reductive 





Scheme 1.9 Peroxy-asymmetric allylic alkylation reaction catalyzed by 
(DHQD)2PHAL 
Chen and co-workers also reported the reaction of MBH carbonates with α,α-
dicyanoalkene catalyzed by tertiary amine derived from cinchona alkaloid. The α,α-
dicyanoalkene as activated ketone has been widely used in the organocatalytic 
symmetric reaction.31 If the tert-butyloxide ion generated from MBH carbonates 
deprotonated the α,α-dicyanoalkene, the successive allylic-allylic alkylation would 
occur. The allylic-allylic alkylation reaction of MBH carbonate and α,α-
dicyanoalkene was successfully catalyzed by (DHQD)2AQN with high 
enantioselectivity.32 The addition of catalytic amount of (S)-BINOL can increase the 
yield dramatically, which indicate that the (S)-BINOL functioned as brønsted acid 
was a suitable co-catalyst. Different substituted MBH carbonates and several α,α-
dicyanoalkene were successfully used in the catalytic system (Scheme 1.10).  
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Scheme 1.10 Asymmetric allylic-allylic alkylation of MBH carbonates 
Chen and co-workers later succeeded in utilizing 3-substituted oxindole as 
potential nucleophiles in the organocatalytic asymmetric allylic substitution reaction 
of MBH carbonates.33 Although the good nucleophilicity of 3-substituted oxindole 
has been widely explored,34 the asymmetric allylic reaction of oxindole was still 
limited to metal catalysis. The asymmetric reaction of MBH carbonates with 3-
substituted oxindoles proceeded smoothly in the presence of (DHQD)2AQN. The 
reaction afforded the allylic alkylation products in good yields, moderate 
diastereoselectivities and excellent enantioselectivities (Scheme 1.11). Different 
substituted oxindoles and MBH carbonates derived from aromatic aldehydes were 
found to be suitable substrates.  
 
Scheme 1.11 Asymmetric allylic alkylation of MBH carbonates with oxindoles 
In 2010, the Chen group explored the asymmetric allylic alkylation reaction of 
MBH carbonate with butenolide catalyzed by cinchona alkaloid derived tertiary 
amine.35 The possible difficulty of this reaction would be the steric hindrance which 
caused by the generation of the product with adjacent quaternary and tertiary 
stereocenters. After the deprotonation of -substituted butenolide by tert-butyloxide 
ion, the subsequent vinylogous addition reaction would occur to give the desired -
addition and -addition product. However, the results showed that only -selective 




chemoselectivity, diastereoselectivity and enantioselectivity were excellent (Scheme 
1.12).  
 
Scheme 1.12 Asymmetric allylic alkylation of MBH carbonates with butenolides 
In the same year, the same group applied α,α-dicyanoalkene in the asymmetric 
allylic substitution reaction of isatin-derived MBH carbonates.36 A lot of asymmetric 
reaction of 3-substituted oxindole has been studied.37 However, few examples used 
the electrophilic oxindole to construct chiral 3,3’-disubstituted oxindole molecule.38 
The MBH carbonate of isatin can provide an electrophilic approach to achieve chiral 
3,3’-disubstituted oxindole. The reaction of MBH carbonate of isatin with α,α-
dicyanoalkene proceeded smoothly in the presence of -isocupreidine and good yields 
and the enantioselectivities were attainable (Scheme 1.13). Different susbstituted 
MBH carbonates of isatin and α,α-dicyanoalkene were suitable substrates and the 
product could be transformed to a spirocyclic oxindole. 
Scheme 1.13 Asymmetric allylic alkylation of MBH carbonates of isatin 
The carbon-phosphorus bond forming reaction of MBH carbonates with 
phosphine oxide was disclosed by Wang and co-workers in the same year.39 The 
nucleophile of phosphorus which was successfully used in asymmetric reaction was 
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usually phosphite [(RO)2P(O)H]or secondary phosphine (R2PH).40 Few examples 
have been reported using secondary phosphine oxide [R2P(O)H] as nucleophile.41 The 
diphenylphosphine oxide was successfully used as nucleophile this study. Quinindine 
served as the best catalyst, and good yields and good enantioselectivities were 
obtained (Scheme 1.14).  The reactivity and enantioselectivity could be improved by 
the addition of 4Å molecular sieves. The less reactive dialkyl phosphine oxide also 
could be utilized in the reaction with MBH carbonate in the presence of additional 
base. These methods described by Wang’s group only tolerated the MBH carbonates 

















































Scheme 1.14 Asymmetric allylic substitution reaction of MBH carbonates with 
phosphine oxides 
In 2011, more nucleophiles have been utilized in the organocatalytic asymmetric 
allylic substitution reactions. Chen’s group developed a direct regioselective 
asymmetric vinylogous alkylation of MBH carbonates with allylic sulfones,42 a class 
of compounds of great biological importance.43 The reaction of MBH carbonates and 




excellent enantioselectivities. When other analogous cinchona alkaloid like 
(DHQD)2PYR was used as catalyst, the -substitution product was observed with 
moderate yields, diastereoselectivities and enantioselectivities (Scheme 1.15). The 
product could be easily transformed to simple allylic-substituted compounds by 
removal of the sulfonyl group. 
 
Scheme 1.15 Asymmetric vinylogous alkylation of allylic sulfones with MBH 
carbonates 
The Chen group also introduced indene as a nucleophile in the asymmetric 
allylic alkylation of MBH carbonates.44 Indene motif has been found widely in the 
biological active compounds.45 The reaction of indene with MBH carbonate catalyzed 
by (DHQD)2AQN was performed in fair to good yields, and moderate to good 
enantioselectivities (Scheme 1.16).  
 
Scheme 1.16 Asymmetric allylic alkylation of MBH carbonates with indene 
Shi and co-workers developed a phosphine-catalyzed asymmetric allylic 
substitution reaction of MBH adducts.46 In their study, the asymmetric allylic 
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alkylation reaction of MBH carbonates with oxazolones was catalyzed by phosphine-
thiourea catalysts. The reaction exhibited good to excellent yields, moderate to good 
diastereoselectivties and excellent enantioselectivities (Scheme 1.17). It was proposed 
that the thiourea plays a key role for inducing stereoselectivity by forming hydrogen 
bonding interactions with the substrates. The product could be transformed to allylic 




























Scheme 1.17 Asymmetric allylic alkylation of MBH carbonates with oxazolone 
Cheng and co-workers described the utilization of   3-substituted benzofuranones 
in the asymmetric allylic alkylation reaction of MBH carbonates.48 Such reactions are 
useful since a number of natural products and biologically active compounds contain 
3-substituted benzofuranone structural motif.49 Good yields, good 
diastereoselectivitiea and excellent enantioselectivities was obtained by using 





Scheme 1.18 Asymmetric allylic alkylation of MBH carbonates with 3-substituted 
benzofuran-2(3H)-ones 
Organoflourine compounds are important in medical chemistry.50 The fluorine 
containing nucleophiles have been applied in asymmetric allylic substitution of MBH 
carbonates. The group of Shibata and Jiang have indenpendently studied the reactions 
of MBH carbonates with fluorobis(phenylsulfonyl)methane (FBMS).51 Shibata and 
co-workers investigated the reaction of the MBH carbonate and FBMS,52 and 
(DHQD)2AQN was found to be the best catalyst. Although the enantioselectivity was 
excellent using simple organocatalyst, the yield was only moderate to good. Further 
study showed that a Lewis acid such as ferric chloride or titanium isopropyloxide as a 
cooperative catalyst could benefit both yield and enantioselectivity (Scheme 1.19). 
The allylic alkylation product could be easily transformed to pure 
monofluormethylate compounds by removing the sulfonyl group. Jiang et al. 
independently investigated the reaction of MBH carbonates with FBMS, and 
(DHQD)2AQN was the best catalyst. A variety of MBH carbonates derived from 
aromatic aldehydes were found to be suitable substrates and the synthetic value of the 
products was also demonstrated. 


































Scheme 1.19 Asymmetric allylic alkylation of MBH carbonates with FBMS 
Asymmetric allylic trifluoromethylation of MBH carbonates was developed 
independently by the Shibata group and the Jiang group.53 The Ruppert’s reagent, 
(trifluoromethyl)trimethylsilane, is commonly employed for the synthesis of 
organofluorine compounds.54 Shibata et al. found that the reaction of MBH acetates 
with (trifluoromethyl)trimethylsilane in the presence of DABCO yielded fluorine-
containing products. The combination of (DHQD)2PHAL and MBH carbonates led to 
an asymmetric trifluromethylation (Scheme 1.20). Jiang and co-workers also reported 





Scheme 1.20 Asymmetric allylic akylation of MBH carbonates with Ruppert’s 
reagent 
Cheng and co-workers applied benzophenone imine as masked ammonia in the 
asymmetric allylic amination reaction of MBH carbonates.55 The reaction of 
benzophenone imines with MBH carbonates proceeded smoothly in the presence of 
(DHQD)2AQN. The amination products were obtained in moderate yields and 
excellent enantioselectivities (Scheme 1.21).  
 
Scheme 1.21 Asymmetric allylic amination of MBH carbonates with masked 
ammonia 
Enamides are interesting sub-structures in a variety of natural products and 
pharmaceutical molecules,56 which can function as versatile and stable enamine and 
the carbon nucleophile.57 Chen and co-workers discovered a chemoselective N-allylic 
alkylation of MBH carbonates with enamides.58 (DHQD)2AQN catalyzed the reaction 
of MBH carbonates with enamides effectively, affording the products in good 
regioselectivities and good enantioselectivities (Scheme 1.22). The allylic amination 
products were converted to dicarbonyl compounds with high selectivity through aza-
Cope rearrangement followed by hydrolysis. The -alkylidene--amino carbonyl 
compounds were also obtained by the treatment of trifluoromethanesulfonic acid 
without impairing the enantioselectivity. 




Scheme 1.22 Asymmetric allylic substitution of MBH carbonates with enamides 
Wang et al. reported the asymmetric allylic amination reaction of MBH 
carbonates with an allylamine.59 The reaction was effectively catalyzed by quinidine 
and good enantioselectivity was obtained. To explored the utility of the allylic 
amination products, biologically useful 2,5-dihydropyrroles were synthesized 
(Scheme 1.23).60 
 
Scheme 1.23 Asymmetric allylic substitution of MBH carbonates with allylamine 
Jiang and co-workers explored the asymmetric allylic substitution of MBH 
carbonates with water,61 which serves as an alternative of asymmetric MBH reaction. 
DHQD)2AQN was found to be the best catalyst, and good yields and excellent 
enantioselectivities were attainable (Scheme 1.24). The deuterium labeling 
experiment supported the mechanism of water as nucleophiles. 
  




The carbon-sulfur bond forming reaction of MBH carbonates has been explored 
by Cheng and co-workers.62 Thiols are well-known nucleophile and chiral sulfur-
containing compounds are well recognized in organic synthesis.63 Alkyl thiols were 
used in the asymmetric allylic substitution reaction of MBH carbonates. 
(DHQD)2PHAL turned out to be the most efficient catalyst. The allylic sulphur 
products were synthesized in good yields and high enantioselectivities (Scheme 1.25). 
Scheme 1.25 Asymmetric allylic substitution of MBH carbonates with alkyl thiols 
In 2012, Chen and co-workers reported the asymmetric allylic alkylation of 
isatin-derived MBH carbonates with -Angelica lactone.64 The readily available O-
methylether of -ICD (Me--ICD) was shown to be the best catalyst, and chiral 
BINOL and 4Å molecular sieves were used as co-catalyst. The products with two 
quaternary stereocenters were prepared in good yields, excellent diasteroselectivities 
and excellent enantioselectivities (Scheme 1.26). The potential useful spirocyclic 
structure was synthesized by simple cyclization reaction of the allylic alkylation 
products. 
Scheme 1.26 Asymmetric allylic alkylation of MBH carbonates with -Angelica 
lactone 
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Recently, our group developed the enantioselective regiodivergent allylic 
alkylations of MBH carbonates with phthalides.65 Phthalides with electron 
withdrawing substitutent at 3-position are good nucleophiles which has been proved 
in several vinylogous reaction.66 The asymmetric allylic alkylation reaction of MBH 
carbonates derived from acrylates with 3-carboxylate phthalides in the presence of the 
phosphine-thiourea catalysderived from amino acid afforded -selective products in 
high yields, high regioselectivities, high diastereoselectivities and enantioselectivities. 
A wide range of MBH carbonates were suitable in the reaction. The mechanism study 
indicated that the thiourea functional group plays a key role in both 
diastereoselectivity and enantioselectivity. Interestingly we found that the solvent 
could influence the regioselectivity. The -selective products became major with low 
enantioselectivity when the reaction performed in strong polar solvent. To develop the 
diversity of the MBH reaction, we also studied the -selective product of MBH 
carbonates with phthalide. The MBH carbonates derived from acrylonitriles afforded 
the -selective products in high yields, high Z/E ratios and enantioselectivities in the 
presence of tertiary amine catalyst (Scheme 1.27). The multi-funcational catalyst 
derived from cinchona alkaloid incorporated with amino acid and thiourea 
functionality was found to be the best catalyst. Two pathway of the reaction 
mechanism were proposed for the synthesis of -selective products. One was the 
Lewis base initiated addition-elimination sequence which the authors preferred; the 
other was a tandem SN2’-SN2 process. Using MBH acetate as substrate, the yield of -
selective products was decreased without damaging selectivity, which may support 
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Scheme 1.27 Asymmetric regiodivergent reaction of MBH carbonates and phthalides  
1.2.2 Organocatalytic Asymmetric [3+2] Annulation Reactions of 
MBH Adducts 
In addition to their uses in asymmetric allylic substitution reaction, MBH adducts 
were also examined in the [3+2] annulation reaction. Due to the acidity of the allylic 
proton of the ammonium or phosphonium intermediate, the MBH carbonate could 
generate allylic ylides to react with activated alkene to form [3+2] annulation 
product.17 
In 2003, the first organocatalytic [3+2] annulation of MBH adducts was reported 
by Lu and co-workers.67 The reaction of MBH adducts with electron-deficient alkenes, 
such as N-phenylmaleimide, was catalyzed by triphenylphosphine in the presence of a 
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stoichiometric amount of additional base (Scheme 1.28). Further study showed that 
the reaction could also take place without the addition of extra base if MBH 
carbonates were used. It is reasoned that the in situ generated tert-butyloxide anion 
functions as a suitable base to facilitate the formation of reactive phosphonium 
ylide.68 
 
Scheme 1.28 The first [3+2] annulation reaction of MBH adducts 
Inspired by the pioneer work, some intramolecular [3+2] annulation reactions 
were reported. In 2007, Tang and co-workers developed the phosphine-catalyzed 
intramolecular [3+2] annulation reaction of modified MBH adducts.69 In 2010, Tang 
and Zhou described a cooperative catalytic system for the intramolecular [3+2] 
annulation reaction.70 The cyclization products were obtained in high yields, high 
regioselectivities and high enantioselectivities using the catalytic system of chiral 
phosphine cooperated with Ti(iPrO)4. However, the organocatalytic asymmetric [3+2] 
annulation reaction of MBH carbonates was not reported until 2011. Barbas and co-
workers developed a phosphine-catalyzed asymmetric [3+2] annulation reaction of 
MBH carbonates and methyleneindolinone.71 Several chiral phosphine ligands were 
examined and (+)-Ph-BPE containing a trialkylphosphine moiety was found to be the 
best catalyst. The aromatic π-π stacking interaction between catalyst and substrate 
might have some influence on the enantioselectivity. Spirocyclopenteneoxindole were 
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Scheme 1.29 Phosphine-catalyzed asymmetric [3+2] annulation reaction of MBH 
carbonates with methyleneindolinones 
Almost at the same time, our group reported a phosphine-catalyzed asymmetric 
[3+2] annulation of MBH carbonates with -dicyanokene derived from isatin.72 We 
recently developed powerful chiral phosphine catalyst derived from amino acid and 
applied them in a number of asymmetric reaction.73 The catalytic effects of various 
bifunctional phosphines on the annulation reaction of MBH carbonates with -
dicyanokene of isatin were examined and phosphine-thiourea catalysts derived from 
threonine were found to be most efficient. The annulation products could be obtained 
in good yields, with good regioselectivities and excellent enantioselectivities (Scheme 
1.30). Interestingly the three component reaction of N-protected isatin, malononitrile 
and MBH carbonate also worked equally well. The hydrogen bonding interactions 
between the thiourea group and the substrate were demonstrated to be important for 
the observed stereoselectivity for the reaction. 




Scheme 1.30 Phosphine-catalyzed asymmetric [3+2] annulation reaction of MBH 
carbonates with -dicyanokenes derived from isatin 
In 2012, Shi and co-workers also developed the asymmetric [3+2] annulation 
reaction of MBH carbonates catalyzed by amino acid derived chiral phosphines.74 The 
electron deficient alkenes containing a trifluoromethyl group was reacted with MBH 
carbonates to afford the trifluromethyl substituted cyclopentenes. (Scheme 1.31). 
 
Scheme 1.31 Asymmetric [3+2] annulation reaction of MBH carbonates with 
trifluoromethyl substituted alkene 
The MBH carbonates derived from ketones was also successfully applied to the 
[3+2] annulation reaction with electron deficient alkenes. In 2012, Liu and co-workers 
reported [3+2] annulation reaction of MBH carbonates of isatins and maleimides 




nature product and pharmaceutical compounds.76 This method led to the formation of 
spirocyclopentaneoindole structures with high regioselectivities, good 
diastereoselectivities and high enantioselectivities (Scheme 1.32).  
 
Scheme 1.32 Asymmetric [3+2] annulation reaction of isatin-derived MBH 
carbonates with N-phenylmaleimide 
The asymmetric [3+2] annulation reaction could also be catalyzed by chiral 
tertiary amine catalyst. In 2011, Chen and co-workers reported the only example of 
tertiary amine catalyzed [3+2] annulation reaction of MBH carbonates.77 The O-
MOM -ICD was found to be the best catalyst, and a variety of MBH carbonates were 
showm to be suitable substrates for this [3+2] reaction. The 
spirocyclopentaneoxindole products were prepared in moderate to good yields, high 
regioselectivities and enantioselectivities (Scheme 1.33).  
 
Scheme 1.33 Tertiary amine-catalyzed asymmetric [3+2] annulation reaction of 
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isatin-derived MBH carbonates with propargyl sulfone 
1.3 Project objectives 
The organocatalytic asymmetric reactions of MBH adducts have been widely 
studied since the MBH adducts are readily available and possess intrinsic good 
reactivity. The main aim of this study is to develop novel organocatalytic asymmetric 
substitution reactions employing MBH carbonates. We intend to use MBH carbonates 
in the organocatalytic asymmetric substitution reactions because upon the reaction 
with suitable nucleophilic catalysts, the in situ generated tert-butoxide ion may 
function as a Brønsted base to activate nucleophile. This is the so-called Lewis base 
assisted Brøsted base catalysis. As discussed above, a wide range of nucleophiles such 
as cyanoester, buenolide, indole, oxindole and phosphine oxide have been used in 
nucleophilic allylic substitution reaction of MBH carbonates in the presence of the 
tertiary amine catalysts. The mechanism of these reactions are believed to be a tandem 
SN2’- SN2’process (Scheme 1.1). Very few examples have been reported on the other 
regioisomers which may undergo a simple SN2’ or SN2’-SN2 mechanism.78 It was our 
goal to utilize novel nucleophiles in the asymmetric allylic alkylation reactions of 
MBH carbonates in a regioselective manner.  






Scheme 1.34 Research plan on novel asymmetric allylic substation reactions 
Nitroalkanes are versatile nucleophiles in organic synthesis and extensively 
explored in asymmetric nucleophilic addition reactions. However, the asymmetric 
allylic substitution reaction of MBH carbonates with nitroalkanes remained to be 
unexplored.80 In this thesis, nitroalkanes will first be examined as nucleophiles for 
their reaction with simple MBH carbonates and isatin-derived MBH carbonates. 
To obtain chiral -butyrolactones, the umpolung formyl aldehydes are needed in 
the reaction with MBH carbonates. 4-Isopropyl-2-oxazolin-5-one has been recognized 
as masked umpolung synthon for formyl anion.81 The asymmetric reaction of MBH 
carbonates and oxazolinones will be explored in this thesis.  
Chapter 2  
33 
 
Chapter 2 Enantioselective Substitution Reaction of 
MoritaBaylisHillman Carbonates with Nitroalkanes 
2.1 Introduction 
Nitroakanes are valuable nucleophiles which have been utilized in many organic 
transformations.82 The allylic alkylation of MBH adducts and nitroalkanes promoted 
by simple base has been reported by the groups of Kim and Batra.83 Different 
regioselectivity could be achieved by using different bases stoichiometrically.84, 83b 
DABCO could promote the allylic substitution reaction, which are supposed to be a 
tandem SN2’-SN2’ process, while the simple SN2’ product could be obtained using 
other bases (Scheme 2.1). When MBH adducts are employed in the reaction, DABCO 
functions as a nucleophilic catalyst to activate MBH adducts, while other bases such 
as K2CO3 or NaOH, activate nitroalkane and the nucleophilic nitroalkanes attack the 
MBH adducts to form -selective products. 
 
Scheme 2.1 Different regioselectivity of the reaction of MBH adducts with 
nitroalkanes 
The catalytic asymmetric version of the reaction of MBH carbonates and 
nitroakanes has not been reported. Both the -selective and -selective products are 
attractive molecules. From the proposed mechanism, the -selective product may be 
obtained by employing a tertiary amine catalyst or tertiary phosphine catalyst. 




reaction would depend on the proper selection of the catalytic systems.  The -






















































Figure 2.1 Typical catalysts in the reaction of MBH carbonates 
Common nucleophilic catalysts used in the reaction of MBH carbonates are 
Lewis bases, such as tertiary amine catalysts or phosphine catalysts, some organic 
catalysts of this nature are illustrated in Figure 2.1. The mechanism of the 
asymmetric allylic alkylation reaction was generally accepted as a tandem SN2’-SN2’ 
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process. The nucleophilic catalyst (a tertiary amine or phosphine) first adds to the 
MBH adduct in an SN2’ fashion, with the concurrent departure of the tert-butoxide 
group, which could be utilized to activate the nucleophile. A second SN2’ reaction 
then affords the -selective product, regenerating the catalyst at the same time. In the 
contrast, there was no examples of catalytic asymmetric reaction of MBH adduct to 
form the -selective product. Based on the stoichiometric base promoted reaction, the 
Lewis base catalyst should activate nitroalkane in the presence of MBH adduct, which 
seems difficult in screening organocatayst with suitable reactivity. Or a dual catalyst 
which could activate both substrates may catalyze the reaction of MBH carbonate and 
nitroalkane. Hydrogen bonding between thiourea functionality and nitro group has 
been well recognized in organocatalytic reaction.14a Tertiaryl amine-thiourea catalyst 
was successfully used in many transformations of compounds containing nitro group. 
The substitution reaction of MBH carbonate and nitroalkane would proceed under the 
tertiary amine catalyst derived from cinchona alkaloid. The novel SN2’-SN2 
mechanism was proposed to afford -selective product in the reaction of MBH 
carbonate and nitroalkane under tertiary amine-thiourea catalyst (Scheme 2.2).  
 
Scheme 2.2 A SN2’-SN2 reaction to obtain -selective product 
Herein, we describe a new type of substitution reaction of MBH carbonates with 




achieved with high enantioselectivity. A SN2’-SN2 mechanism was proposed in the 
asymmetric regioselective reaction.  
2.2 Results and Discussion 
2.2.1 Preliminary Screening 
We firstly examined the reaction of MBH carbonate 2-3 with nitromethane. 
Tertiary amine catalyst derived from cinchona alkaloid was firstly tested. The -
selective product 2-5‘ was obtained with good selectivity using -ICD as catalyst. The 
yield and regioselectivity was good, but the diastereoselectivity was only 3.5:1 and 
the ee of the major isomer was 23%. Other cooperative catalytic systems were also 
tested in the reaction. DABCO was the effective catalyst in the substitution reaction of 
MBH adduct to give -selective product. Tertiary amine-thiourea catalyst derived 
from cinchona alkaloid was effective in many reaction of nitro compound. The 
DABCO and thiourea catalyst derived from quinidine was used in the reaction of 
MBH carbonate and nitroalkane to activate both substrates with good selectivity. 
However, the mixture of compounds 2-5 and 2-5‘ was often observed. The two 
catalyst seems not working cooperatively. This results may also indicate that the 
tertiary amine-thiourea catalyst could provide -selective product 2-5 with high 
regioselectivity and enantioselectivity (Scheme 2.3). The MBH acetate was applied 
under the same catalytic system and the conversion of the reaction was low. It shows 
that the strong Brøsted basicity of tert-butoxide ion plays a key role in this 
transformation. 




Scheme 2.3 Preliminary results of the reaction of MBH carbonate with nitroalkane 
Based on the good regioselectivity and enantioselectivity, the bifunctional 
catalyst with tertiary amine and hydrogen bonding donor moiety may be effective to 
achieve the -selective product in the reaction of MBH carbonate and nitroalkane. A 
series of bifunctional catalyst was prepared according to literature procedure. The 
tertiary-sulfonamide with strong hydrogen bonding catalyst cannot catalyze this 
reaction. Other bifunctional catalysts with different scaffold were also not effective in 
this transformation. Only tertiary amine-thiourea catalyst can promote this reaction 
with good regioselectivity and enantioselectivty. The catalyst 2-C1 dervided from 
quinidine provided the -selective product with moderate yield, good regioselectivity 
and enantioselectivity (Table 2.1).  
Table 2.1 Preliminary screening of bifunctional catalyst in the reaction of MBH 






Entry Catalyst Yield (%)b ee (%)c 
1 2-C1 58 91 
2 2-C2 71 79 
3 2-C3 75 82 
4 2-C4 - - 
a The reaction was performed with 2-3 (0.025 mmol),  nitroethane (0.25 mmol) and the 
catalyst (0.005 mmol) in anhydrous THF (0.2 mL) at room temperature for 24 h. b Isolated 
yield. c Determined by HPLC analysis on a chiral stationary phase. 
The different substituent of ester in the MBH carbonates would infulence the 
enantioselectivity. The readily availabe MBH carbonate was synthesized using 
different acrylate ester and examined in the reaction of MBH carbonate and 
nitroethane. The reaction of MBH carbonate with tert-butyl ester and nitroethane 
could not proceed under the best catalyst after two days. The best results were 
obtained using MBH carbonate 2-1a with ethyl ester (Scheme 2.4). 
  
Scheme 2.4 Asymmetric reaction of MBH carbonate 2-1a with nitroethane 
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2.2.2 Reaction Optimization 
The reaction of MBH carbonate 2-1a and nitroethane was chose to be the model 
reaction. The solvents were screening under the best catalyst 2-C1 at 
roomtemperature. THF was proved to be the best solvent. Other ether type of solvent 
ether could provide the same level of enantioselectivity with slightly lower yield. 
Dichloromethane and trichloromethane could afford the product with slightly lower 
enantioselectivity compared with THF as solvent. Small polar solvent, such as hexane, 
toluene, could provide moderate yield and good enantioselectivity. The moderate 
yield and low enantioselectivity was achieved using polar protic solvent MeOH. 
When polar solvent DMF was used, both yield and enantioselectivity were decrease 
(Table 2.2). 
Table 2.2 Solvent screening for the reaction of MBH carbonate with nitroethane a 
 
Entry Solvent Yield (%)b ee (%)c 
1 THF 96 93 
2 Et2O 84 90 
3 CH2Cl2 87 90 
4 CHCl3 96 90 
5 toluene 95 91 
6 hexane 60 92 
7 MeOH 76 36 
8 DMF 24 8 
a The reaction was performed with 2-1a (0.025 mmol), nitroethane (0.25 mmol) and 2-9a 
(0.005 mmol) in solvent (0.1 mL) at room temperature for 48 h.  b Isolated yield. c 




2.2.3 Substrate Scope 
Under the optimized condition, substrate scope was examined (Table 2.3). The 
MBH carbonate derived from aromatic aldehyde was suitable substrate for this 
reaction. Other MBH carbonate was utilized in the reaction with nitroethane under the 
catalyst 2-C1 in THF at room temperature. When the MBH carbonate derived from 4-
chlorobenzaldehyde was used, the -selective product 2-2c was achieve with good 
yield and poor enantioselectivity (50% ee). Further study showed that the addition of 
4 Å molecular sieves could increase the enantioselectivity dramatically, which could 
reach to 92% ee (Table 2.3, entry 3 and 4). The reason of the additive effect should be 
that the trace amount of water will influence the formation of the hydrogen bonding 
between substrate 2-4 and the bifuncational catalyst. 
Table 2.3 Substrate scope of the reaction of MBH carbonates with nitroalkanesa 
 
Entry R1 R2 Yield (%)b ee (%)c 
1 Ph Me 95 92 
2 4-F-Ph Me 84 95 
3 4-Cl-Ph Me 90 92 
4d 4-Cl-Ph Me 89 50 
5 4-Br-Ph Me 97 90 
6 3-Br-Ph Me 94 92 
7 2-Br-Ph Me 84 66 
8 4-CF3-Ph Me 89 92 
9 3-CF3-Ph Me 89 92 
10 2-CF3-Ph Me 89 62 
11 4-CH3-Ph Me 85 88 
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12 3-CH3-Ph Me 85 92 
13 2-CH3-Ph Me 84 79 
14 4-CH3O-Ph Me 87 92 
15 2-Naphthyl Me 76 89 
16 1-Naphthyl Me 43 72 
17 2-furyl Me 84 84 
18 e i-butyl Me <30 - 
19f Ph n-Pr 95 94 
20f Ph n-Bu 90 92 
21f Ph n-Pentyl 87 93 
22g Ph n-Pentyl 93 85 
a The reaction was performed with 2-1 (0.025 mmol), 2-4 (0.25 mmol),  4 Å molecular sieves (10 
mg) and 2-C1 (0.005 mmol) in solvent (0.1 mL) at room temperature for 48 h.  b Isolated yield. c 
Determined by HPLC analysis on a chiral stationary phase. d Reaction proceeded without the 
addition of 4 Å molecular sieves. e Reactions were proceed for 5 days. f Reactions were performed 
under neat condition with 50 equivalent nitroalkane without the addition of 4 Å molecular sieves. g 
Reaction was performed at 50 oC. 
Further study on substrate scope chose the condition of catalyst  2-C1, and the 
addition of 4 Å molecular sieves at room temperature. The -selective asymmetric 
reaction of MBH carbonates and nitroalkanes was investigated under the best 
condition. The MBH carbonates derived from aromatic aldehyde possessed good 
reactivity under the catalytic system. The electron property on the phenyl ring seems 
not affecting the selectivity. Both the MBH carbonates with electron donating and 
electron withdrawing group on the phenyl ring could afford the -selective with high 
regioselectivity and enantioselectivity (Table 2.3, entry 8, 9, 11, 12and 14). The MBH 
carbonates with halogen substituted on the phenyl ring had good reactivity and 
selectivity (Table 2.3, entry 2, 3, 5 and 6) except the ortho-substituted substrate 




could provide the product with poor enantioselectivity. The enantioselectivity was 
decreased with the increase of the steric hindrance of the ortho-substituent (Table 2.3, 
entry 7, 10, 13). The MBH carbonates derived from naphthyl aldehyde could provide 
the desired -selective product under the best condition. Although the good 
regioselectivity could be obtained, the reactivity decreased apparently (Table 2.3, 
entry 15 and 16). The MBH carbonate containing 1-naphthyl substituent could afford 
the product with lower eanantioselectivity due to the steric hindrance (Table 2.3, entry 
16). The MBH carbonate with hetero-aromatic substituent could give the product with 
good yield but slightly lower enantioselectivity (Table 2.3, entry 17). The MBH 
carbonate derived from aliphatic aldehyde was also tested under the optimized 
condition. However, the reactivity was too low (Table 2.3, entry 18). The -selective 
product from MBH carbonate with aromatic substituent was a conjugative system, 
which may benefit the product formation dynamically.  
To further explore the substrate scope, other nitroalkane was used in the reaction. 
Under the optimized condition, the reaction of MBH carbonate 2-1a and nitropropane 
was slow. The reactivity of nitroalkanes was dropped with the extension of alkyl 
chain. To achieve the desire -selective product, using nitroalkane with longer alkyl 
chain as substrate, the neat condition or harsh condition was need. Nitrohexane was 
used in the -selective substitution reaction of MBH carbonate under the optimized 
condition at 50 oC. Good reactivity, regioselectivity and enantioselectivity were 
observed with desire product (Table 2.3, entry 22). Under the neat condition, the 
products were achieved with high yield, regioselectivity and enantioselectivity using 
nitropropane, nitrobutane, and nitrohexane (Table 2.3, entry 19, 20 and 21). 
2.2.4 Synthetic Utility  
Chapter 2  
43 
 
To explore the utility of this regioselective asymmetric reaction, -methylene--
butyrolactams were synthesized by simple reduction. -Methylene--butyrolactams 
have been recieved much attetion because these compounds possess biological 
activity and are useful in medecinal chemistry.85 
 
Scheme 2.5 Synthesis of -alkylidene--butyrolactam  
The -selective product 2-2e could transform to  -alkylidene--butyrolactam 2-
6 in the presence of iron and acetic acid under the condition of reflux (Scheme 2.5). 
Furthermore, the X-ray structure of the single crystal of 2-6 was obtained. This may 
induce that the absolute configuration of 2-2e was S configuraion. The absolute 
configuration of other compounds 2-2 were asigned by anology of 2-2e. 
Pyrrolidinones are biologically important compounds and useful building block 
in organic synthesis. Many natural product and biological active compounds possess 
the motif of pyrrolindiones.84 Our -selective product of MBH carbonate and 
nitroalkane could transform to chiral pyrrolidinone compounds. The Fe/HOAc was 
used to reduce nitro group of compound 2-2a to form -alkylidene--butyrolactam 2-
7 (Scheme 2.6). Then the hydrogenation was used to form the chiral pyrrolidinone 
compound 2-8 with moderate but acceptable diastereoselectivity. Several metal 
catalysts such as Pd(OH)2, Raney-Ni, Pd/AlO(OH), have been examined in this 
hydrogenation reaction. The palladium carbon provided the best diastereoselectivity. 




using the condition of 20 mol% palladium carbon, THF as solvent and hydrogen 
balloon. 
 
Scheme 2.6 Synthesis of chiral pyrrolidinone compound 
2.2.5 Plausible Reaction Mechanism 
The organocatalytic asymmetric allylic alkylation reaction of MBH adduct was 
well explored to achieve -selective product. The mechanism was well accepted as a 
SN2’-SN2’ process. In the contrast, there was less report on the enantioselective 
substitution reaction of MBH carbonates with high -selectivity. The mechanism of 
-selective reaction of MBH carbonate was also less studied. This may also result in 
the less explored reaction of -selective reaction of MBH carbonate. Only one 
example has been reported to achieve the -selective chiral product using 
organocatalyst.78 The reaction of MBH acetate and benzophenone imine of glycine 
ester has been reported under phase transfer catalyst derived from cinchona alkaloid. 
A tandem addition-elimination was occurred under the base condition. The ion change 
of phase transfer catalyst and additional base would occur and the nucleophile would 
generate after deprotonation by base. The nucleophile would add to the MBH acetate 
in a SN2’ fashion so the OAc group would eliminate to be neutralized by the base in 
the reaction. The thiourea catalyst derived from quinidine could only activate 
nitroalkane which has been reported in Henry reaction and aza-Henry reaction.86 In 
our catalytic system, the simple SN2’ could happen if the catalyst only activates 
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nitroalkane. The addition of carbon-carbon double bond of activated nitroalkane 
would cause the elimination of the leaving group. To test this assumed addition-
elimination mechanism, MBH adduct with other leaving group could also give the -
selective product. We used the MBH acetate as substrate in the reaction with 
nitroethane under the optimized condition. But the reaction cannot proceed. That 
indicate the reaction may not undergo in a simple SN2’ process or the addition-
elimination process. 
Herein, we proposed that the reaction mechanism was in a SN2’-SN2 process 
(Scheme 2.7). The tertiary amine of the bifunctional catalyst severs as a nucleophile 
which could attack the carbon-carbon double bond of MBH carbonate and the leaving 
group Boc would in situ generate a tert butyl oxide ion and carbon dixoide. The tert-
butyl oxide ion would function as a base to deprotonate -proton of nitroethane, 
which plays a key role in this asymmetric reaction. After the SN2’ reaction, a tandem 
SN2 process would happen with the facilitation of the hydrogen bonding between the 
catalyst and nitroethane. The activated nitroethane would selectively attack the MBH 
carbonate from the front side through path A and regenerate the catalyst. The product 
indicates that a SN2’- SN2 reaction occurs rather than SN2’-SN2’ reaction. The good 
regioselectivity could generate because the reaction would go through path A rather 
than path B due to the steric hindrance. The thiourea functional also plays a key role 















































Scheme 2.7 Proposed mechanism for the -selective reaction of MBH 
carbonates with nitroalkanes 
Preliminary study on the proposed mechanism has been done. Other tertiary 
amine catalyst such as quinidine, O-protected quinidine was used, and the reaction of 
nitroethane and MBH carbonate 2-1a gave the mixture of -selective product 2-2a 
and -selective product 2-2a’. When the catalyst containing the thiourea group at the 
6’ position of -ICD was used, the reaction of MBH carbonate 2-1a and nitroethane 
afforded the regioselective product 2-2a’. The specific thiourea functionality of 
catalyst 2-C1 plays an important role in the regioselectivity of the reaction. Deng and 
co-workers has also revealed that the spatial relationship between hydrogen bonding 
donor and acceptor could alter the orientation of two substrates which would 
influence the enantioselectivity.87 Other nucleophile without nitro group could not 
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provide -selective product with high regioselectivity. Howerver, nucleophiles such 
as ethyl 2-nitroacetate could afford the -selective product with high regioselectivity. 
This may indicate that the specific interaction of hydrogen bonding between thiourea 
and nitro group is very important. The ortho substituted MBH carbonate only gave the 
desired product with moderate enantioselectivity. This may be due to the steric 
hindrance interference on the hydrogen bond formation between nitroethane and 
catalyst. The existence of water also could decrease the enantioselectivity of the 
reaction. The reason is that the hydrogen bonding formation may be destroyed in the 
presence of water. 
2.3 Conclusions 
In conclusion, we have developed the method that an asymmetric substitution 
reaction of nitroalkane with MBH carbonates catalyzed by cinchona derived 
bifunctional catalyst. A novel regioselective reaction of MBH adduct was investigated. 
A range of -selective products 2-2 was achieved in the reaction of MBH carbonates 
2-1and nitroalkanes 2-4 under the catalyst of 2-C1. The -selective products 2-2 were 
obtained with high regioselectivity, good to excellent yield and moderate to excellent 
enantioselectivity. The utility of this method was examined by synthesizing useful 
compounds. Pyrrolidinones 2-8 and -alkylidene--butyrolactam 2-6 was prepared 
by simple transformation of the -selective products 2-2. The absolute configuration 
was assigned by analysis of X-ray determination of compound 2-6 and analogy. The 
mechanism was proposed as a tandem SN2’- SN2 rather than SN2’- SN2’. The 
preliminary results of the mechanism study were also discussed. Although no enough 
evidence could support the proposed mechanism, the results could be well explained 




plays an important role in the highly regioselective and enantioselective 
transformation. 
2.4 Experimental section 
2.4.1 Material and General Methods 
All the starting materials were obtained from commercial sources and used 
without further purification unless otherwise stated. Toluene, THF and diethyl ether 
were dried and distilled from sodium benzophenone ketyl prior to use. CHCl3 and 
CH2Cl2 were distilled from CaH2 prior to use. 1H and 13C NMR spectra were recorded 
on a Bruker ACF300 or AMX500 (500 MHz) spectrometer. Chemical shifts were 
reported in parts per million (ppm), and the residual solvent peak was used as an 
internal reference: proton (chloroform δ 7.26), carbon (chloroform δ 77.0). 
Multiplicity was indicated as follows: s (singlet), d (doublet), t (triplet), q (quartet), m 
(multiplet), dd (doublet of doublet), br s (broad singlet). Coupling constants were 
reported in Hertz (Hz). Low resolution mass spectra were obtained on a 
Finnigan/MAT LCQ spectrometer in EI mode, and all high resolution mass spectra 
were obtained on a Finnigan/MAT 95XL-T spectrometer. For thin layer 
chromatography (TLC), Merck pre-coated TLC plates (Merck 60 F254) were used, 
and compounds were visualized with a UV light at 254 nm. Further visualization was 
achieved by staining with KMnO4, iodine, or ceric ammonium molybdate followed by 
heating on a hot plate. Flash chromatographic separationswere performed on Merck 
60 (0.040–0.063 mm) mesh silica gel. The enantiomeric excesses of products were 
determined by HPLC analysis on a chiral stationary phase. 
The MBH carbonates 2-1 were prepared according literature procedure.88 The 
catalysts 2-C were prepared according literature procedure with small modification.89 
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2.4.2 Catalyst Preparation 
 
Scheme 2.8 Typical procedure for synthesis of tertiary amine-thiourea catalysts 
derived from cinchona alkaloid 
The synthesis of catalyst 2-C1 was taken as an example. Other catalysts were 
prepared by the same procedure from other cinchona alkaloid (Scheme 2.8). 
To the solution of quinidine (3.24 g, 10 mmol) in CH2Cl2 (50 mL) was added 
NEt3 (2.7 mL, 20 mmol) in a 250 mL round bottom flask. At 0 oC, methanesulfonyl 
chloride (0.93 mL, 12 mmol) was slowly added by dropwise to the solution of 
quinidine. The reaction mixture was allowed to room temperature after the addition of 
MsCl. The reaction was followed by TLC monitor and quenched with water after the 
quinidine was consumed completely. The aqueous layer was extracted with 
dichloromethane for three times. The combined organic layer was washed with brine 
and dried with anhydrous Na2SO4. The crude product was obtained after removing the 
solvent. Without further purification, the crude product was directly used for the next 
step. In a 100 mL RBF, to the solution of mesilate protected quinidine in 30 mL DMF 




for 24 h. The reaction was cooled to room temperature when the reaction was 
complete. Water was added and the reaction mixture was extracted with 
dichloromethane for three times. The combined organic layer was washed with water 
several times to remove DMF. After removing the solvent, the crude product of azide 
was obtained and directly used in the next step. To the solution of azide compound in 
dry THF was added triphenylphosphine (2.62 g, 10 mmol). The reaction mixture was 
then heated to 40 oC. The reaction was stopped when there was no gas released from 
the reaction. The solvent was removed to achieve the crude product. The desired 
compound (2.46g, 7.6 mmol) of amine derived from qunindine was obtained after 
purification by column chromatography on silica gel. 
To the solution of amine derived from quinidine (232 mg, 1.0 mmol) in 10 mL 
CH2Cl2 was added 3,5-bis(trifluoromethyl)phenyl isothiocyanate (0.2 mL, 1.0 mmol) 
by dropwise. After the completion of addition, the reaction was followed by TLC 
analysis. When the amine was consumed completely, the solvent was removed. The 
crude product was purified by column chromatography on silica gel to afford the 
desired product 2-C1 (540 mg, 90%). 

















Scheme 2.9Typical procedure for synthesis of MBH carbonates 
The representative procedure of synthesis of MBH carbonates was described as 
the synthesis of substrate 2-1a (Scheme 2.9). To the mixture of benzaldehyde (0.10 
mL, 1.0 mmol) and ethyl acrylate (0.11 mL, 1.0 mmol) was added DABCO (112 mg, 
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1.0 mmol). The reaction mixture was stirred at room temperature for one day. The 
mixture was directly purified by column chromatography on silica gel to afford the 
MBH product (189 mg, 92%). To the MBH product in 5 mL dry CH2Cl2 was added 
the solution of Boc2O (0.21 mL, 0.92 mmol) and DMAP (5.6 mg, 0.046 mmol) in 2 
mL dry CH2Cl2 at 0 oC by dropwise. The reaction mixture was stirred at room 
temperature for one day. When the MBH product was consumed completely, the 
solvent was removed under reduced pressure. The residue was purified by column 
chromatography on silica gel to afford the MBH carbonate 2-1a (260 mg, 92%). 
2.4.4 Representative Procedure for the Reaction of MBH Carbonates 
and Nitroalkanes 
 
Scheme 2.10 Typical procedure for the reaction of MBH carbonates with nitroalkanes 
MBH carbonate 2-1e (9.6 mg, 0.025 mmol) was mixed with catalyst 2-C1 (3.0 
mg, 0.005 mmol) and 4Å molecular sieves (10 mg) in THF (0.1 mL). Nitroethane (18 
μL, 0.25mmol) was added to the reaction mixture and the resulting reaction mixture 
was stirred for 2 days at room temperature. Molecular sieves were filtered off; the 
filtrate was concentrated under reduced pressure. The residue was directly purified by 





2.4.5 Representative Procedure for Butyrolactams and 
Pyrrolidinones 
To the compound 2-2e (8.0 mg, 0.023 mmol) in AcOH (1.0 mL) was added Fe 
(13 mg, 0.23mmol). The reaction mixture was heated to reflux for 2 hours. The 
reaction mixture was cooled to roomtemperature. The solid was filtered off and wased 
with dichloromethane 3 mL for 2 times. To the resulting filtrate was added 10 mL 
water.  The aqueous layer was extracted with 10 mL CH2Cl2 for 2 times. The 
combined organic layer was washed with water, brine and dried with anhydrous 
Na2SO4. The solvent was removed under reduced pressure. The residue was purified 
purified by column chromatography on silica gel to afford the -alkylidene--
butyrolactam 2-6 (4.9 mg, 80 %).  
The -alkylidene--butyrolactam compound 2-7 was obtained using the above 
method. To the compound 2-7 (50.0 mg, 0.27 mmol) in THF (0.5 mL) was added 
Pd/C (10.0 mg). The reaction mixture was charged with hydrogen in a balloon and 
stirred for overnight. The Pd/C was filtered off and the resulting filtrate was 
concentrated under reduced pressure. The residue was purified purified by column 
chromatography on silica gel to afford the pyrrolidinone 2-8 (46.0 mg, 90%). 
2.4.6 Analytical Data of MBH Carbonates 





A colorless oil, 1H-NMR (300 MHz, CDCl3) δ 1.18 (t, J = 7.1 Hz, 3H), 1.44 (s, 
9H), 4.13 (q, J = 5.05 Hz, 2H), 5.90 (s, 1H), 6.39 (s, 1H), 6.44 (s, 1H), 6.98-7.01 (m, 
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2H), 7.35-7.37 (m, 2H); 13C-NMR (75 MHz, CDCl3) δ 14.0, 27.7, 61.0, 75.2, 82.7, 
115.3, 115.4, 125.3, 129.6, 129.7, 139.7, 152.3, 164.7; HRMS-EI calcd for 
C17H21O5F3 324.1373, found: 324.1376. 
Ethyl 2-((4-bromophenyl)((tert-butoxycarbonyl)oxy)methyl)acrylate 2-1d 
 
A colorless oil, 1H-NMR (300 MHz, CDCl3) δ 1.26 (t, J = 7.08 Hz, 3H), 1.48 (s, 
9H), 4.15-4.22 (q, J = 6.06 Hz, 2 H), 5.94 (s, 1H), 6.43 (s, 1H), 6.45 (s, 1H), 7.31 (d, J 
= 7.44 Hz, 2H), 7.49 (d, J = 7.44 Hz, 2H); 13C-NMR(75 MHz, CDCl3) δ 13.9, 27.6, 
61.0, 75.1, 82.6, 122.4, 125.6, 129.3, 131.5, 136.8, 139.4, 152.2, 164.6; HRMS-EI 
calcd for C17H21O579Br1 and C17H21O581Br1 , 384.0572 and 386.0552, found: 384.0586 
and 386.0565. 
Ethyl 2-((3-bromophenyl)((tert-butoxycarbonyl)oxy)methyl)acrylate 2-1e 
 
A colorless oil, 1H-NMR (300 MHz, CDCl3) δ 1.23 (t, J = 7.1 Hz, 3H), 1.46 (s, 
9H), 4.11-4.20 (m, 2H), 5.92 (s, 1H), 6.42(s, 2H), 7.20-7.54 (m, 4H); 13C-NMR (75 
MHz, CDCl3) δ 14.0, 27.7, 61.1, 75.1, 83.0, 125.4, 126.1, 127.9, 130.7, 139.3, 141.8, 
152.2, 164.6; HRMS-EI calcd for C17H21O579Br1 and C17H21O581Br1 , 384.0572 and 




Ethyl 2-(((tert-butoxycarbonyl)oxy)(4-(trifluoromethyl)phenyl)methyl)acrylate 2-1g 
  
A colorless oil, 1H-NMR (300 MHz, CDCl3) δ 1.22 (t, J = 7.2 Hz, 3H), 1.45 (s, 
9H), 4.12-4.19 (m, 2H), 5.93 (s, 1H), 6.43 (s, 1H), 6.51 (s, 1H), 7.51-7.60 (m, 4H); 
13C-NMR (75 MHz, CDCl3) δ 13.9, 27.6, 61.0, 71.5, 82.9, 125.3, 125.4, 126.0, 
127.9,139.3, 141.8, 152.2, 164.6; HRMS-EI calcd for C18H21O5F3 374.1341, found: 
374.1346. 
Ethyl 2-(((tert-butoxycarbonyl)oxy)(3-(trifluoromethyl)phenyl)methyl)acrylate 2-1h 
 
A colorless oil, 1H-NMR (300 MHz, CDCl3) δ 1.20 (t, J = 7.2 Hz, 3H), 1.44 (s, 
9H), 4.10-4.17 (m, 2H), 5.94 (s, 1H), 6.43 (s, 1H), 6.50 (s, 1H), 7.44-7.65 (m, 4H); 
13C-NMR (75 MHz, CDCl3) δ 13.8, 27.6, 61.0, 75.1, 82.9,124.3, 124.4, 125.1, 125.2, 
125.9, 128.9, 131.0, 138.9, 139.3, 152.1, 164.5; HRMS-EI calcd for C18H21O5F3 
374.1341, found: 374.1346. 
Ethyl 2-(((tert-butoxycarbonyl)oxy)(m-tolyl)methyl)acrylate 2-1k 
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A colorless oil, 1H-NMR (300 MHz, CDCl3) δ 1.23 (t, J = 7.2 Hz, 3H), 1.46 (s, 
9H), 2.33 (s, 3H), 4.14-4.21 (m, 2H), 5.88 (s, 1H), 6.39 (s, 1H), 6.45 (s, 1H), 7.09-
7.26 (m, 4H); 13C-NMR (75 MHz, CDCl3) δ 14.0, 21.3, 27.7, 60.9, 75.9, 82.5, 124.8, 
125.4, 128.2, 128.3, 129.1, 137.4, 138.0, 139.9, 152.4, 164.9; HRMS-EI calcd for 
C18H24O5 320.1618, found: 320.1611. 
Ethyl 2-(((tert-butoxycarbonyl)oxy)(o-tolyl)methyl)acrylate 2-1l 
 
A colorless oil, 1H-NMR (300 MHz, CDCl3) δ 1.23 (t, J = 7.1 Hz, 3H), 1.46 (s, 
9H), 2.41 (s, 3H), 4.14-4.21 (q, J = 7.1 Hz, 2H), 5.70 (s, 1H), 6.42 (s, 1H), 6.73 (s, 
1H), 7.17-7.31 (m, 4H); 13C-NMR (75 MHz, CDCl3) δ 14.0, 19.1, 27.7, 60.9, 72.7, 
82.4, 126.0, 126.6, 127.0, 128.3, 130.5, 135.6, 136.3, 139.3, 152.5, 165.1; HRMS-EI 
calcd for C18H24O5 320.1618, found: 320.1611. 
Ethyl 2-(((tert-butoxycarbonyl)oxy)(naphthalen-2-yl)methyl)acrylate 2-1n 
 
A light yellow solid, 1H-NMR (300 MHz, CDCl3) δ 1.22 (t, J = 7.2 Hz, 3H), 1.47 
(s, 9H), 4.12-4.19 (q, J = 7.2 Hz, 2H), 5.96 (s, 1H), 6.45 (s, 1H), 6.66 (s, 1H), 7.46-
7.49 (m, 3H), 7.81-7.88 (m, 4H); 13C-NMR (75 MHz, CDCl3) δ 14.0, 27.8, 61.0, 76.0, 
82.7, 125.2, 125.7, 126.2, 126.3, 127.1, 127.6, 128.2, 133.1, 135.0, 139.8, 152.4, 




2.4.7 Analytical Data of Products of MBH carbonates and 
nitroalkanes 
(S,E)-Methyl 2-benzylidene-4-nitropentanoate 2-5 
 
A colorless oil, 58% yield; [α]c = -25.8 (c = 0.48, CHCl3); 91% ee, determined 
by HPLC analysis [Daicel Chiralpak IB, n-hexane/i-PrOH = 98/2, 0.5 mL/min, λ = 
254 nm, t (major) = 21.41 min, t (minor) = 19.47 min]; 1H-NMR (300 MHz, CDCl3) δ 
1.48 (d, J = 5.6 Hz, 3H), 2.95-3.00 (m, 1H), 3.22-3.30 (m, 1H), 3.85 (s, 3H), 4.87-
4.92 (m, 1H), 7.28-7.42 (m, 5H), 7.89 (s, 1H). 
(S,E)-Ethyl 2-benzylidene-4-nitropentanoate 2-2a 
 
A colorless oil, 96% yield; [α]c = -18.1 (c = 0.42, CHCl3); 92% ee, determined 
by HPLC analysis [Daicel Chiralcel OJ, n-hexane/i-PrOH = 98.5/0.5, 0.5 mL/min, λ = 
254 nm, t (major) = 49.81min, t (minor) = 44.80 min]; 1H-NMR (300 MHz, CDCl3) δ 
1.38 (t, J = 7.6 Hz, 3H), 1.47 (d, J = 6.7 Hz, 3H), 2.93-2.99 (m, 1H), 3.22-3.29 (m, 
1H), 4.30 (q, J = 7.1 Hz, 2H), 4.85-4.94 (m, 1H), 7.28-7.41 (m, 5H), 7.89 (s, 1H). 
(S,E)-Ethyl 2-(4-fluorobenzylidene)-4-nitropentanoate 2-2b 




A colorless oil, 84% yield; [α]c = -20.9 (c = 0.41, CHCl3); 95% ee, determined 
by HPLC analysis [Daicel Chiralpak AD, n-hexane/i-PrOH = 99/1, 0.5mL/min, λ = 
254 nm, t (major) = 26.38 min, t (minor) = 30.85 min]; 1H NMR (300 MHz, CDCl3) δ 
1.36 (t, J = 7.1 Hz, 3H), 1.48 (d, J = 6.7 Hz, 3H), 2.89-2.95 (m, 1H), 3.19-3.26 (m, 
1H), 4.26-4.33 (q, J = 7.1 Hz, 2H), 4.85-4.94 (m, 1H), 7.07-7.13 (m, 2H), 7.27-7.31 
(m, 2H), 7.83 (s, 1H); 13C-NMR (75 MHz, CDCl3) δ 14.2, 18.9, 32.8, 61.4, 81.7, 
115.8, 116.0, 127.6, 130.7. 130.8, 142.0, 161.2, 167.0; HRMS-APCI calcd for 
C14H16FNO4 280.1001, found: 280.0991. 
(S,E)-Ethyl 2-(4-chlorobenzylidene)-4-nitropentanoate 2-2c 
 
A colorless oil, 90% yield; [α]c =+12.0 (c = 0.85, CHCl3); 92% ee, determined 
by HPLC analysis [Daicel Chiralcel OJ, n-hexane/i-PrOH = 99/1, 0.5 mL/min, λ = 
254 nm, t (major) = 56.71 min, t (minor) = 49.25 min]; 1H-NMR (300 MHz, CDCl3) δ 
1.40 (t, J = 7.0 Hz, 3H), 1.51 (d, J = 7.0 Hz, 3H), 2.92-2.96 (m, 1H), 3.22-3.27 (m, 
1H), 4.32-4.36 (q, J = 6.9 Hz, 2H), 4.91-4.98 (m, 1H), 7.28 (d, J = 10.1 Hz, 2H), 7.42, 
(d, 2H), 7.85 (s, 1H); 13C-NMR (75 MHz, CDCl3) δ 14.2, 18.9, 29.7, 61.4, 81.7, 128.2, 
129.0, 130.1, 133.1, 134.9, 141.9, 166.9; HRMS-APCI calcd for C14H16ClNO4 




(S,E)-Ethyl 2-(4-bromobenzylidene)-4-nitropentanoate 2-2d 
 
A colorless oil, 97% yield; [α]c = -23.7 (c = 0.63, CHCl3); 90% ee, determined 
by HPLC analysis [Daicel Chiralcel OJ, n-hexane/i-PrOH = 99.5/0.5, 0.5 mL/min, λ = 
254 nm, t (major) = 95.91 min, t (minor) = 84.66 min]; 1H-NMR (300 MHz, CDCl3) δ 
1.36 (t, J = 7.2 Hz, 3H), 1.47 (d, J = 6.7 Hz, 3H), 2.86-2.93 (m, 1H), 3.16-3.24 (m, 
1H), 4.26-4.34 (q, J = 7.1 Hz), 4.85-4.96 (m, 1H), 7.15-7.18 (d, J = 8.6 Hz, 2H), 7.53-
7.56 (d, J = 8.6 Hz, 2H), 7.79 (s, 1H); 13C-NMR (75 MHz, CDCl3) δ 14.2, 18.9, 29.7, 
32.9, 61.5, 81.6, 123.2, 128.3, 130.3, 132.0, 133.6, 141.9, 166.9; HRMS-EI calcd for 
C14H16O4N179Br1  and C14H16O4N181Br1 341.0263 and 343.0242, found: 341.0247 and 
343.0228. 
(S,E)-Ethyl 2-(3-bromobenzylidene)-4-nitropentanoate 2-2e 
 
A colorless oil, 94% yield; [α]c = -5.3 (c = 0.60, CHCl3); 92% ee, determined by 
HPLC analysis [Daicel Chiralcel OJ, n-hexane/i-PrOH = 99/1, 0.5 mL/min, λ = 254 
nm, t (major) = 63.32 min, t (minor) = 56.93 min]; 1H-NMR (300 MHz, CDCl3) 1.31 
(t, J = 7.1 Hz, 3H), 1.43 (d, J = 6.7 Hz, 3H), 2.80-2.87 (m, 1H), 3.11-3.18 (m, 1H), 
4.22-4.29 (q, J = 7.1 Hz, 2H), 4.82-4.89 (m, 1H), 7.15-7.43 (m, 4H), 7.74 (s, 1H); 
13C-NMR (75 MHz, CDCl3) δ 14.2, 18.9, 32.8, 61.5, 81.6, 122.7, 127.1, 129.0, 130.2, 
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131.5, 131.7, 136.7, 141.4, 166.7; HRMS-EI calcd for C14H16O4N179Br1  and 
C14H16O4N181Br1 341.0263 and 343.0242, found: 341.0247 and 343.0228. 
(S,E)-Ethyl 2-(2-bromobenzylidene)-4-nitropentanoate 2-2f 
 
A colorless oil, 84% yield; [α]c = +11.3 (c = 0.30, CHCl3); 66% ee, determined 
by HPLC analysis [Daicel Chiralcel OJ, n-hexane/i-PrOH = 99/1, 0.5 mL/min, λ = 
254 nm, t (major) = 33.01 min, t (minor) =45.65 min]; 1H-NMR (300 MHz, CDCl3) δ 
1.35-1.42 (m, 6H), 2.77-2.84 (m, 1H), 3.02-3.09 (m, 1H), 4.28-4.35 (q, J = 7.1 Hz, 
2H), 4.82-4.93 (m, 1H), 7.15-7.35 (m, 4H), 7.82 (s,1H).13C-NMR (75 MHz, CDCl3) 
14.2, 18.7, 32.9, 61.4, 81.5, 123.4, 127.4, 129.1, 129.7, 130.0, 132.8, 135.4, 142.6, 
166.5. HRMS-EI calcd for C14H16O4N1Br 1 343.0242, found: 343.0228. 
(S,E)-Ethyl 4-nitro-2-(4-(trifluoromethyl)benzylidene)pentanoate 2-2g 
 
A colorless oil, 89% yield; [α]c = +25.9 (c = 0.54, CHCl3); 92% ee, determined 
by HPLC analysis [Daicel Chiralcel OJ, n-hexane/i-PrOH = 99/1, 0.5 mL/min, λ = 
254 nm, t (major) = 37.45 min, t (minor) = 33.97 min]; 1H-NMR (300 MHz, CDCl3) δ 
1.38 (t, J = 7.2 Hz, 3H), 1.48 (d, J = 6.7 Hz, 3H), 2.84-2.91 (m, 1H), 3.13-3.21 (m, 
1H), 4.29-4.36 (q, J = 7.2 Hz, 2H), 4.87-4.96 (m, 1H), 7.36-7.39 (d, J = 7.7 Hz, 2H), 




33.0, 61.6, 81.6, 125.6, 125.7, 128.1, 128.9, 129.6, 141.5, 166.6; HRMS-EI calcd for 
C15H16O4N1F3 331.1031, found: 331.1028. 
(S,E)-Ethyl 4-nitro-2-(3-(trifluoromethyl)benzylidene)pentanoate 2-2h 
 
A colorless oil, 89% yield; [α]c = +28.9 (c = 0.45, CHCl3); 92% ee, determined 
by HPLC analysis [Daicel Chiralcel OB, n-hexane/i-PrOH = 99.5/0.5, 0.5 mL/min, λ 
= 254 nm, t (major) = 33.83 min, t (minor) = 44.35 min]; 1H-NMR (300 MHz, CDCl3) 
δ 1.37 (t, J = 7.1 Hz, 3H), 1.48 (d, J = 6.6 Hz, 3H), 2.85-2.91 (m, 1H), 3.14-3.22 (m, 
1H), 4.28-4.35 (q, J = 7.1 Hz, 2H), 4.89-4.96 (m, 1H), 7.45-7.64 (m, 4H), 7.87 (s, 1H); 
13C-NMR (75 MHz, CDCl3) δ 14.2, 19.0, 32.9, 61.6, 81.6, 125.4, 125.5, 129.3, 129.4, 
131.8, 135.5, 141.4, 166.6. HRMS-EI calcd for C15H16O4N1F3 331.1031, found: 
331.1028. 
(S,E)-Ethyl 4-nitro-2-(2-(trifluoromethyl)benzylidene)pentanoate 2-2i 
 
A colorless oil, 89% yield; [α]c = +205.8 (c = 0.31, CHCl3); 62% ee, determined 
by HPLC analysis [Daicel Chiralpak IC, n-hexane/i-PrOH = 98/2.0, 0.5 mL/min, λ = 
254 nm, t (major) = 22.34 min, t (minor) = 25.89 min]; 1H-NMR δ 1.37-1.41 (m, 6H), 
2.72-2.78 (m, 1H), 2.91-2.99 (m, 1H), 4.29-4.36 (q, J = 7.1 Hz, 2H), 4.77-4.96 (m, 
1H), 7.17-7.20 (m, 1H), 7.45-7.73 (m, 3H), 8.01 (s, 1H).13C-NMR (75 MHz, CDCl3) 
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14.1, 18.8, 33.3, 61.5, 81.4, 126.2, 128.6, 129.8, 130.2, 131.9, 140.1, 166.3. HRMS-EI 
calcd for C15H16O4N1F3   331.1031, found: 331.1028. 
(S,E)-Ethyl 2-(4-methylbenzylidene)-4-nitropentanoate 2-2j 
 
A colorless oil, 85% yield; [α]c = +21.0 (c = 0.30, CHCl3); 88% ee, determined 
by HPLC analysis [Daicel Chiralpak IC, n-hexane/i-PrOH = 99/1, 0.5 mL/min, λ = 
254 nm, t (major) = 48.48 min, t (minor) = 40.99 min]; 1H-NMR (300 MHz, CDCl3) δ 
1.36 (t, J = 7.2 Hz, 3H), 1.47 (d, J = 6.6 Hz, 3H), 2.38 (s, 1H), 2.83-3.03 (m, 1H), 
3.24-3.32 (m, 1H), 4.26-4.33 (q, J = 7.1 Hz, 2H), 4.86-4.93 (m, 1H), 7.22-7.25 (m, 
4H), 7.85 (s, 1H); 13C-NMR (75 MHz, CDCl3) δ 14.2, 18.7, 32.8, 61.2, 81.7, 126.6, 
128.9, 129.5, 131.8, 139.2, 143.2, 167.3; HRMS-EI calcd for C15H19O4N1 277.1314, 
found: 277.1310. 






A colorless oil, 85% yield; [α]c = -16.0 (c = 0.37, CHCl3); 92% ee, determined 
by HPLC analysis [Daicel Chiralpak IC, n-hexane/i-PrOH = 98/2, 0.5 mL/min, λ = 
254 nm, t (major) = 27.09 min, t (minor) = 24.65 min]; 1H-NMR (300 MHz, CDCl3) δ 
1.36 (t, J = 7.1 Hz, 3H), 1.47 (d, J = 1.66 Hz, 3H), 2.38 (s, 3H), 2.93-3.00 (m, 1H), 




4H), 7.85 (s, 1H); 13C-NMR (75 MHz, CDCl3) δ 14.4, 18.7, 21.4, 32.8, 61.3, 81.7, 
125.8, 127.3, 128.6, 129.5, 129.7, 134.6, 138.4, 143.4, 167.2; HRMS-EI calcd for 
C15H19O4N1 277.1314, found: 277.1310. 
(S,E)-Ethyl 2-(2-methylbenzylidene)-4-nitropentanoate 2-2l 
 
A colorless oil, 84% yield; [α]c = +21.0 (c = 0.30, CHCl3); 79% ee, determined 
by HPLC analysis [Daicel Chiralcel OJ, n-hexane/i-PrOH = 98.5/0.5, 0.5 mL/min, λ = 
254 nm, t (major) = 29.39 min, t (minor) = 36.03 min]; 1H-NMR (300 MHz, CDCl3) δ 
1.35-1.41 (m, 6H), 2.75-2.82 (m, 1H), 3.06-3.14 (m, 1H), 4.28-4.35 (q, J = 7.1 Hz, 
2H), 4.80-4.92 (m, 1H), 7.04-7.25 (m, 4H), 7.91 (s, 1H); 13C-NMR (75 MHz, CDCl3) 
δ 14.2, 18.8, 19.8, 61.3, 81.8, 125.8, 127.9, 128.2, 128.7, 130.2, 134.1, 136.6, 143.2, 
166.9. HRMS-EI calcd for C15H19O4N1 277.1314, found: 277.1310. 
(S,E)-Ethyl 2-(4-methoxybenzylidene)-4-nitropentanoate 2-2m 
 
A colorless oil, 87% yield; [α]c = +22.0 (c = 0.30, CHCl3); 92% ee, determined 
by HPLC analysis [Daicel Chiralpak IC, n-hexane/i-PrOH = 98.5/0.5, 0.5 mL/min, λ 
= 254 nm, t (major) = 64.93 min, t (minor) = 55.08 min]; 1H-NMR (300 MHz, CDCl3) 
δ 1.36 (t, J = 7.1 Hz, 3H), 1.49 (d, J = 6.5 Hz, 3H), 2.99-3.06 (m, 1H), 3.27-3.34 (m, 
1H), 3.85 (s,3H), 4.25-4.32 (q, J = 7.1 Hz, 2H), 4.87-4.94 (m, 1H), 6.92-6.95 (d, J = 
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5.9 Hz, 2H), 7.31-7.34 (d, J = 8.4 Hz, 2H), 7.82 (s, 1H); 13C-NMR (75 MHz, CDCl3) 
δ 14.2, 18.7, 32.8, 55.3, 61.2, 114.3, 125.3, 127.0, 130.9, 142.8, 160.3. HRMS-APCI 
calcd for C15H18NO5 292.1202, found: 292.1190. 





A colorless oil, 76% yield; [α]c = -91.9 (c = 0.45, CHCl3); 79% ee, determined 
by HPLC analysis [Daicel Chiralcel OJ, n-hexane/i-PrOH = 99/1, 0.5 mL/min, λ = 
254 nm, t (major) = 37.84 min, t (minor) = 20.30 min]; 1H-NMR (300 MHz, CDCl3) δ 
1.39 (t, J = 7.1 Hz, 3H), 1.48 (d, J = 6.8 Hz, 3H), 3.02-3.09 (m, 1H), 3.32-3.39 (m, 
1H), 4.30-4.37 (q, J = 7.2 Hz, 2H), 4.93-5.00 (m, 1H), 7.41-7.43 (m, 1H), 7.44-7.54 
(m, 2H), 7.80-7.89 (m, 4H), 8.04 (s, 1H); 13C-NMR (75 MHz, CDCl3) δ 14.2, 18.8, 
33.0, 61.3, 81.7, 126.0, 126.6, 127.7, 128.4, 128.7, 132.1, 133.1, 143.2, 167.2. 
HRMS-EI calcd for C18H19O4N1 313.1314, found: 313.1310. 





A colorless oil, 43% yield; [α]c = -30.4 (c = 0.30, CHCl3); 72% ee, determined 
by HPLC analysis [Daicel Chiralcel OJ, n-hexane/i-PrOH = 99/1, 0.5 mL/min, λ = 




1.38-1.43 (m, 6H), 2.63-2.80 (m, 1H), 3.14-3.21 (m, 1H), 4.20-4.23 (m, 1H), 4.30-
4.38 (q, J = 7.2 Hz, 2H), 7.37-7.56 (m, 6H), 7.69-7.70 (m, 1H), 7.71 (s, 1H); 13C-
NMR (75 MHz, CDCl3) δ 14.2, 18.7, 33.4, 61.4, 81.7, 124.5, 125.2, 125.8, 126.4, 
126.6, 128.6, 129.1, 142.3, 166.8. HRMS-EI calcd for C18H19O4N1   313.1314, found: 
313.1310.  





A colorless oil, 84% yield; [α]c = +61.8 (c = 0.40, CHCl3); 84% ee, determined 
by HPLC analysis [Daicel Chiralcel OJ, n-hexane/i-PrOH = 99/1, 0.5 mL/min, λ = 
254 nm, t (major) = 52.01 min, t (minor) = 47.23 min]; 1H-NMR (300 MHz, CDCl3) δ 
1.34 (t, J = 7.1 Hz, 3H), 1.55 (d, J = 5.3 Hz, 3H), 3.24-3.31 (m, 1H), 3.46-3.53 (m, 
1H), 4.23-4.30 (q, J = 7.1 Hz, 2H), 4.81-4.90 (m, 1H), 6.51-6.52 (m, 1H), 6.52-6.70 
(m, 1H),7.52 (s, 1H), 7.57 (s, 1H); 13C-NMR (75 MHz, CDCl3) δ 14.2, 18.5, 33.1, 
61.3, 82.4, 112.3, 117.5, 122.6, 128.1, 145.2, 150.7, 167.4. HRMS-EI calcd for 
C12H15O5N1 253.0950, found: 253.0948. 
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A colorless oil, 95% yield; [α]c = -12.5 (c =0.73, CHCl3); 94% ee, determined by 
HPLC analysis [Daicel Chiralcel OJ, n-hexane/i-PrOH = 99/1, 0.5 mL/min, λ = 254 
nm, t (major) = 31.78 min, t (minor) = 27.24 min]; 1H-NMR (500 MHz, CDCl3) δ 
0.89 (t, J = 7.0 Hz, 3H), 1.26-1.31 (m, 2H), 1.37 (t, J = 7.0 Hz, 3H) 1.60-1.67 (m, 1H), 
1.88-1.95 (m, 1H), 2.90-2.96 (m, 1H), 3.20-3.25 (m, 1H), 4.28-4.33 (q, J = 7.0 Hz, 
2H), 4.80-4.86 (m, 1H), 7.28-7.412 (m, 5H), 7.87 (s, 1H); 13C-NMR (125 MHz, 
CDCl3) δ 13.3, 14.2, 19.0, 31.7, 35.4, 61.3, 86.8, 127.7, 128.7, 134.8, 143.2, 167.2; 
HRMS-EI calcd for C16H21O4N1 291.1471, found 291.1465. 





A colorless oil, 90% yield; [α]c = -153.9 (c = 0.36, CHCl3); 92% ee, determined 
by HPLC analysis [Daicel Chiralcel OJ, n-hexane/i-PrOH = 99/1, 0.5 mL/min, λ = 
254 nm, t (major) = 23.42 min, t (minor) = 19.59 min]; 1H-NMR (500 MHz, CDCl3) δ 
0.85 (t, J = 7.0 Hz, 3H), 1.20-1.31 (m, 4H), 1.37 (t, J = 7.0 Hz, 3H) 1.65-1.70 (m, 1H), 
1.87-1.95 (m, 1H), 2.92-2.96 (m, 1H), 3.20-3.24 (m, 1H), 4.28-4.32 (q, J = 7.0 Hz, 
2H), 4.78-4.83 (m, 1H), 7.28-7.41 (m, 5H), 7.87 (s, 1H); 13C-NMR (125 MHz, CDCl3) 
δ 13.6, 14.2, 22.0, 27.7, 31.6, 33.1, 61.3, 87.1, 127.6, 128.6, 128.8, 134.7, 143.2, 
167.1; HRMS-EI calcd for C17H23O4N1 305.1627, found 305.1626. 





A colorless oil; 87% yield; [α]c = +28.1 (c = 0.26, CHCl3); 93% ee, determined 
by HPLC analysis [Daicel Chiralcel OJ, n-hexane/i-PrOH = 99/1, 0.5 mL/min, λ = 
254 nm, t (major) = 20.70 min, t (minor) = 18.17 min]; 1H-NMR (500 MHz, CDCl3) δ 
0.88 (t, J = 7.0 Hz, 3H ), 1.24-1.25 (m, 6H), 1.37 (t, J = 7.0 Hz, 3H), 1.63-1.67 (m, 
1H), 1.87-1.93 (m, 1H), 2.92-2.95 (m, 1H), 3.20-3.24 (m, 1H), 4.28-4.32 (q, J = 7.0 
Hz, 2H), 4.78-4.83 (m, 1H), 7.28-7.42 (m, 5H), 7.87 (s, 1H); 13C-NMR (125 MHz, 
CDCl3) δ 13.8, 14.2, 22.2, 25.3, 31.0, 31.6, 33.4, 61.3, 87.1, 127.6, 128.6, 128.7, 
128.8, 134.7, 153.6, 167.1; HRMS-EI calcd for C18H25O4N1 319.1784, found: 
319.1781. 




A white solid; 80% yield; [α]c = +33.3 (c = 2.9, CHCl3); 92% ee, determined by 
HPLC analysis [Daicel Chiralpak IC, n-hexane/i-PrOH = 80/20, 1.0 mL/min, λ = 254 
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nm, t (major) = 19.01 min, t (minor) = 16.78 min]; 1H-NMR (300MHz, CDCl3) δ 1.33 
(d, J = 6.2 Hz, 3H), 2.61-2.69 (m, 1H), 3.26-3.35 (m, 1H), 3.87-3.97 (m, 1H), 6.79 (s, 
1H), 7.24-7.47 (m, 4H), 7.59 (s, 1H); 13C-NMR (75 MHz, CDCl3) δ 23.4, 34.9, 47.4, 
122.8, 128.3, 129.1, 130.2,131.4, 131.9, 137.8, 171.2; HRMS-EI calcd for 
C12H12O1N1Br1 267.0082, found: 267.0064. 
Data of X-ray diffraction of compound 2-6 
       
Identification code  2-6 
Empirical formula  C12 H14 Br N O2 
Formula weight  284.15 
Temperature  100(2) K 
Wavelength  0.71073 Å 




Space group  P2(1) 
Unit cell dimensions a = 12.722(3) Å = 90°.　  
 b = 4.8282(11) Å = 96.755(5)°.　  
 c = 19.810(5) Å  = 90°.　  
Volume 1208.4(5) Å3 
Z 4 
Density (calculated) 1.562 Mg/m3 
Absorption coefficient 3.387 mm-1 
F(000) 576 
Crystal size 0.50 x 0.20 x 0.06 mm3 
Theta range for data collection 1.04 to 27.50°. 
Index ranges -15<=h<=16, -6<=k<=6, -24<=l<=25 
Reflections collected 8403 
Independent reflections 5107 [R(int) = 0.0351] 
Completeness to theta = 27.50° 99.5 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.8226 and 0.2822 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5107 / 5 / 309 
Goodness-of-fit on F2 0.993 
Final R indices [I>2sigma(I)] R1 = 0.0443, wR2 = 0.1054 
R indices (all data) R1 = 0.0569, wR2 = 0.1118 
Absolute structure parameter 0.021(14) 
Largest diff. peak and hole 1.552 and -0.563 e.Å-3 








1H-NMR (500 MHz, CDCl3) δ 1.16 (m, 3H), 1.33-144 (m, 1H), 2.24-2.29 (m, 1H), 
2.61-2.75 (m, 2H), 3.30-3.33 (m, 1H), 3.65-3.66 (m, 1H), 6.03 (s, 1H), 7.22-7.31 (m, 
5H); 13C-NMR (125 MHz, CDCl3) δ 22.0, 36.2, 36.8, 44.2, 48.0, 126.2, 128.4, 128.9, 
129.0, 139.7, 178.6; HRMS-ESI calcd for [M + Na] C12H15NNaO, 212.1046, found: 
212.1040. 
The relative configuration was determined by COSY and NOESY spectrum which 
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Chapter 3 Enantioselective Allylic Substitution Reaction of 
Isatin-Derived MoritaBaylisHillman Carbonates with 
Nitroalkanes 
3.1 Introduction 
The 3,3’-disubstituted oxindole motifs are widely present in natural products and 
pharmaceutical compounds.90 Due to the significance of the oxindole scaffolds, many 
methods have been developed for the synthesis of chiral 3,3’-disubstituted oxindoles 
(Figure 3.1). Utilization of isatins as a precursor to obtain versatile oxindole 
compounds has become an important approach for constructing oxindole motifs. The 
nucleophilicity of 3-substituted oxindole has been well realized and utilized in the 
organocatalytic asymmetric reactions.34, 37 Our group reported the asymmetric 
reaction of 3-substituted oxindole and vinyl sulfones employing multi-funcational 
catalysts derived from cinchona alkaloids and amino acids.91 The electrophilic 
approaches were also explored by several research groups.38 The MBH carbonates 
derived from isatins would serve as an ideal reaction partner to access 3,3’-
disubstituted oxindoles. The allylic substitution of MBH carbonates of isatins with 
-dicyanoalkene was reported by Chen and co-workers in 2010.36 The nucleophilic 
catalyst -isocupreidine promoted the reaction well, affording products with up to 
88% ee. This method provided the first example of organocatalytic asymmetric allylic 
substitution reaction using MBH carbonates derived from ketones. It was till 2012 
that other nucleophiles were successfully applied in the organocatalytic asymmetric 
allylic alkylation reaction with MBH carbonates of isatins. Chen and co-workers 
reported an asymmetric allylic alkylation of MBH carbonates with aliphatic 




The reaction could be slightly accelerated by the addition of 4Å molecular sieves and 
(R)-BINOL.  
 
Figure 3.1 Representative natural products and bioactive compounds with the 3,3’-
disubstituted oxindole framework 
Our group has developed several organocatalytic asymmetric reactions of MBH 
carbonates.92 To develop practical synthetic method, we reported the reaction of MBH 
carbonates and nitroalkanes in a proposed SN2’-SN2 mechanism, which has been well 
elaborated in the Chapter 2. The asymmetric reaction of MBH carbonates of isatins 
has attracted much attention, although nucleophiles employed in this type of reaction 
are very limited. There was no report on the application of nitroalkanes in the reaction 
with MBH carbonates. In this thesis, we investigated asymmetric allylic alkylation of 
MBH carbonates of isatins and nitroalkanes. The products of MBH carbonates of 
isatins and nitroalkanes could be derived to interesting structural motifs which may be 
important in medicinal chemistry or pharmaceutical industry. 
 
Scheme 3.1 Research plan for the asymmetric reaction of MBH carbonates of isatin 
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Herein, we will discuss the organocatalytic asymmetric reaction of MBH 
carbonates of isatins and nitroalkanes. Based on the successful reaction of MBH 
carbonates and nitroalkanes catalyzed by tertiary amine-thiourea catalyst, both types 
of products were our target molecules (Scheme 3.1). 
3.2 Results and Discussion 
3.2.1 Preliminary Screening 
The reaction of MBH carbonates with nitroalkanes was examined in the presence 
of the tertiary amine-thiourea catalyst derived from quinidine and the -selective 
products were obtained in high regioselectivity and enantioselectivity. We first 
planned to test the reaction of isatin-derived MBH carbonates with nitroalkane using 
the same catalytic system to afford the -selective product with oxindole scaffold. 
The reaction of MBH carbonate 3-1a derived from N-methylisatin with nitroethane 
was examined in the  presence of tertiay amine-thiourea catalyst 2-C1. However, only 
starting material MBH carbonates  could be seen from TLC even the reaction mixture 
was heated to 50 ℃for two days (Scheme 3.2). We reasoned that the big steric 
hindrance of quinidine scaffold and isatin unit suppress the first step of nucleophilic 
addition of catalyst 2-C1 to MBH carbonate 3-6. Then we decided to use other 
tertiary amine-thiourea catalysts with less rigid scaffold such as Takemoto’s catalyst 
in the asymmetric reaction of MBH carbonate 3-1a and nitroethane. However, the 
same result was obtained. This may indicate that the steric hindrance of isatin unit 





Scheme 3.2 Preliminary screening of asymmetric reaction of isatin-derived MBH 
carbonate with nitroethane 
Other nucleophilic catalysts were also tested in the reaction of MBH carbonates 
of isatin with nitroalkanes. Nitromethane which is more nucleophilic than nitroethane 
was chosen in the reaction of MBH carbonate 3-1a derived from N-methylisatin. 
When other catalysts such as quinindine, catalyst 2-C2, were applied in the reaction, 
the same results were obtained. This also may be caused by the big steric hindrance. 
The other type of catalyst -isocupreidine which has been found effective in the 
asymmetric catalytic MBH reaction of isatin and acrylate with high enantioselectivity 
could catalyze the asymmetric allylic amination reaction of MBH carbonate to afford 
-selective product. The reaction of compound 3-1a and nitromethane proceeded 
smoothly under the condition of -isocupreidine 3-C1 at room temperature in less 
than one day. The compound 3-3a was obtained with high regioselectivity, moderate 
yield and high enantioselectivity (Scheme 3.3). The starting material 3-1a was 
consumed completely and other by-products could not be identified. Futhermore, 
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isatin-derived MBH carbonates with different protecting group were used in this 
reaction. When MBH carbonates derived N-Boc isatin was used in the asymmetric 
allylic alkylation reaction with nitromethane, no desired product could be obtained. 
The MBH carbonates derived from N-Bn isatin was used in the same condition and 
the allylic substitution product was obtained with fair yield and good 
enantioselectivity (33%, 86% ee).  
 
Scheme 3.3 Preliminary screening of asymmetric reaction of isatin-derived MBH 
carbonate with nitromethane 
3.2.2 Reaction Optimization 
Further study has been done due to the highly enantioselective allylic 
substitution of isatin-derived MBH carbonates with nitromethane. To improve the 
reaction yield, the reaction concentration, catalyst loading and solvent were screened 
consecutively.  Lowering the catalyst loading could decrease the reaction rate and the 
yield and selectivity of major product 3-3a dropped (Table 3.1, entry 1, 2 and 3). 
Decreasing the concentration of the reaction mixture could generate the desired 
product 3-3a with the same yield and higher enantioselectivity. Increasing the 
concentration would decrease both yield and enantioselectivity (Table 3.1, entry 1, 4 
and 5). It seems that the yield and enantioselectivity of the compound 3-3a could not 
be improved by simple adjustment of concentration and catalyst loading. Then 




diethyl ether could provide the product 3-3a with the similar yield but lower 
enantioselectivity (Table 3.1, entry 6). The reaction using dichloromethane or 
chloroform could afford the product 3-3a with lower yield and lower 
enantioselectivity (Table 3.1, entry 7 and 8). Small polar solvent such as toluene also 
coud not provide the good result (Table 3.1, entry 9). The strong polar solvent DMF 
and polar protic solvent MeOH could give the compound 3-3a with both lower yield 
and lower enantioselectivity (Table 3.1, entry 10 and 11). 
Table 3.1 Optimization of asymmetric allylic substitution of MBH carbonate of isatin 
with nitromethane  
 
 
Entry concentration (mol/L) 
Catalyst 
loading (%) solvent Yield (%)
c ee (%)d 
1 0.25 10 THF 68 90 
2d 0.25 5 THF 51 89 
3d 0.25 1 THF 28 74 
4 0.50 10 THF 32 86 
5 0.13 10 THF 68 92 
6 0.25 10 Et2O 68 83 
7 0.25 10 CH2Cl2 55 81 
8 0.25 10 CH3Cl 50 65 
9 0.25 10 toluene 68 85 
10 0.25 10 DMF 17 <60 
11 0.25 10 MeOH <10 64 
a Reactions were conducted with 3-1a (0.025 mmol), nitromethane (0.25 mmol) and the 
catalyst (x mol%) at room temperature for one day. b Isolated yield. c The ee value was 
determined by HPLC analysis on a chiral stationary phase. d The reaction proceeded for two 
days. 
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It seems that the reaction yield could not be improved under the catalyst 3-C1. 
Other nucleophilic catalysts were also tested in the asymmetric allylic substitution 
reaction (Scheme 3.4). (DHQD)2AQN which was successful in many asymmetric 
allylic substitution reaction was utilized in the asymmetric reaction of MBH carbonate 
of isatin 3-1a and nitromethane. The reaction could not proceed which would be 
expected as the steric hindrance between catalyst and substrate 3-1a. The thiourea 
catalyst 3-C2 derived from 3-C1 could give better yield of the desire product 3-3a (90, 
79% ee). However the enantioselectivity was dropped a lot. For further study, we 
chose the catalyst 3-C1 as the best catalyst and THF as the best solvent. 
 
Scheme 3.4 Catalyst screening of asymmetric reaction of MBH carbonate of isatin 
with nitromethane 
3.2.3 Substrate Scope 
With the optimized reaction conditions in hand, the substrate scope of MBH 
carbonate 3-1a derived from isatin was studied in the reaction with nitromethane 
(Table 3.2). The MBH carbonate 3-1 with different substituent was used in the 




containing substituent on the oxindole ring at 5-position would be suitable substrate in 
this asymmetric allylic substitution reaction with nitromethane. The desired product 
3-3 could be obtained with reasonable yield and good enantioselectivity (Table 3.2, 
entry 2, 3, 4 and 5). However, the reaction of MBH carbonate 3-1g with a 5-nitro 
substituent and nitromethane could not provide the desired product 3-3g and the 
complicated result would be observed (Table 3.2, entry 7). The good electron 
withdrawing property result in the good reactive of the MBH carbonate 3-1g which 
could be too reactive to obtain the desired product. The 7-substituent on the MBH 
carbonate could also not provide the desired allylic product and messy reaction was 
observed (Table 3.2, entry 8 and 9). The good reactivity of substrate 3-3h and 3-3i 
caused the complicated reaction of MBH carbonate and nitromethane under the 
catalyst 3-C1. Moreover, the MBH carbonate 3-3f with 5,7-dimethyl substituent could 
provide the desired product 3-3f with moderate yield and good enantioselectivity.  
Table 3.2 Enantioselective allylic substitution reactions of MBH carbonate 3-1 with 
nitromethanea 
 
Entry R Product Yield (%)b ee (%)c 
1 H 3-3a 68 92 
2d 5-F 3-3b 81 88 
3 5-Cl 3-3c 52 95 
4 5-Br 3-3d 65 92 
5 5-MeO 3-3e 50 90 
6d 5,7-Dimethyl 3-3f 50 88 
7e 5-NO2 3-3g - - 
8e 7-F 3-3h - - 
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9e 7-Cl 3-3i - - 
a Unless otherwise specified, reactions were conducted with 3-1 (0.025 mmol), 
nitromethane (0.25 mmol) and  3-C1 (10 mol%) in THF (0.2 mL) at room temperature. b 
Isolated yield. c The ee value was determined by HPLC analysis on a chiral stationary 
phase. d The solvent was used in 0.1 mL. eNo desired product. 

Although the yield of the asymmetric allylic alkylation reaction of MBH 
carbonate derived from isatin and nitromethane was not satisfying, the 
enantioselectivity was good. The reason for the low yield may be that the reactivity of 
nitromethane and MBH carbonate was too good to form byproducts. Less reactive 
nitroalkane was examined in the allylic substitution reaction of MBH carbonate of 
isatin. Considering that the increased stereocenter would cause more stereoisomer, we 
decided to use 2-nitropropane as substrates in the reaction with MBH carbonate 3-1a. 
The reaction could not go due to the steric hindrance which would generate in the 
process of forming the product 3-2a. The low acidity of -proton of 2-nitropropane 
may also suppress the reaction with MBH carbonate 3-1a. Therefore nitroethane was 
utilized in the asymmetric allylic substitution reaction of MBH carbonate of isatin. 
The reaction of MBH carbonate 3-1a and nitroethane was firstly examined under the 
catalyst 3-C1. The reaction could proceed with full conversion (90% conversion from 
crude 1H-NMR), low diastereoselectivity, high regioselectivity and enantioselectivity. 
The two diastereomer 3-2a and 3-2a’ could be separated easily by simple column 
chromatography. The major isomer 3-2a was tested with reasonable yield and high 
enantioselectivity (Table 3.2, entry 1). The minor isomer 3-2a’ was also obtained with 
33% yield and 91% ee. Other MBH carbonates of isatin were also useful under this 
catalytic system. The MBH carbonate of isatin with 5-substituent could provide the 
desired product with high enantioselectivity except the 5-nitro substituted MBH 




provide desired product. In the reaction of MBH carbonate 3-1g and nitroethane, the 
nitro substituent may interact with the catalyst which would result in the messy 
reaction. Other 5-substituted MBH carbonate of isatin would provide the product with 
low diastereoselectivity and high enantioselectivity. As expected, 5,7-dimethyl 
substituted substrate 3-1f would react with nitroethane to afford the product with 
excellent conversion, low diastereoselectivity and high enantioselectivity (Table 3.2, 
entry 6). The 7-substituent of MBH carbonate of isatin was also applicable in the 
reaction with nitroethane under the catalyst 3-C1. The desired product could be 
obtained with excellent conversion, low diastereoselectivity and high 
enantioselectivity (Table 3.2, entry 8 and 9). In contrast with 5-substituted MBH 
carbonate, the enantioselectivity was slightly decreased. It should be noted that the 
diastereoselectivity was the same for all the asymmetric allylic alkylation reaction (d.r. 
= 2:1). All the diastereomers generated from each reaction could be sepereated easily 
by column chromatography. 
Table 3.3 Enantioselective allylic substitution reaction of MBH carbonates 3-1 with 
nitroethanea 
 
Entry R Yield (%)b d.r.c ee (%)d 
1 H 66 2:1 90/91 
2 5-F 54 2:1 89/89 
3 5-Cl 54 2:1 89/87 
4 5-Br 55 2:1 89/89 
5 5-MeO 57 2:1 90/85 
6 5,7-Dimethyl 55 2:1 90/89 
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7 5-NO2 - - - 
8 7-F 50 2:1 87/86 
9 7-Cl 62 2:1 84/81 
a Unless otherwise specified, reactions were conducted with 3-1 (0.025 mmol), 
nitromethane (0.25 mmol) and  3-C1 (10 mol%) in THF (0.1 mL) at room temperature. b 
Isolated yield of major isomer. c The diastereoselectiuvity was determined by crude 1H-
NMR. d The ee value was determined by HPLC analysis on a chiral stationary phase.  
 
Moreover, we intended to explore the substrate scope with other nitroalkanes. 
Nitropropane was chose to react with MBH carbonate 3-1a under the catalyst 3-C1. 
The sluggish reaction happened when nitropropane and nitrobutane were used. The 
neat condition was used in the reaction of MBH carbonate and nitropropane (Scheme 
3.5). The reaction of MBH carbonate 3-1a and nitropropane (50 equivalents) could 
provide the compound 3-4a with full conversion under neat condition. The product 
(3-4a) could be obtained with high yield, high diastereoselectivity and high 
enantioselectivity. The MBH carbonate with 5-Methoxyl substituent was used in the 
reaction with nitropropane to afford the product 3-4e. The best diastereoselectivity 
was achieved in this asymmetric allylic alkylation reaction. The compound 3-4e was 
obtained with high yield, high diastereoselectivity and high enantioselectivity. In the 
contrast, 5-bromo substituted MBH carbonate 3-1d would provide the allylic product 
with full conversion, low diastereoselectivity and high enantioselectivity. The reaction 
of MBH carbonate and nitropropane catalyzed by bifuncational catalyst 3-C1 possess 
good reactivity and good enantioselectivity under the neat condition. The substrate 
with electron donating substituent on the 5 position could give the product with high 
diastereoselectivity. The substrate with halogen substituent on the 5 position could 





Scheme 3.5 Asymmetric allylic substitution reaction of MBH carbonates of isatin 
with nitropropane 
3.2.4 Synthetic Utility 
The product of asymmetric allylic alkylation of MBH carbonate and nitroalkane 
could be transforedm to a spirocyclic oxindole compound, which possesses interesting 
structure and may be potentially useful in medicinal chemistry. 76, 90 The compound 3-
5 could be achieved by simple treatment of asymmetric allylic alkylation product 3-3a 
using Zn/HOAc (Scheme 3.5).  
 
Scheme 3.5 Preparation of a spirocyclic oxindole derivative 
The absolute configuration of the chiral allylic product was determined by the 
analysis of single crystal of compound 3-4d. The X-ray diffraction experiment 
showed that the absolute configuration of compound 3-4d was (R, R). The absolute 
configuration of other allylic products 3-2, 3-3, and 3-4 was determined by the 
analogy of compound 3-4d.  
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3.2.5 Plausible Reaction Mechanism  
Since the asymmetric allylic alkylation reaction of MBH carbonate of isatin and 
nitroalkanes was successfully developed, the reaction mechanism was proposed 
(Scheme 3.6). The asymmetric allylic substitution reaction of MBH carbonate has 
been well explored under the tertiary amine catalyst derived from cinchona alkaloid 
and the well accepted mechanism was a SN2’-SN2’ process. Herein, we also proposed 




































Scheme 3.7 Proposed mechanism of asymmetric allylic substitution reaction of isatin-
derived MBH carbonates with nitroalkane 
The nucleophilic catalyst 3-C1 could attack the carbon-carbon double bond of 
MBH carbonate 3-1a. A SN2’ reaction occurred and dicarbon oxide and tert-butyl 




deprotonated by the Brønsted base tert-butyl oxide ion. With the assistance of 
hydrogen bonding between hydroxyl group on catalyst and nitro group, the 
nucleophilic nitromethane could attack the activated MBH carbonate. The catalyst 3-
C1 could be regenerate after a second SN2’ and the product 3-3a was formed. 
The π-π stacking effect could exist between nucleophilic catalyst 3-C1 and MBH 
carbonate 3-1 which may benefit the good reactivity. The nucleophile nitromethane 
could attack from the front side of isatin due to the catalyst configuration and hydron 
bonding which result in the R configuration of the product 3-3a. For other 
nucleophiles, the absoluate configuration at 3 position of oxindole was also R 
configuration. The diastereoselectivity may be mainly influenced by the electron 
property of MBH carbonate 3-1. The less stereocontrol of the prochiral center 
nitroethane may also the reason for low diatereoselectivity. 
3.3 Conclusions 
In summary, we have developed a new organocatalytic asymmetric allylic 
alkylation reaction of MBH carbonate derived from isatin. The reaction of MBH 
carbonate 3-1 and nitroalkane would occur under the bifunctional catalyst 3-C1 
derived from cinchona alkaloid. The allylic alkylation product 3-2, 3-3, 3-4 could be 
obtained with moderate to high yield, low to high diastereoselectivity and high 
enantioselectivity. The allylic product 3-3a with oxindole scaffold could easily 
transform to the spiro compound 3-5 under reducing condition without impairing the 
enantioselectivity. The spiro compounds could be potentially useful in medicinal 
chemistry because there are wide existence of biologically active molecules with 
spirooxindole motif in nature and pharmaceutical industry. 
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3.4 Experimental Section 
3.4.1 General Methods 
        All the starting materials were obtained from commercial sources and used 
without further purification unless otherwise stated. Toluene, THF and diethyl ether 
were dried and distilled from sodium benzophenone ketyl prior to use. CHCl3 and 
CH2Cl2 were distilled from CaH2 prior to use. 1H and 13C NMR spectra were recorded 
on a Bruker ACF300 or AMX500 (500 MHz) spectrometer. Chemical shifts were 
reported in parts per million (ppm), and the residual solvent peak was used as an 
internal reference: proton (chloroform δ 7.26), carbon (chloroform δ 77.0). 
Multiplicity was indicated as follows: s (singlet), d (doublet), t (triplet), q (quartet), m 
(multiplet), dd (doublet of doublet), br s (broad singlet). Coupling constants were 
reported in Hertz (Hz). Low resolution mass spectra were obtained on a 
Finnigan/MAT LCQ spectrometer in EI mode, and all high resolution mass spectra 
were obtained on a Finnigan/MAT 95XL-T spectrometer. For thin layer 
chromatography (TLC), Merck pre-coated TLC plates (Merck 60 F254) were used, 
and compounds were visualized with a UV light at 254 nm. Further visualization was 
achieved by staining with KMnO4, iodine, or ceric ammonium molybdate followed by 
heating on a hot plate. Flash chromatographic separationswere performed on Merck 
60 (0.040–0.063 mm) mesh silica gel. The enantiomeric excesses of products were 
determined by HPLC analysis on a chiral stationary phase. 
The MBH carbonates 3-1 were prepared according to the similar procedure of 

















Scheme 3.8 Synthesis of catalyst 3-C1 
To the solution of quinidine (1.62 g, 5.0 mmol) in phosphoric acid (25 mL) was 
added potassium bromide (5.95 g, 5.0 mmol) at room temperature. The reaction 
mixture was then heated to 100℃ and stirred for 10 days. To the solution was slowly 
added 25% KOH at 0 ℃ . The reaction mixture was acidified to PH = 5 using 
concentrate HCl, and then neutralized with aqueous ammoniua to PH = 8. The 
resulting solution was extracted with CHCl3 (100 mL) for three times. The combined 
organic layer was washed with water, brine and dried with anhydrous Na2SO4. After 
filtration, the organic solvent was removed under reduced pressure. The residue was 
purified by column chromatography on silica gel to afford the white solid as the 
compound 3-C1 (821 mg, 53%). 
3.4.3 Preparation of MBHcarbonates of isatin 




Scheme 3.9 Preparation of MBH carbonate of isatin 
The representative procedure of synthesis of MBH carbonate 3-1a was described 
as following (Scheme 3.8). Other MBH carbonates 3-1 were prepared in the same 
method. 
To isatin (147 mg, 1.0 mmol) in 5 mL anhydrous DMF was added sodium 
hydride (60% dispersion in oil, 48 mg, 1.2 mmol) in one portion at 0℃. The reaction 
mixture was stirred for 5 min. Then iodomethane (0.09 mL, 1.5 mmol) was added to 
the reaction mixture. After 30 min, the reaction mixture was poured into saturated 
NH4Cl and extracted with EtOAc (4 × 10 mL). The combined organic layer was 
washed with water and brine, and dried with anhydrous Na2SO4. The product N-
methyl isatin could be obtained with enough purity after removing the solvent under 
reduced pressure.  
The N-methyl isatin was mixed with methyl acrylate (0.10 mL, 1.0 mmol) and 
DABCO (112 mg, 0.1 mmol) in 0.2 mL THF. The reaction mixture was stirred at 
room temperature for 6 days. After removing solvent under reduced pressure, the 
residue was purified by column chromatography on silica gel to afford the MBH 
product (240 mg, 97%).  




butyl dicarbonate (0.28 mL, 1.2 mmol) and DMAP (5.9 mg, 0.049 mmol) in 2 mL dry 
CH2Cl2 by dropwise at  0 ℃. After the addition was complete, the reaction mixture 
was allowed to warm to room temperature and stirred overnight. The solvent was 
removed under reduced pressure. The residue was directly purified by column 
chromatography on silica gel to afford the product MBH carbonate 3-1a (230 mg, 
68%). 
3.4.4 Analytical Data of MBHcarbonates of isatin 
Methyl 2-(3-((tert-butoxycarbonyl)oxy)-1-methyl-2-oxoindolin-3-yl) acrylate 3-1a 
 
A white solid; 1H NMR (500 MHz, CDCl3) δ 1.34 (s, 9H), 3.29 (s, 3H), 3.57 (s, 
3H), 6.53 (s, 1H), 6.56 (s, 1H), 6.85 (m, 1H), 6.98-7.01 (m, 1H), 7.17-7.18 (m, 1H), 
7.32-7.35 (m, 1H); 13C NMR (125 MHz, CDCl3) δ 26.7, 27.5, 52.0, 83.4, 108.2, 122.4, 
123,3, 126.5, 128.5, 130.5, 136.5, 145.8, 149.8, 164.0, 172.6; HRMS-ESI calcd for 




A white solid; 1H NMR (300 MHz, CDCl3) δ 1.36 (s, 9H), 3.28 (s, 3H), 3.59 (s, 
3H), 6.53 (s, 1H), 6.58 (s, 1H), 6.76-6.80 (m, 1H), 6.94-7.26 (m, 2H); 13C NMR (75 
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MHz, CDCl3) δ 26.9, 27.5, 52.1, 83.7, 108.7, 108.8, 111.4, 111.8, 116.4, 116.7, 129.1, 
136.0, 141.8, 149.8, 163.8, 172.4; HRMS-ESI calcd for [M+Na] C18H20FNNaO6, 




A white solid; 1H NMR (300 MHz, CDCl3) δ 1.36 (s, 9H), 3.28 (s, 3H), 3.59 (s, 
3H), 6.55 (s, 1H), 6.59 (s, 1H), 6.78-6.79 (m, 1H), 7.14-7.15 (m, 1H), 7.29-7.32 (m, 
1H); 13C NMR (75 MHz, CDCl3) δ 26.8, 27.6, 52.1, 79.3, 83.7, 109.2, 123.8, 127.6, 
128.1, 129.1, 130.3, 136.0, 144.5, 149.8, 163.8, 172.3; HRMS-ESI calcd for [M+Na] 




A white solid; 1H NMR (300 MHz, CDCl3) δ 1.37 (s, 9H), 3.27 (s, 3H), 3.60 (s, 
3H), 6.55 (s, 1H), 6.60 (s, 1H), 6.72-6.75 (m, 1H), 7.27-7.28 (m, 1H), 7.44-7.47 (m, 
1H); 13C NMR (75 MHz, CDCl3) δ 26.8, 27.6, 52.1, 83.8, 109.7, 114.8, 126.4, 128.5, 









A light yellow solid; 1H NMR (500 MHz, CDCl3) δ 1.35 (s, 9H), 3.26 (s, 3H), 
3.57 (s, 3H), 3.75 (s, 3H), 6.51 (s, 1H), 6.55 (s, 1H), 6.74-6.76 (m, 1H), 6.80-6.86 (m, 
2H); 13C NMR (125 MHz, CDCl3) δ 26.8, 27.5, 52.0, 55.7, 70.5, 80.0, 83.4, 108.5, 
110.8, 114.4, 123.5, 127.6, 128.6, 136.4, 139.2, 149.7, 155.8, 163.9, 172.3; HRMS-
ESI calcd for [M+Na] C19H23NNaO7, 400.1367, found: 400.1376. 
Methyl 2-(3-((tert-butoxycarbonyl)oxy)-1,5,7-trimethyl-2-oxoindolin-3-yl) acrylate 3-
1f 
 
A yellow solid; 1H NMR (300 MHz, CDCl3) δ 1.35 (s, 9H), 2.22 (s, 3H), 2.53 (s, 
3H), 3.53 (s, 3H), 3.58 (s, 3H), 6.51 (s, 1H), 6.53 (s, 1H), 6.80 (s, 1H), 6.85 (s, 1H); 
13C NMR (75 MHz, CDCl3) δ 18.9, 20.7, 27.6, 30.2, 52.0, 83.1, 119.4, 121.9, 127.1, 
128.1, 131.7, 134.7, 137.0, 141.1, 149.7, 164.0, 173.5; HRMS-ESI calcd for [M+Na] 
C20H25NNaO6, 398.1574, found: 398.1571. 
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Methyl 2-(3-((tert-butoxycarbonyl)oxy)-5-nitro-1-methyl-2-oxoindolin-3-yl) acrylate 
3-1g 
 
A yellow solid; 1H NMR (300 MHz, CDCl3) δ 1.36 (s, 9H), 3.36 (s, 3H), 3.60 (s, 
3H), 6.65 (s, 1H), 6.67 (s, 1H), 6.92-6.94 (m, 1H), 8.03-8.04 (m, 1H), 8.31-8.33 (m, 
1H); 13C NMR (75 MHz, CDCl3) δ 27.1, 27.5, 52.2, 78.4, 84.3, 107.8, 119.1, 127.6, 
127.7, 129.9, 135.5, 143.2, 149.9, 151.7, 163.8, 172.3; HRMS-ESI calcd for [M+Na] 




A light yellow solid; 1H NMR (300 MHz, CDCl3) δ 1.35 (s, 9H), 3.50 (s, 3H), 
3.59 (s, 3H), 6.55 (s, 1H), 6.57 (s, 1H), 6.89-7.26 (m, 3H); 13C NMR (75 MHz, CDCl3) 
δ 27.5, 29.3, 52.1, 79.4, 83.8, 118.5, 118.8, 119.0, 119.1, 123.0, 128.8, 136.2, 149.2, 








A white solid; 1H NMR (300 MHz, CDCl3) δ 1.35 (s, 9H), 3.59 (s, 3H), 3.64 (s, 
3H), 6.55 (s, 1H), 6.57 (s, 1H), 6.87-6.92 (m, 1H), 7.02-7.05 (m, 1H), 7.23-7.26 (m, 
1H); 13C NMR (75 MHz, CDCl3) δ 27.5, 30.1, 52.1, 79.0, 83.7, 115.6,121.7, 123.1, 
128.8, 129.3, 132.8, 136.2, 141.8, 149.6, 163.8, 173.1; HRMS-ESI calcd for [M+Na] 
C18H20ClNNaO6, 404.0871, found: 404.0887. 
3.4.5 Representative Procedure of Reaction of MBH Carbonates of 
Isatin with Nitroalkanes 
 
Scheme 3.10 Representative procedure for reaction of MBH carbonates of isatin with 
nitroethanes  
The representative procedure of asymmetric allylic alkylation reaction of MBH 
carbonate 3-1 and nitroalkanes was described as following (Scheme 3.8). To MBH 
carbonate 3-1a (8.7 mg, 0.025 mmol) derived from isatin in 0.25 mL dry THF was 
added catalyst 3-C1 (0.8 mg, 0.0025 mmol) and nitroethane (18 μL, 0.25mmol) at 
room temperature. After the compound 3-1a was completely consumed, the reaction 
was stopped. The solvent was removed under reduced pressure. The 
diastereoselectivity was determined by 1H-NMR analysis of the residue. Then the 
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residue was purified by column chromatography on silica gel to afford the desired 
product 3-2a (5.0 mg, 66%) and 3-2a’ (2.5 mg, 33%). 
3.4.6 Analytical Data of Products 
(R)-methyl 2-(1-methyl-3-(nitromethyl)-2-oxoindolin-3-yl)acrylate 3-3a 
 
A light yellow solid; 68% yield; [α]D25 = +105 (c = 0.13, CHCl3); 92% ee, 
determined by HPLC analysis [Daicel Chiralpak IA, n-hexane/i-PrOH = 90/10, 1.0 
mL/min, λ = 254 nm, t (major) = 12.4 min, t (minor) = 16.1 min]; 1H NMR (500 MHz, 
CDCl3) δ 3.30 (s, 3H), 3.71 (s, 3H), 5.11-5.14 (d, J = 13.3 Hz, 1H), 5.46-5.49 (d, J = 
13.3 Hz, 1H), 5.85 (s, 1H), 6.39 (s, 1H), 6.88-6.90 (m, 1H), 7.04-7.06 (m, 1H), 7.32-
7.40 (m, 2H); 13C NMR (125 MHz, CDCl3) δ 26.9, 52.4, 54.1, 108.9, 123.0, 124.4, 
126.5, 128.5, 129.7, 144.3, 165.4, 174.4; HRMS-ESI calcd for [M+Na] 
C14H14N2NaO5, 313.0795, found: 313.0795. 
(R)-Methyl 2-(5-fluoro-1-methyl-3-(nitromethyl)-2-oxoindolin-3-yl) acrylate 3-3b 
 
A light yellow solid; 42% yield; [α]D25 =+11.7 (c = 0.51, CHCl3); 90% ee, 
determined by HPLC analysis [Daicel Chiralpak IC, n-hexane/i-PrOH = 90/10, 1.0 




CDCl3) δ 3.30 (s, 3H), 3.75 (s, 3H), 5.07-5.10 (d, J = 13.5 Hz, 1H), 5.49-5.52 (d, J = 
14.3 Hz, 1H), 6.44 (s, 1H), 6.81-6.83 (m, 1H), 7.02-7.06 (m, 1H), 7.22-7.24 (m, 1H); 
13C NMR (125 MHz, CDCl3) δ 27.0, 29.7, 52.5, 54.5, 109.3, 109.4, 112.9, 113.1, 
113.3, 115.9, 116.1, 118.8, 129.2, 135.5, 165.3; HRMS-ESI calcd for [M+Na] 
C14H13FN2NaO5, 331.0701, found: 331.0708. 
 (R)-Methyl 2-(5-chloro-1-methyl-3-(nitromethyl)-2-oxoindolin-3-yl) acrylate 3-3c 
 
A light yellow solid; 40% yield; [α]D25 = +53.0 (c = 0.37, CHCl3); 90% ee, 
determined by HPLC analysis [Daicel Chiralpak IC, n-hexane/i-PrOH = 90/10, 1.0 
mL/min,, λ = 254 nm, t (major) = 26.6 min, t (minor) = 36.7 min]; 1H NMR (500 
MHz, CDCl3) δ 3.30 (s, 3H), 3.75 (s, 3H), 5.08-5.10 (d, J = 13.9 Hz 1H), 5.46-5.49 (d, 
J = 13.9 Hz, 1H), 5.88 (s, 2H), 6.45 (s, 1H), 7.22-7.33 (m, 2H), 7.42 (s, 1H); 13C 
NMR (125 MHz, CDCl3) δ 27.0, 29.7, 52.6, 54.2, 109.8, 125.0, 128.4, 129.1, 129.7, 
135.5, 143.0, 165.1, 174.1; HRMS-ESI calcd for C14H13ClN2NaO5 347.0405, found: 
347.0407. 
  (R)-methyl 2-(5-bromo-1-methyl-3-(nitromethyl)-2-oxoindolin-3-yl)acrylate 3-3d 
 
A light yellow solid; 43% yield; [α]D25 = +14.2 (c = 0.43, CHCl3); 92% ee, 
determined by HPLC analysis [Daicel Chiralpak IC, n-hexane/i-PrOH = 90/10, 1.0 
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mL/min, λ = 254 nm, t (major) = 28.8 min, t (minor) = 50.3 min]; 1H NMR (500 MHz, 
CDCl3) δ 3.29 (s, 3H), 3.74 (s, 3H), 5.06-5.11 (d, J = 22.8 Hz, 1H), 5.44-5.49 (d, J = 
22.8 Hz, 1H), 5.88 (s, 1H), 6.46 (s, 1H), 6.76-6.79 (m, 1H), 7.45-7.48 (m, 1H), 7.54-
7.55 (m, 1H); 13C NMR (125 MHz, CDCl3) δ 26.8, 27.6, 52.1, 79.3, 83.7, 109.7, 
114.8, 126.5, 128.6, 129.0, 133.2, 136.1, 145.0, 149.8, 163.8, 172.2; HRMS-ESI calcd 
for [M+Na] C14H1379BrN2NaO5 and C14H1381BrN2NaO5, 390.9900 and 392.9880, 
found: 390.9910 and 392.9881. 
 (R)-Methyl 2-(5-methoxy-1-methyl-3-(nitromethyl)-2-oxoindolin-3-yl)acrylate 3-3e 
 
A light yellow solid; 50% yield; [α]D25 = +21.2 (c = 0.42, CHCl3); 89% ee, 
determined by HPLC analysis [Daicel Chiralpak IC, n-hexane/i-PrOH = 80/20, 1.0 
mL/min, λ = 254 nm, t (major) = 30.5 min, t (minor) = 53.3 min]; 1H NMR (500 MHz, 
CDCl3) δ 3.28 (s, 3H), 3.73 (s, 3H), 3.77 (s, 3H), 5.09-5.12 (d, J = 13.9 Hz, 1H), 5.46-
5.49 (d, J = 13.25 Hz, 1H), 5.86 (s, 1H), 6.40 (s, 1H), 6.78-6.80 (m, 1H), 6.84-6.86 (m, 
1H), 7.04-7.05 (m, 1H); 13C NMR (125 MHz, CDCl3) δ 27.0, 29.7, 52.4, 54.5, 55.8, 
109.2, 112.1, 113.9, 127.9, 128.7, 136.0, 137.7, 156.2, 165.4, 174.1; HRMS-ESI calcd 
for [M+Na] C15H16N2NaO6, 343.0901, found: 343.0911. 





A light yellow solid; 50% yield; [α]D25 = -279 (c = 0.01, CHCl3); 88% ee, 
determined by HPLC analysis [Daicel Chiralpak IC, n-hexane/i-PrOH = 80/20, 1.0 
mL/min, λ = 254 nm, t (major) = 21.5 min, t (minor) = 26.7 min]; 1H NMR (500 MHz, 
CDCl3) δ 2.24 (s, 3H), 2.53 (s, 3H), 3.54 (s, 3H), 3.71 (s, 3H), 5.12-5.15 (d, J = 13.9 
Hz, 1H), 5.34-5.37  (d, J = 13.9 Hz, 1H), 5.78 (s, 1H), 6.37 (s, 1H), 6.86 (s, 1H), 6.69 
(s, 1H); 13C NMR (125 MHz, CDCl3) δ 27.0, 29.7, 52.4; 54.5, 55.8, 109.2, 112.1, 
113.9, 12.9, 12.7, 1360, 17.7, 156.2, 1.4, 174.1; HRMS-ESI calcd for [M+Na] 
C16H18N2NaO5, 341.1108, found: 341.1098. 
Methyl 2-((R)-1-methyl-3-((R)-1-nitroethyl)-2-oxoindolin-3-yl)acrylate 3-2a 
 
A light yellow solid; 66% yield; [α]D25 = -72.1 (c = 0.10, CHCl3); 90% ee, 
determined by HPLC analysis [Daicel Chiralcel OD, n-hexane/i-PrOH = 95/5, 1.0 
mL/min, λ = 254 nm, t (minor) = 13.2 min, t (major) = 16.0 min]; 1H NMR (300 MHz, 
CDCl3) δ 1.70 (d, J = 7.1 Hz, 3H), 3.27 (s, 3H), 3.74 (s, 3H), 5.92 (s, 1H), 6.06-6.13 
(q, J = 7.1 Hz, 1H), 6.37 (s, 1H), 6.84-6.87 (m, 1H), 7.03-7.08 (m, 1H), 7.29-7.30 (m, 
1H), 7.32 (m, 1H); 13C NMR (125 MHz, CDCl3) δ 15.1, 26.6, 52.4, 56.9, 85.1, 108.6, 
123.0, 125.1, 126.9, 129.0, 129.5, 136.4, 143.9, 166.1, 173.7; HRMS-ESI calcd for 
[M+Na] C15H16N2NaO5, 327.0951, found: 327.0939. 
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Methyl 2-((R)-1-methyl-3-((S)-1-nitroethyl)-2-oxoindolin-3-yl)acrylate 3-2a’ 
 
A light yellow solid; 33% yield; [α]D25 = +22.6 (c = 0.23, CHCl3); 91% ee, 
determined by HPLC analysis [Daicel Chiralcel OD, n-hexane/i-PrOH = 95/5, 1.0 
mL/min, λ = 254 nm, t (minor) = 26.0 min, t (major) = 31.5 min]; 1H NMR (500 MHz, 
CDCl3) δ 1.48 (d, J = 6.9 Hz, 3H), 3.25 (s, 3H), 3.83(s, 3H), 5.62 (s, 1H), 6.03-6.07 (q, 
J = 6.9 Hz, 1H), 6.22 (s, 1H), 6.88-6.89 (m, 1H), 7.08-7.11 (m, 1H), 7.34-7.35 (m, 
1H), 7.37 (m, 1H).  
Methyl 2-((R)-5-fluoro-1-methyl-3-((R)-1-nitroethyl)-2-oxoindolin-3-yl)acrylate 3-2b 
 
A light yellow solid; 89% yield; [α]D25 = +37.1 (c = 0.56, CHCl3); 89% ee, 
determined by HPLC analysis [Daicel Chiralpak IC, n-hexane/i-PrOH = 90/10, 1.0 
mL/min, λ = 254 nm, t (major) = 12.9 min, t (minor) = 20.7 min]; 1H NMR (500 MHz, 
CDCl3) δ 1.71 (d, J = 7.0 Hz, 3H), 3.26 (s, 3H), 3.76 (s, 3H), 5.96 (s, 1H), 6.01-6.05 
(q, J = 6.9 Hz, 1H), 6.42 (s, 1H), 6.77-6.79(m, 1H), 7.01-7.05 (m, 1H), 7.31-7.33(m, 
1H); 13C-NMR (125 MHz, CDCl3) δ 15.2, 26.8, 52.6, 57.1, 85.1, 109.0, 109.1, 113.5, 
113.7, 115.7, 115.9, 129.7, 135.8, 139.9, 165.8, 173.5; HRMS-ESI calcd for [M+Na] 
C15H15FN2NaO5, 345.0863, found: 345.0858. 





A light yellow solid; 25% yield; [α]D25 = +11.6 (c = 0.37, CHCl3); 89% ee, 
determined by HPLC analysis [Daicel Chiralpak IC, n-hexane/i-PrOH = 80/20, 1.0 
mL/min, λ = 254 nm, t (major) = 32.7min, t (minor) = 56.3 min]; 1H NMR (500 MHz, 
CDCl3) δ 1.43 (d, J = 7.0 Hz, 3H), 3.25 (s, 3H), 3.84 (s, 3H), 5.65 (s, 1H), 5.99-6.03 
(q, J = 7.0 Hz, 1H), 6.27 (s, 1H), 6.80-6.83 (m, 1H), 7.05-7.09 (m, 1H), 7.37-7.39 (m, 
1H). 
Methyl 2-((R)-5-chloro-1-methyl-3-((R)-1-nitroethyl)-2-oxoindolin-3-yl)acrylate 3-2c 
 
A light yellow solid; 54% yield; [α]D25 = +24.2 (c = 0.73, CHCl3); 89% ee, 
determined by HPLC analysis [Daicel Chiralpak IC, n-hexane/i-PrOH = 90/10, 1.0 
mL/min, λ = 254 nm, t (major) = 12.1 min, t (minor) = 20.0 min]; 1H NMR (500 MHz, 
CDCl3) δ 1.72 (d, J = 7.0 Hz, 3H), 3.26 (s, 3H), 3.76 (s, 3H), 5.95 (s, 1H), 5.99-6.03 
(q, J = 6.9 Hz, 1H), 6.43 (s, 1H), 6.78 (m, 1H), 7.29-7.31 (m, 1H), 7.51 (m, 1H); 13C 
NMR (125 MHz, CDCl3) δ 15.2, 26.8, 52.6, 56.8, 85.1, 109.5, 125.6, 129.5, 129.7, 
135.8, 142.4, 165.7, 173.4; HRMS-ESI calcd for [M+Na] C15H15ClN2NaO5, 361.0562, 
found: 361.0557. 
Methyl 2-((R)-5-chloro-1-methyl-3-((S)-1-nitroethyl)-2-oxoindolin-3-yl)acrylate 3-2c’ 




A light yellow solid; 25% yield; [α]D25 = +33.7 (c = 0.46, CHCl3); 87% ee, 
determined by HPLC analysis [Daicel Chiralpak IC, n-hexane/i-PrOH = 80/20, 1.0 
mL/min, λ = 254 nm, t (major) = 30.3 min, t (minor) = 51.2 min]; 1H NMR (500 MHz, 
CDCl3) δ 1.46 (d, J = 7.0 Hz, 3H), 3.25 (s, 3H), 3.84 (s, 3 H), 5.64 (s, 1 H), 5.98-6.02 
(q, J = 7.0 Hz, 1H), 6.27 (s, 1 H), 6.81-6.82 (m, 1 H), 7.33-7.35 (m, 1 H), 7.56-7.57 
(m, 1 H).  
Methyl 2-((R)-5-bromo-1-methyl-3-((R)-1-nitroethyl)-2-oxoindolin-3-yl)acrylate 3-2d 
 
A light yellow solid; 55% yield; [α]D25 = +24.4 (c = 0.59, CHCl3); 89% ee, 
determined by HPLC analysis [Daicel Chiralpak IC, n-hexane/i-PrOH = 90/10, 1.0 
mL/min, λ = 254 nm, t (major) = 12.5 min, t (minor) = 20.7 min]; 1H NMR (500 MHz, 
CDCl3) δ 1.72 (d, J = 7.0 Hz, 3H), 3.26 (s, 3H), 3.76 (s, 3H), 5.95 (s, 1H), 5.97-6.02 
(q, J = 7.0 Hz, 1H), 6.42 (s, 1H), 6.72-6.74 (m, 1H), 7.44-7.46 (m, 1H), 7.6-7.65 (m, 
1H); 13C NMR (125 MHz, CDCl3) δ 15.2, 26.8, 52.6, 56.8, 85.1, 110.0, 115.6, 128.3, 
129.6, 132.4, 135.9, 143.0, 165.7, 173.4; HRMS-ESI calcd for [M+Na] 








A light yellow solid; 25% yield; [α]D25 = -58.2 (c = 0.44, CHCl3); 89% ee, determined 
by HPLC analysis [Daicel Chiralpak IC, n-hexane/i-PrOH = 80/20, 1.0 mL/min, λ = 
254 nm, t (major) = 31.1 min, t (minor) = 51.7 min]; 1H NMR (500 MHz, CDCl3) δ 
1.46 (d, J = 6.3 Hz, 3H), 3.24 (s, 3H), 3.84 (s, 3H), 5.64 (s, 1H), 5.98-6.02 (q, J = 6.3 




A light yellow solid; 57% yield; [α]D25 = +15.0 (c = 0.34, CHCl3); 90% ee, 
determined by HPLC analysis [Daicel Chiralpak IC, n-hexane/i-PrOH = 80/20, 1.0 
mL/min, λ = 254 nm, t (major) = 15.8 min, t (minor) = 24.1 min]; 1H NMR (500 MHz, 
CDCl3) δ 1.68 (d, J = 6.9 Hz, 3H), 3.24 (s, 3H), 3.75 (s, 3H), 3.77 (s, 3H), 5.92 (s, 
1H), 6.04-6.08 (q, J = 6.9 Hz, 1H), 6.37 (s, 1H), 6.75-6.77 (m, 1H), 6.84-6.86 (m, 1H), 
7.13 (m, 1H); 13C NMR (125 MHz, CDCl3) δ 11.4, 21.4, 26.7, 29.7, 52.4, 55.8, 58.9, 
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90.3, 109.1, 113.3, 113.6, 127.8, 128.2, 137.0,137.3, 166.3, 172.8; HRMS-ESI calcd 




 A light yellow solid; 25% yield; [α]D25 = +11.3 (c = 0.31, CHCl3); 85%, 
determined by HPLC analysis [Daicel Chiralpak IC, n-hexane/i-PrOH = 70/30, 1.0 
mL/min, λ = 254 nm, t (major) = 40.3 min, t (minor) = 73.8 min]; 1H NMR (500 MHz, 
CDCl3) δ 1.44 (d, J = 7.0 Hz, 3H), 3.23 (s, 3H), 3.79 (s, 3H), 3.83 (s, 3H), 5.64 (s, 
1H), 6.00-6.04 (q, J = 7.0 Hz, 1H), 6.24 (s, 1H), 6.78-6.79 (m, 1H), 6.86-6.88 (m, 1H), 
7.21 (m, 1H). 
Methyl 2-((R)-1,5,7-trimethyl-3-((R)-1-nitroethyl)-2-oxoindolin-3-yl)acrylate 3-3f 
 
A light yellow solid; 55% yield; [α]D25 = +58.5 (c = 0.49, CHCl3); 90% ee, 
determined by HPLC analysis [Daicel Chiralpak IC, n-hexane/i-PrOH = 90/10, 1.0 
mL/min, λ = 254 nm, t (major) = 21.9 min, t (minor) = 38.8 min]; 1H NMR (500 MHz, 
CDCl3) δ 1.70 (d, J = 6.9 Hz, 3H), 2.25 (s, 3H), 2.51 (s, 3H), 3.51 (s, 3H), 3.74 (s, 
3H), 5.84 (s, 1H), 6.01-6.06 (q, J = 7.0 Hz, 1H), 6.34 (s, 1H), 6.84 (s, 1H), 7.05 (s, 




123.1, 128.6, 132.3, 133.8, 166.1, 174.5; HRMS-ESI calcd for [M+Na] 
C17H20N2NaO5, 355.1264, found: 355.1268. 
Methyl 2-((R)-1,5,7-trimethyl-3-((R)-1-nitroethyl)-2-oxoindolin-3-yl)acrylate 3-3f’ 
 
Minor isomer: 25% yield; [α]D25 = +18.6 (c = 0.26, CHCl3); 89% ee, determined 
by HPLC analysis [Daicel Chiralpak AD, n-hexane/i-PrOH = 70/30, 1.0 mL/min, λ = 
254 nm, t (major) = 9.3 min, t (minor) = 12.9 min]; 1H NMR (500 MHz, CDCl3) δ 
1.46 (d, J = 6.4 Hz, 3H), 2.28 (s, 3H), 2.52 (s, 3H), 3.50 (s, 3H), 3.82 (s, 3H), 5.59 (s, 
1H), 5.97-6.01 (q, J = 6.4 Hz, 1H), 6.20 (s, 1H),  6.87 (s, 1H), 7.16 (s, 1H). 
Methyl 2-((R)-7-fluoro-1-methyl-3-((R)-1-nitroethyl)-2-oxoindolin-3-yl)acrylate 3-3h 
 
A light yellow solid; 50% yield; [α]D25 = +111.7 (c = 0.36, CHCl3); 87% ee, 
determined by HPLC analysis [Daicel Chiralpak IC, n-hexane/i-PrOH = 90/10, 1.0 
mL/min, λ = 254 nm, t (major) = 9.8 min, t (minor) = 12.3 min]; 1H NMR (500 MHz, 
CDCl3) δ 1.73(d, J = 7.0 Hz, 3H), 3.49 (d, J = 2.5 Hz, 3H), 3.75 (s, 3H), 5.93 (s, 1H), 
6.03-6.07 (q, J = 7.0 Hz, 1H), 6.40 (s, 1H), 6.97-7.06 (m, 2H), 7.26 (m, 1H); 13C-
NMR (125MHz, CDCl3) δ 15.0, 29.1, 29.2, 29.7, 52.5, 85.2, 117.5, 117.6, 120.7, 
123.4, 129.4, 136.1, 146.8, 148.7, 165.8, 173.5; HRMS-ESI calcd for [M+Na] 
C15H15FN2NaO5, 345.0863, found: 345.0858. 
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Methyl 2-((R)-7-fluoro-1-methyl-3-((R)-1-nitroethyl)-2-oxoindolin-3-yl)acrylate 3-3h’ 
 
A light yellow solid; 25% yield; [α]D25 = -129.0 (c = 0.10, CHCl3); 86% ee, 
determined by HPLC analysis [Daicel Chiralpak IC, n-hexane/i-PrOH = 80/20, 1.0 
mL/min, λ = 254 nm, t (major) = 26.8 min, t (minor) = 48.4 min]; 1H NMR (500 MHz, 
CDCl3) δ 1.50 (d, J = 7.0 Hz, 3H), 3.47 (s, 3H), 3.82 (s, 3H), 5.61 (s, 1H), 6.00-6.04 
(q, J = 7.0 Hz, 1H), 6.25 (s, 1H), 7.00-7.11 (m, 2H), 7.31-7.32 (m, 1H). 
Methyl 2-((R)-7-chloro-1-methyl-3-((R)-1-nitroethyl)-2-oxoindolin-3-yl)acrylate 3-3i 
 
A light yellow solid; 62% yield; [α]D25 = +36.1 (c = 0.64, CHCl3); 84% ee, 
determined by HPLC analysis [Daicel Chiralpak IC, n-hexane/i-PrOH = 90/10, 1.0 
mL/min, λ = 254 nm, t (major) = 9.7 min, t (minor) = 11.2 min]; 1H NMR (500 MHz, 
CDCl3) δ 1.74 (d, J = 6.8 Hz, 3H), 3.65 (s, 3H), 3.74 (s, 3H), 6.02-6.06 (q, J = 6.8 Hz, 
1H), 6.41 (s, 1H), 6.93-6.97 (m, 1H), 7.23-7.25 (m, 1H), 7.35-7.37 (m, 1H); 13C NMR 
(125 MHz, CDCl3) δ 15.1, 30.1, 52.5, 56.3, 85.3, 116.0, 123.2, 123.6, 129.8, 131.9, 
136.1, 139.8, 165.8, 174.2; HRMS-ESI calcd for [M+Na] C15H15ClN2NaO5, 361.0562, 
found: 361.0557. 





A light yellow solid; 30% yield; [α]c = -20.8 (c = 0.50, CHCl3); 81% ee, 
determined by HPLC analysis [Daicel Chiralpak IC, n-hexane/i-PrOH = 80/20, 1.0 
mL/min, λ = 254 nm, t (major) = 29.2 min, t (minor) = 59.4 min]; 1H NMR (500 MHz, 
CDCl3) δ 1.47 (d, J = 7.0 Hz, 3H), 3.63 (s, 3H), 3.82 (s, 3H), 5.60 (s, 1H), 5.99-6.03 
(q, J = 7.0 Hz, 1H), 6.26 (s,1H), 6.98-7.00 (m, 1H), 7.26-7.27 (m, 1H), 7.29-7.43 (m, 
1H).  







A light yellow solid; 90% yield; [α]D25 = +13.1 (c = 0.45, CHCl3); 88% ee, 
determined by HPLC analysis [Daicel Chiralpak IA, n-hexane/i-PrOH = 90/10, 1.0 
mL/min, λ = 254 nm, t (minor) = 8.6 min, t (major) = 10.5 min]; 1H NMR (500 MHz, 
CDCl3) δ 0.98 (t, J = 7.6 Hz, 3H), 3.65 (s, 3H), 3.74 (s, 3H), 6.02-6.06 (q, J = 6.8 Hz, 
1H), 6.41 (s, 1H), 6.93-6.97 (m, 1H), 7.23-7.25 (m, 1H), 7.35-7.37 (m, 1H); 13C NMR 
(125 MHz, CDCl3) δ 15.1, 30.1, 52.5, 56.3, 85.3, 116.0, 123.2, 123.6, 129.8, 131.9, 








A light yellow solid; 70% yield; [α]D25 = -80.0 (c = 0.30, CHCl3); 87% ee, 
determined by HPLC analysis [Daicel Chiralpak IC, n-hexane/i-PrOH = 80/20, 1.0 
mL/min, λ = 254 nm, t (major) = 19.7 min, t (minor) = 27.9 min]; 1H NMR (500 MHz, 
CDCl3) δ 1.74 (d, J = 6.8 Hz, 3H), 3.65 (s, 3H), 3.74 (s, 3H), 6.02-6.06 (q, J = 6.8 Hz, 
1H), 6.41 (s, 1H), 6.93-6.97 (m, 1H), 7.23-7.25 (m, 1H), 7.35-7.37 (m, 1H); 13C NMR 
(125 MHz, CDCl3) δ 15.1, 30.1, 52.5, 56.3, 85.3, 116.0, 123.2, 123.6, 129.8, 131.9, 
136.1, 139.8, 165.8, 174.2; HRMS-ESI calcd for [M+Na] C16H18N2NaO579Br and 




A light yellow solid; 92% yield; [α]D25 = -37.7 (c = 0.61, CHCl3); 90% ee, 
determined by HPLC analysis [Daicel Chiralpak IC, n-hexane/i-PrOH = 70/30, 1.0 
mL/min, λ = 254 nm, t (major) = 23.8 min, t (minor) = 39.9 min]; 1H NMR (500 MHz, 
CDCl3) δ 1.74 (d, J = 6.8 Hz, 3H), 3.65 (s, 3H), 3.74 (s, 3H), 6.02-6.06 (q, J = 6.8 Hz, 
1H), 6.41 (s, 1H), 6.93-6.97 (m, 1H), 7.23-7.25 (m, 1H), 7.35-7.37 (m, 1H); 13C NMR 




136.1, 139.8, 165.8, 174.2; HRMS-ESI calcd for [M+H] C17H21N2O6, 349.1394, 
found: 349.1403. 
3.4.7 Procedure of Synthesis Derivatives 
 
Scheme 3.11 Synthetic procedure for compound 3-5 
To the chiral allylic alkylation product 3-3a (7.3 mg, 0.025 mmol) in 1.0 mL 
HOAc was added Zn (4.8 mg, 0.075 mmol) in one portion at room temperature. Then 
the reaction mixture was heated to reflux for 2 hours. Then the reaction mixture was 
cooled to room temperature. The solid was filtered off; the filtrate was added to water. 
The reaction mixture was extracted with EtOAc and the combined organic layer was 
washed with water, brine and dried with anhydrous Na2SO4. After filtration, the 
solvent was removed under reduced pressure. The residue was purified by column 
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A light yellow solid; 89% yield; [α]D25 = -8.5 (c = 0.60, CHCl3); 92% ee, 
determined by HPLC analysis [Daicel Chiralpak IB, n-hexane/i-PrOH = 80/20, 1.0 
mL/min, λ = 254 nm, t (major) = 16.8 min, t (minor) = 21.8 min]; 1H NMR (300 MHz, 
CDCl3) δ 3.26 (s, 3H), 3.60 (d, J = 9.7 Hz, 1H), 3.87 (d, J = 9.7 Hz, 1H), 5.04 (s, 1H), 
6.11 (s, 1H), 6.52 (br s, 1H), 6.89-6.92 (m, 1H), 7.08-7.11 (m, 1H), 7.13-7.25 (m, 1H), 
7.32-7.37 (m, 1H); 13C NMR (125 MHz, CDCl3) δ 26.7, 48.9, 53.4, 108.5, 118.3, 
123.1, 123.6, 129.1, 132.3, 142.1, 143.5, 168.7, 176.5; HRMS-ESI calcd for [M+Na] 
C13H12N2NaO2, 251.0791, found: 251.0797. 
3.4.8 X-Ray Crystallographic Analysis of Compounds 3-4d 
   
Identification code  3-4d 
Empirical formula  C16 H17 Br N2 O5 
Formula weight  397.23 
Temperature  223(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P2(1)2(1)2(1) 
Unit cell dimensions a = 7.9316(5) Å = 90°.　  
 b = 11.5927(7) Å = 90°.　  




Volume 1752.69(19) Å3 
Z 4 
Density (calculated) 1.505 Mg/m3 
Absorption coefficient 2.373 mm-1 
F(000) 808 
Crystal size 0.60 x 0.50 x 0.20 mm3 
Theta range for data collection 2.06 to 27.47°. 
Index ranges -10<=h<=10, -15<=k<=11, -24<=l<=24 
Reflections collected 12370 
Independent reflections 4010 [R(int) = 0.0407] 
Completeness to theta = 27.47° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.6483 and 0.3302 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4010 / 0 / 220 
Goodness-of-fit on F2 0.977 
Final R indices [I>2sigma(I)] R1 = 0.0403, wR2 = 0.0860 
R indices (all data) R1 = 0.0663, wR2 = 0.0945 
Absolute structure parameter 0.018(9) 
Largest diff. peak and hole 0.199 and -0.377 e.Å-3 
Chapter 4  
109 
 
Chapter 4 Enantioselective Allylic Substitution Reaction of 
Morita-Baylis-Hillman Carbonates with an Azlactone 
4.1 Introduction 
We have developed the asymmetric reactions of MBH carbonates with 
nitroalkanes, and the products of these reactions could be easily converted to -
methylene--butyrolactams, which are protentially useful molecules in medicinal 
chemistry. -Methylene--butyrolactones are also often found in biologically active 
molecules. We thus intend to develop a practical method using MBH carbonates as 













Scheme 4.1 Research plan for asymmetric reaction of MBH carbonates with 
azlactone 
In our projected reaction, we required a formyl anion as a potential nucleophile 
in the allylic substitution reaction. One strategy is to use carbene catalyst to form 
umpolung synthons, which seemed to be inappropriate because the catalyst may 
activate either the MBH carbonates or formic aldehyde. 4-Isopropyl-2-oxazolin-5-one 
was found as a masked umpolung synthon for formyl or hydroxylcarbonyl anions, 
which has been reported in several reactions.95 The products of the allylic substitution 
reaction of MBH carbonates with the masked umpolung formyl anion could be 
transformed readily to -methylene--butyrolactones.  
Utilization of 4-isopropyl-2-oxazolin-5-one as a nucleophile has been 




and co-workers developed a Michael reaction of 4-isopropyl-2-oxazolin-5-one with 
-unsaturated ketone, providing the products with high regioselectivity and 
enantioselectivity in the presence of the phase transfer catalyst derived from amino 
acid.81a The highly regioselective reaction took place at the 2-position of 4-isopropyl-
2-oxazolin-5-one. Two years later, the same group investigated the asymmetric 
Michael reaction of 4-isopropyl-2-oxazolin-5-one to nitroolefin in the presence of the 
same catalyst.81b  In the contrast, employment of 4-isopropyl-2-phenyloxazol-5(4H)-
one often led to nucleophilic substitution at the 4-position. In 2011, Shi and 
coworkers developed an asymmetric reaction of MBH adducts with 4-isopropyl-2-
phenyloxazol-5(4H)-one.46  
The reaction of MBH adducts with 4-isopropyl-2-oxazolin-5-one has not been 
investigated. We envisioned that a reaction of MBH carbonates with 4-isopropyl-2-
oxazolin-5-one may be promoted by nucleophilic catalyst via a SN2’-SN2’ process. 
Herein we describe the first asymmetric allylic substitution reaction of MBH 
carbonates with 4-isopropyl-2-oxazolin-5-one. The allylic substitution products were 
obtained in high yields, and with good regioselectivity, diastereoselectivity and 
enantioselectivity. 
4.2 Results and Discussion 
4.2.1 Reaction Optimization 
We first took the reaction of MBH carbonate 4-1a and 4-isopropyl-2-oxazolin-5-
one 4-2 as a model reaction. The cinchona alkaloid derived tertiary amine catalyst -
ICD was chosen to catalyze the model reaction. The product 4-3a could be obtained 
as the only product in low yield and low enantioselectivity (Table 4.1, entry 6). Since 
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our group has developed bifunctional phosphine catalysts which have been 
successfully applied in several reactions as nucleophlic catalysts, we decided to screen 
some phosphine catalysts. The phosphine-thiourea catalysts were tested in the model 
reaction. The catalyst 4-C1 derived from threonine could provide the product 4-3a in 
good yield, high diastereoselectivity and high enantioselectivity (Table 4.1, entry 1 
and 11). The catalyst 4-C2 also gave the product 4-3a with slightly lower 
enatioselectivity, which means that the silyl group on the catalysts could slightly 
influence the enantioselectivity (Table 4.1, entry 2). The phosphine-thiourea catalyst 
4-C3 derived from valine could provide the product 4-3a with moderate 
enantioselectivity which may indicate the impotence of scaffold of catalysts (Table 
4.1, entry 3). Other bifunctional catalysts e.g. 4-C4, 4-C5 with stronger or weaker 
hydrogen bonding moiety could give the product 4-3a with low enantioselectivity 
(Table 4.1, entry 4 and 5). 






































Entry Catalyst Solvent Yield (%)b ee (%)c 
1 4-C1 toluene 76 98 
2 4-C2 toluene 76 94 
3 4-C3 toluene 51 82 
4 4-C4 toluene 62 6 
5d 4-C5 toluene 51 31 
6 4-C6 toluene - 26 
7 4-C1 CH2Cl2 83 92 
8 4-C1 Et2O 58 95 
9 4-C1 THF 61 92 
10d 4-C1 CH3CN - 84 
11e 4-C1 toluene 87 98 
a The reaction was performed with 4-1a (0.025 mmol), 4-2 (0.050mmol) and catalyst (10 mol%) 
in solvent (0.10 mL) at room temperature for 24 h. b Yield of isolated product. c Determined by 
HPLC analysis on a chiral stationary phase. d The reaction yield was low and not calculated. e 
The reaction was performed for 48 h. 
The solvent was also screened in the presence of the best catalyst 4-C1. The 
strong polar solvent acetonitrile could provide the product with low yield and 
moderate enantioselectivity (Table 4.1, entry 10). When other solvents such as 
CH2Cl2, THF, Et2O were used, the product with good enantioselectivity could be 
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obtained (Table 4.1, entry 7, 8 and 9). Toluene was found to be the best solvent. 
4.2.2 Substrate Scope 
The scope of the reaction was next investigated under the best reaction condition 
(Table 4.2). Different substituted MBH carbonates 4-1 were used in the allylic 
substitution reaction. All the substrates 4-1 could provide the products 4-3 with 
excellent diastereoselectivity and good to excellent enantioselectivity. The MBH 
carbonates with halogen substituent could give the product with moderate to good 
yield and high enantioselectivity (Table 4.2, entry 2, 3, 4, 5, 6 and 7). Even the 
disubsituted substrate 4-1g could afford the product with moderate yield and high 
enantioselectivity (Table 4.2, entry 7). The MBH carbonates containing electron 
withdrawing group on the phenyl ring could provide the product with excellent yield 
and high enantioselectivity (Table 4.2, entry 8, 9 and 10). In the contrast, when the 
MBH carbonate with electron donating group on the phenyl ring was used, the 
product was also obtained with high enantioselectivity, but the yield was slightly 
lower (Table 4.2, entry 11, 12 and 13). The high enantioselectivity could also be 
obtained using MBH carbonates with naphthyl group or heteroaromtic substituent 
(Table 4.2, entry 14, 15, 16 and 17). Even the MBH carbonate derived from aliphatic 
aldehyde 4-1r could give the product with moderate yield and high enantioselectivity 
using 20 mol% catalyst loading (Table 4.2, entry 18). The reactivity could decrease 
using MBH carbonate with steric hindrance (Table 4.2, entry 6, 13 and 14). We 
reasoned that the first SN2’ reaction may be suppressed by the steric hindrance. 









Entry R d. r.b Yield (%)c ee (%)d 
1 Ph >19:1 87 98 
2 4-FPh >19:1 99 93 
3 4-ClPh >19:1 99 95 
4 4-BrPh >19:1 87 96 
5 3-BrPh >19:1 87 94 
6 2-BrPh >19:1 49 94 
7 3,4-Cl-C6H3 >19:1 77 93 
8 4-CF3Ph >19:1 99 96 
9 3-CF3Ph >19:1 99 90 
10 4-NO2Ph >19:1 99 90 
11 4-MePh >19:1 87 94 
12 3-MePh >19:1 77 92 
13 2-MePh >19:1 66 94 
14 1-naphthyl >19:1 65 95 
15 2-naphthyl >19:1 98 94 
16 3-furyl >19:1 79 91 
17 2-thioyl >19:1 59 92 
18e i-Butyl >19:1 63 89 
aThe reaction was performed with 4-1 (0.025 mmol), 4-2 (0.050 mmol)andcatalyst 4-C1 
(10 mol%) in toluene (0.1 mL) at room temperature for 48 h. b Diastereoselectivity was 
determined by 1H NMR. c Yield of isolated product. d Determined by HPLC analysis on 
a chiral stationary phase. e The catalyst loading was 20 mol%. 
 
4.3 Conclusions 
In summary, we have developed the asymmetric allylic substitution reaction of 
MBH carbonate with an azlactone. A number of MBH carbonates 4-1 could react with 
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azlactone 4-2 to afford the products 4-3 with high diastereoselectivity and 
enantioselectivity (49-99%, 89-98% ee). The product 4-3 could transform to -
methylene--butyrolactones because azlactone 4-2 could function as masked formyl 
anion.  
4.4 Experimental Section 
4.4.1 General Methods 
All starting materials were obtained from commercial sources and were used 
without further purification unless otherwise stated. Toluene, THF and Et2O were 
dried and distilled from sodium and benzophenone prior to use. CHCl3 and CH2Cl2 
were distilled from CaH2 prior to use. All solvents used in reactions involving 
phosphorus-containing compounds were degassed using N2. Melting points were 
determined using a Büchi B-540 melting point apparatus. Optical rotations were 
measured using a Jasco DIP-1000 polarimeter. 1H and 13C NMR spectra were 
recorded on a Bruker ACF300 or AMX500 (500 MHz) spectrometer. Chemical shifts 
are reported in parts per million (ppm), and the residual solvent peak was used as an 
internal reference: proton (CHCl3, δ 7.26), carbon (CHCl3, δ 77.0). Multiplicities are 
indicated as follows: s (singlet), d (doublet), t (triplet), m (multiplet). Coupling 
constants are reported in hertz (Hz). High-resolution mass spectra were obtained on a 
Finnigan/MAT 95XL-T spectrometer. TLC was accomplished using Merck pre-
coated TLC plates (Merck 60 F254), and compounds were made visual with UV light 
at 254 nm. Flash chromatographic separations were performed on Merck 60 (0.040–
0.063 mm) mesh silica gel. Enantiomeric excesses were determined by HPLC 




4-Isopropyl-2-oxazolin-5-one was prepared according to the literature reported 
procedure and stored under N2 at room temperature.95,  
4.4.2 Representative Procedure for Catalyst synthesis 
 
Scheme 4.2 Procedure for the catalyst synthesis 
To a solution of (2R,3S)-3-amino-4-(diphenylphosphino)butan-2-ol (273 mg, 1.0 
mmol) in CH2Cl2 (6 mL) was added 4-fluorophenyl isothiocyanate (170 mg, 1.1 
mmol) under N2, and the resulting mixture was stirred at room temperature for 2 hrs. 
Solvent was removed under reduced pressure, and the residue was directly subjected 
to column chromatographic separation on silica gel using hexane/ethyl acetate (12:1 
to 8: 1) as an eluent to afford1-((2S,3R)-1-(diphenylphosphino)-3-hydroxybutan-2-
yl)-3-(4-fluorophenyl)thiourea as a white solid (354 mg, 83% yield). To a solution of 
the above phosphine thiourea catalyst (57.5 mg, 0.14 mmol) in THF (1 mL) at 0 oC 
was added NaH (22.4 mg, 0.60 mmol, 60% (w/w) in mineral oil) and the mixture was 
stirred at this temperature for 10 min, followed by the addition of tert-
butyldimethylsilyl chloride (27.1 mg, 0.18 mmol). The reaction mixture was stirred 
for 2 hours, and then water (2 mL) was added to quench the reaction. The reaction 
mixture was extracted with EtOAc (3 x 3 mL), and the combined organic extracts 
were dried over Na2SO4 and concentrated. The residue was purified by column 
chromatography using hexanes/ethyl acetate (10:1 to 5:1) as an eluent to afford 4-C1 
as a white solid (59.5 mg, 73% yield).72 1H NMR (300 MHz, CDCl3) δ 0.80 (br, 21H), 
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1.01 (d, J = 6.2 Hz, 3H), 2.06 (t, J = 10.5 Hz, 1H), 2.51-2.58 (m, 1H), 4.34 (d, J = 5.7 
Hz, 2H), 6.25 (d, J = 8.5 Hz, 1H), 6.87-6.90 (m, 2H), 6.92-7.00 (m, 2H), 7.12-7.27 (m, 
8H), 7.48-7.53 (m, 2H), 7.83 (br, 1H); 13C NMR (75 MHz, CDCl3) δ 12.49, 18.06, 
18.09, 32.11 (d, J = 15.8 Hz), 58.90 (d, J = 18.5 Hz), 69.20 (d, J = 8.2 Hz), 116.96 (d, 
J = 22.4 Hz), 128.07 (d, J = 8.7 Hz), 128.27, 128.37, 128.40, 128.48, 128.74, 131.82, 
132.62, 132.87, 132.98, 133.23, 137.34, 137.50, 139.00, 161.48 (d, J = 246.6 Hz), 
180.48; 31P NMR (121 MHz, CDCl3) δ -23.69; HRMS (ESI) m/z calcd for 
C39H45FN2OPSSi [M+H]+ =583.2665, found 583.2746. 
4.4.3 Procedure for Synthesis Azlactone 4-2 
 
Scheme 4.3 Procedure for the synthesis of azlactone 4-2 
The mixture of valine (4.68 g, 40 mmol), formic acid (7.5 mL, 200 mmol) and 
acetyl anhydride (15.1 mL, 160 mmol) was dissolved in acetic acid (160 mL) at room 
temperature. The reaction mixture was stirred for 4 hours. Afterwards, all the volatiles 
were removed under reduced pressure and the residue was recrystallized from ethyl 
acetate to afford the white solid as N-formyl-valine (4.35 g, 75%). 
To a solution of N-formyl-valine (4.35, 30 mmol) in EtOAc (40 mL) was added 
dicyclohexylcarbodiimide (6.2 g, 30 mmol) at 0 ℃. The reaction mixture was allowed 
to room temperature and stirred for 2 hours. The precipitated urea was removed by 




residue was purified by distillation (b.p. 60-62 ℃, 3 mm/Hg) to afford the compound 
4-2 as colorless oil (2.39 g, 62%).96 
4.4.4 Representative Procedure  
 
Scheme 4.4 Procedure for asymmetric allylic substitution reaction of MBH 
carbonates 4-1 with azlactone 4-2 
To the mixture of MBH carbonate 4-1a (7.7 mg, 0.025 mmol), azlactone 4-2 (6.4 
mg, 0.05 mmol), and Catalyst 4-C1 (1.5 mg, 0.0025 mmol) was added toluene (0.1 
mL) at room temperature. The reaction mixture was stirred for 48 hours. The resulting 
solution was directly purified by column chromatography on silica gel to afford the 
colorless oil (6.5 mg, 82%). 
4.4.5 Analytical Data of Product 4-3 
Ethyl 2-((4-isopropyl-5-oxo-2,5-dihydrooxazol-2-yl)(phenyl)methyl)acrylate 4-3a 
 
A colorless oil; 82%; [α]25D = +47.1(c 0.27, CHCl3); 98% ee, determined by 
HPLC analysis [Daicel Chiralpak IB, n-hexane/i-PrOH = 99.0 /1.0, 0.5 mL/min, λ = 
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220 nm, t (major) = 17.2 min, t (minor) = 20.5 min]; 1H NMR (500 MHz, CDCl3) δ 
0.96 (d, J = 6.3 Hz, 3H), 1.13 (d, J = 6.9 Hz, 3H), 1.20 (t, J = 7.0 Hz, 3H), 2.72-2.77 
(m, 1H), 4.08-4.19 (m, 2H), 4.62 (d, J = 3.8 Hz, 1H), 6.31-6.32 (m, 1H), 6.37 (s, 1H), 
6.61 (s, 1H), 7.15-7.26 (m, 5H); 13C NMR (125 MHz, CDCl3) δ 14.0, 18.6, 18.7, 27.9, 
49.2, 61.2, 99.1, 127.7, 128.1, 129.8, 134.0, 138.0, 164.4, 166.0, 169.0. HRMS (ESI): 




A colorless oil; 99%;[α]25D = +8.8 (c 1.74, CHCl3); 93% ee, determined by 
HPLC analysis [Daicel Chiralpak IC, n-hexane/i-PrOH = 99.0 /1.0, 0.5 mL/min, λ = 
220 nm, t (major) = 10.3 min, t (minor) = 16.5 min]; 1H NMR (500 MHz, CDCl3) δ 
0.98 (d, J = 7.0 Hz, 3H), 1.14 (d, J = 6.9 Hz, 3H), 1.21 (t, J = 6.9 Hz), 2.73-2.79 (m, 
1H), 4.10-4.18 (m, 2H), 4.60 (d, J = 3.8 Hz, 1H), 6.28-6.29 (m, 1H), 6.41 (s, 1H), 
6.61 (s, 1H), 6.91-6.95 (m, 2H), 7.10-7.13 (s, 2H); 13C NMR (125 MHz, CDCl3) δ 
14.0, 18.6, 18.7, 27.9, 48.5, 61.2, 98.8, 114.9, 115.0, 127.9, 131.4, 131.5, 137.9, 163.2, 








A colorless oil; 99%; [α]25D = +9.8 (c 2.20, CHCl3); 95% ee, determined by 
HPLC analysis [Daicel Chiralpak IC, n-hexane/i-PrOH = 99.0 /1.0, 0.5 mL/min, λ = 
220 nm, t (major) = 10.2 min, t (minor) = 16.4 min];1H NMR (500 MHz, CDCl3) δ 
0.99 (d, J = 7.0 Hz, 3H), 1.14 (d, J = 7.0 Hz, 3H), 1.21 (t, J = 6.9 Hz, 3H), 2.74-2.80 
(m, 1H), 4.09-4.19 (m, 2H), 4.58 (d, J = 3.8 Hz, 1H), 6.28-6.30 (m, 1H), 6.39 (s, 1H), 
6.62 (s, 1H), 7.08-7.10 (m, 2H), 7.21-7.23 (m, 2H);  13C NMR (125 MHz, CDCl3) δ 
14.0, 18.7, 27.9, 48.6, 61.3, 98.7, 128.1, 128.2, 131.1, 132.5, 133.7, 137.7, 164.3, 





A colorless oil; 87%; [α]25D = +48.8 (c 0.34, CHCl3); 96% ee, determined by 
HPLC analysis [Daicel Chiralpak IB, n-hexane/i-PrOH = 99.0 /1.0, 0.5 mL/min, λ = 
220 nm, t (major) = 10.6 min, t (minor) = 16.6 min];1H NMR (500 MHz, CDCl3): δ 
0.98 (d, J = 6.9 Hz, 3H) 1.14 (d, J = 0.69 Hz, 3H), 1.22 (t, J = 6.9 Hz, 3H), 2.72-2.82 
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(m, 1H), 4.10-4.18 (m, 2H), 4.56 (d, J = 3.8 Hz, 1H), 6.28-6.30 (m, 1H), 6.38 (s, 1H), 
6.62 (s, 1H), 7.01-7.04 (m, 2H), 7.36-7.39 (m, 2H); 13C NMR (125 MHz, CDCl3): δ 
14.0, 18.7, 27.9, 48.7, 61.3, 98.7, 121.9, 128.2, 131.2, 131.5, 133.1, 137.7, 164.3, 









A colorless oil; 87%; [α]25D = +45.8 (c 0.44, CHCl3); 94% ee, determined by 
HPLC analysis [Daicel Chiralpak IB, n-hexane/i-PrOH = 99.0 /1.0, 0.5 mL/min, λ = 
220 nm, t (major) = 20.3 min, t (minor) = 22.8 min]; 1H NMR (500 MHz, CDCl3): δ 
0.98 (d, J = 6.9 Hz, 3H) 1.16 (d, J = 6.9 Hz, 3H), 1.22 (t, J = 7.1 Hz, 3H), 2.73-2.83 
(m, 1H), 4.10-4.21 (m, 2H), 4.59 (d, J = 3.3 Hz, 1H), 6.28-6.30 (m, 1H), 6.42 (s, 1H), 
6.64 (s, 1H), 7.12-7.14 (m, 2H), 7.24 (m, 1H), 7.33-7.37 (m, 1H); 13C NMR (125 
MHz, CDCl3): δ 14.0, 18.7, 28.0, 48.8, 61.3, 98.6, 122.0, 128.4, 129.0, 129.7, 130.8, 
132.5, 136.3, 137.4, 164.2, 165.7, 169.4; HRMS (ESI): m/z [M+H]+ calcd for 







A colorless oil; 49%; [α]25D = +17.6 (c 0.46, CHCl3); 94% ee, determined by 
HPLC analysis [Daicel Chiralpak IC, n-hexane/i-PrOH = 95.0 /5.0, 0.5 mL/min, λ = 
220 nm, t (major) = 14.2 min, t (minor) = 30.0 min]; 1H NMR (500 MHz, CDCl3) δ 
1.13 (d, J = 7.0 Hz), 1.20-1.24 (m, 6H), 2.94-2.90 (m, 1H), 4.10-4.17 (m, 2H), 5.07 (d, 
J = 5.1 Hz, 1H), 6.12 (s, 1H), 6.32-6.33 (m, 1H), 6.59 (s, 1H), 7.08-7.12 (m, 1H), 
7.22-7.25 (m, 1H), 7.29-7.31 (m, 1H), 7.57-7.59 (m, 1H); 13C NMR (125 MHz, CDCl3) 
δ 14.0, 18.7, 18.8, 28.1, 48.4, 61.2, 99.4, 126.4, 127.0, 128.6, 129.1, 130.2, 133.4, 
135.2, 137.5, 164.3, 165.7, 169.1. HRMS (ESI): m/z [M+H]+ calcd for C18H21BrNO4: 




A colorless oil; 77%; [α]25D = +25.6 (c 0.40, CHCl3); 93% ee, determined by 
HPLC analysis [Daicel Chiralpak IC, n-hexane/i-PrOH = 95.0 /5.0, 0.5 mL/min, λ = 
220 nm, t (major) = 10.2 min, t (minor) = 17.6 min];1H NMR (500 MHz, CDCl3) δ 
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1.13 (d, J = 7.0 Hz, 3H), 1.20-1.23 (m, 6H), 2.85-2.91 (m, 1H), 4.10-4.16 (m, 2H), 
5.01 (d, J = 6.3 Hz, 1H), 6.14 (s, 1H), 6.30 (m, 1H), 6.59 (s, 1H), 7.17-7.18 (m, 1H), 
7.19-7.24 (m, 1H), 7.41 (s, 1H); 13C NMR (125 MHz, CDCl3) δ 14.0, 18.8, 18.9, 28.1, 
45.4, 61.3, 99.0, 126.6, 128.7, 129.8, 130.9, 132.2, 134.1, 136.2, 137.1, 164.2, 165.4, 




A colorless oil; 99%; [α]25D = +33.6 (c 0.43, CHCl3); 96% ee, determined by 
HPLC analysis [Daicel Chiralpak IC, n-hexane/i-PrOH = 99.0 /1.0, 0.5 mL/min, λ = 
220 nm, t (major) = 18.4 min, t (minor) = 20.7 min]; 1H NMR (500 MHz, CDCl3) δ 
0.93 (d, J = 6.9 Hz, 3H), 1.12 (d, J = 6.9 Hz, 3H), 1.19-1.24 (t, J = 7.2 Hz, 3H), 2.71-
2.81 (m, 1H), 4.09-4.20 (m, 2H), 4.66 (d, J = 3.8 Hz, 1H), 6.31-6.34 (m, 1H), 6.42 (s, 
1H), 6.66 (s, 1H), 7.28-7.30 (m, 2H), 7.50-7.53 (m, 1H); 13C NMR (125 MHz, CDCl3) 
δ 14.0, 18.6, 27.9, 49.0, 61.4, 98.5, 125.0,128.6, 130.1, 137.4, 164.2, 165.7, 169.4; 
HRMS (ESI): m/z [M+H]+ calcd for C19H21F3NO4: 384.141.7; found: 384.1426. 
Ethyl2-((4-isopropyl-5-oxo-2,5-dihydrooxazol-2-yl)(3-(trifluoromethyl)-phenyl)-





A colorless oil; 99%; [α]25D = +24.8 (c 0.73, CHCl3); 90% ee, determined by 
HPLC analysis [Daicel Chiralpak IC, n-hexane/i-PrOH = 99.0 /1.0, 0.5 mL/min, λ = 
220 nm, t (major) = 18.7 min, t (minor) = 20.4 min]; 1H NMR (500 MHz, CDCl3) δ 
0.93 (d, J = 6.9 Hz, 3H), 1.13 (d, J = 6.9 Hz, 3H), 1.19-1.23 (t, J = 7.1 Hz, 3H), 2.69-
2.79 (m, 1H), 4.09-4.20 (m, 2H), 4.68 (d, J = 3.8 Hz, 1H), 6.31-6.32 (m, 1H), 6.48 (s, 
1H), 6.68 (s, 1H), 7.36-7.38 (m, 1H), 7.39-7.40 (m, 1H), 7.46-7.50 (m, 1H); 13C NMR 
(125 MHz, CDCl3) δ 14.0, 18.5, 18.6, 27.9, 48.9, 61.4, 98.5, 124.6, 126.1, 126.2, 
128.6, 133.6, 135.1, 137.3, 164.1, 165.7, 169.6; HRMS (ESI): m/z [M+H]+ calcd for 




A yellow oil; 99%; [α]25D = +18.8 (c 0.81, CHCl3); 90% ee, determined by 
HPLC analysis [Daicel Chiralpak IC, n-hexane/i-PrOH = 95.0 /5.0, 1.0 mL/min, λ = 
220 nm, t (major) = 30.7 min, t (minor) = 41.2 min]; 1H NMR (500 MHz, CDCl3) δ 
0.98 (d, J = 7.0 Hz, 3H), 1.14 (d, J = 6.3 Hz, 3H), 1.20-1.23 (t, J = 6.9 Hz, 3H), 2.75-
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2.81 (m, 1H), 4.11-4.17 (m, 2H), 4.68 (d, J = 3.8 Hz, 1H), 6.34-6.35 (m, 1H), 6.44 (s, 
1H), 6.68 (s, 1H), 7.35-7.37 (m, 2H), 8.11-8.13 (m, 1H); 13C NMR (125 MHz, CDCl3) 
δ 14.0, 18.8, 28.0, 49.1, 61.5, 98.3, 123.2, 128.9, 130.7, 137.1, 141.9, 147.4, 164.0, 
165.5, 169.7; HRMS (ESI): m/z [M+H]+ calcd for C18H19N2O6: 359.1249; found: 
359.1239. 
Ethyl 2-((4-isopropyl-5-oxo-2,5-dihydrooxazol-2-yl)(p-tolyl)methyl)acrylate 4-3k 
 
A colorless oil; 87%; [α]25D = +68.4 (c 0.14, CHCl3); 94% ee, determined by 
HPLC analysis [Daicel Chiralpak IB, n-hexane/i-PrOH = 99.0 /1.0, 0.5 mL/min, λ = 
220 nm, t (major) = 15.2 min, t (minor) = 17.7 min]; 1H NMR (500 MHz, CDCl3) δ 
0.98 (d, J = 7.0 Hz, 3H), 1.14 (d, J = 7.0 Hz, 3H), 1.21 (t, J = 7.5 Hz, 3H), 2.27 (s, 
3H), 2.73-2.79 (m, 1H), 4.10-4.17 (m, 2H), 4.57 (d, J = 2.8 Hz, 1H), 6.29-6.30 (m, 
1H), 6.33 (s, 1H), 6.56 (s, 1H), 7.04 (m, 4H); 13C NMR (125 MHz, CDCl3) δ 14.0, 
18.6, 18.7, 21.0, 27.9, 48.9, 61.1, 99.2, 127.8, 128.8, 129.7, 130.9, 137.3, 138.1, 164.6, 
166.1, 168.9; HRMS (ESI): m/z [M+H]+ calcd for C19H24NO4: 330.1700; found: 
330.1713. 









A colorless oil; 77%; [α]25D = +41.2 (c 0.54, CHCl3); 94% ee, determined by 
HPLC analysis [Daicel Chiralpak IB, n-hexane/i-PrOH = 99.0 /1.0, 0.5 mL/min, λ = 
220 nm, t (major) = 15.2 min, t (minor) = 17.7 min];  1H NMR (500 MHz, CDCl3) δ 
0.97 (d, J = 6.9 Hz, 3H), 1.14 (d, J = 6.9 Hz, 3H), 1.21 (t, J = 7.5 Hz, 3H), 2.28 (s, 
3H), 2.73-2.78 (m, 1H), 4.11-4.18 (m, 2H), 4.59 (d, J = 3.8 Hz, 1H), 6.30-6.31 (m, 
3H), 6.34 (s, 1H), 6.58 (s, 1H), 6.95-6.97 (m, 2H), 7.01-7.02(m, 1H), 7.11-7.14 (m, 
1H); 13C NMR (125 MHz, CDCl3) δ 14.0, 18.6, 18.7, 21.3, 27.9, 49.1, 61.2, 99.1, 
126.9, 127.9, 128.4,130.4, 133.9, 137.5, 138.0, 164.5, 166.1, 168.9; HRMS (ESI): m/z 
[M+H]+ calcd for C19H24NO4: 330.1700; found: 330.1713. 






A colorless oil; 66%;  [α]25D = +15.7 (c 0.60, CHCl3); 94% ee, determined by 
HPLC analysis [Daicel Chiralpak IB, n-hexane/i-PrOH = 99.0 /1.0, 0.5 mL/min, λ = 
220 nm, t (major) = 15.3 min, t (minor) = 17.5 min];   1H NMR (500 MHz, CDCl3) δ 
1.05 (d, J = 7.0 Hz), 1.17 (m, 1.22), 2.40 (s, 1H), 2.77-2.83 (m, 1H), 4.08-4.16 (m, 
2H), 4.88 (d, J = 4.5 Hz, 1H), 6.28 (s, 1H), 6.31-6.32 (m, 1H), 6.56 (s, 1H), 7.06-7.14 
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(m, 4H); 13C NMR (125 MHz, CDCl3) δ 14.0, 18.6, 18.8, 19.8, 28.0, 44.7, 61.1, 99.8, 
123.6, 125.2, 127.5, 127.9, 129.0, 130.7, 132.9, 138.0, 138.3, 164.3, 166.1, 168.9. 




A colorless oil; 65%; [α]25D = +11.0 (c 0.64, CHCl3); 95% ee, determined by 
HPLC analysis [Daicel Chiralpak IB, n-hexane/i-PrOH = 99.0 /1.0, 0.5 mL/min, λ = 
220 nm, t (major) = 23.9 min, t (minor) = 38.6 min];  1H NMR (500 MHz, CDCl3) δ 
1.10 (d, J = 6.9 Hz, 3H), 1.15-1.21 (m, 6H), 2.83-2.89 (m, 1H), 4.13-4.17 (q, J = 7.0 
Hz, 2H), 5.60 (d, J = 3.8 Hz, 1H), 5.96 (s, 1H), 6.49-6.50 (m, 2H), 7.42-7.53 (m, 3H), 
7.62-7.64 (m, 1H), 7.77-7.84 (m, 2H), 8.11-8.13 (m, 1H); 13C NMR (125 MHz, CDCl3) 
δ 14.0, 18.8, 18.9, 28.0, 43.9, 61.3, 99.7, 123.7, 124.8, 125.7, 126.4, 126.5, 128.4, 
128.8, 129.5, 134.0, 137.4, 164.5, 166.2, 169.0. HRMS (ESI): m/z [M+H]+ calcd for 







A colorless oil; 98%;  [α]25D = +17.5 (c 0.96, CHCl3); 94% ee, determined by 
HPLC analysis [Daicel Chiralpak IB, n-hexane/i-PrOH = 99.0 /1.0, 0.5 mL/min, λ = 
220 nm, t (major) = 22.3 min, t (minor) = 24.7 min];  1H NMR (500 MHz, CDCl3) δ 
0.87 (d, J = 7.0 Hz, 3H), 1.10 (d, J = 6.9 Hz, 3H), 1.21 (t, J = 7.0 Hz), 2.67-2.73 (m, 
1H), 4.09-4.16 (m, 2H), 4.80 (d, J = 3.8 Hz, 1H), 6.42 (s, 2H), 6.65 (s, 1H), 7.27-7.29 
(m, 1H), 7.44-7.45 (m, 2H), 7.63-7.78 (m, 3H); 13C NMR (125 MHz, CDCl3) δ 14.0, 
18.6, 18.7, 27.8, 49.3, 61.2, 99.2, 126.1, 127.5, 127.7, 127.9, 128.1, 128.8, 131.7, 
132.7, 132.9, 138.0, 164.4, 166.0, 169.1. HRMS (ESI): m/z [M+H]+ calcd for 
C22H24NO4: 366.1700; found: 366.1698. 
Ethyl 2-(furan-3-yl(4-isopropyl-5-oxo-2,5-dihydrooxazol-2-yl)methyl)acrylate 4-3p 
 
A colorless oil; 79%;  [α]25D = +37.8 (c 0.31, CHCl3); 94% ee, determined by 
HPLC analysis [Daicel Chiralpak IB, n-hexane/i-PrOH = 99.0 /1.0, 0.5 mL/min, λ = 
220 nm, t (major) = 17.4 min, t (minor) = 19.9 min]; 1H NMR (500 MHz, CDCl3) δ 
1.14 (d, J = 7.0 Hz, 3H), 1.21 (d, J = 7.0 Hz, 3H), 1.29 (t, J = 7.6 Hz, 3H), 2.85-2.91 
(m, 1H), 4.19-4.24 (q, J = 7.6 Hz, 2H), 4.59 (d, J = 3.8 Hz, 1H), 6.09 (s, 1H), 6.22-
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6.24 (m, 2H), 6.50 (s, 1H), 7.32-7.33 (m, 2H); 13C NMR (125 MHz, CDCl3) δ 14.1, 
18.8, 28.1, 40.6, 61.3, 99.0, 111.2, 119.8, 128.9, 137.1, 141.3, 142.9, 164.6, 166.1, 




A yellow oil; 59%; [α]25D = +21.9 (c 0.44, CHCl3); 92% ee, determined by 
HPLC analysis [Daicel Chiralpak IB, n-hexane/i-PrOH = 99.0 /1.0, 0.5 mL/min, λ = 
220 nm, t (major) = 17.4 min, t (minor) = 19.9 min]; 1H NMR (500 MHz, CDCl3) δ 
1.05 (d, J = 7.0 Hz, 3H), 1.18 (d, J = 7.0 Hz), 1.27 (t, J = 7.0 Hz), 2.80-2.86 (m, 1H), 
4.18-4.23 (m, 2H), 4.96 (d, J = 3.8 Hz), 6.27-6.28 (m, 1H), 6.35 (s, 1H), 6.60 (s, 
1H),6.88-6.92 (m, 2H), 7.17-7.18 (m, 1H); 13C NMR (125 MHz, CDCl3) δ 14.1, 18.7, 
28.0, 44.2, 61.4, 98.7, 125.4, 126.8, 127.7, 129.1, 137.5, 164.5, 165.8, 169.4; HRMS 










A colorless oil; 63%;  [α]25D = +90.2 (c 0.13, CHCl3); 89% ee, determined by 
HPLC analysis [Daicel Chiralpak IC, n-hexane/i-PrOH = 95.0 /5.0, 0.5 mL/min, λ = 
220 nm, t (major) = 7.2 min, t (minor) = 9.7 min]; 1H NMR (500 MHz, CDCl3) δ 
0.89-0.93 (m, 6H), 1.20-1.35 (m, 10H), 2.90-2.94 (m, 1H), 3.47-3.51 (m, 1H), 4.01-
4.04 (m, 1H), 4.18-4.23 (m, 1H), 5.62 (s, 1H), 5.96-5.97 (m, 1H), 6.37 (s, 1H),; 13C 
NMR (125 MHz, CDCl3) δ 14.2, 18.9, 19.1, 21.7, 23.3, 25.3, 39.1,41.4, 61.0, 100.6, 
123.6, 128.2, 136.9, 165.2, 166.5, 168.8; HRMS (ESI): m/z [M+H]+ calcd for 







1. Lin, G.-Q.; Li, Y.-M.; Chan, A. S. C. Principles and Applications of Asymmetric 
Synthesis. Wiley-VCH, New York, 2001. 
2. FDA’s Policy statement for the development of new stereoisomeric, Chirality 4, 
1992, p.338-340. 
3. (a). Jacoben, E. N.; Pfaltz, A.; Yamamoto, H. Comprehensive Asymmetric 
Catalysis, I-III, Springer, 1999. (b). Ojima, I. Catalytic Asymmetric Synthesis, 
Wiley-VCH, New York, 1993.  
4. Gotor, V.; Alfonso, I.; Carcía-Urdiales, E. Asymmetric Organic Synthesis with 
Enzymes. VCH, New York, 2008. 
5. Beller, M.; Bolm, C. Transition Metals for Organic Synthesis. Wiley-VCH, New 
York, 2004. 
6. Berkessel, A.; Grger, H. Asymmetric Organocatalysis-From Biomimtic Concepts 
to Applications in Asymmetric Synthesis. Wiley-VCH, New York, 2005. 
7. Breding, G.; Balcom, R. W. Ber. Deutsch. Chem. Ger. 1908, 41, 740. 
8. (a) Eder, U.; Sauer, G.; Wiechert, R. Angew. Chem., Int. Ed. 1971, 10, 496. (b) 
Hajos, Z. G.; Parrish, D. R. J. Org. Chem. 1974, 39, 1615. 
9.  (a) Ruble, J. C.; Latham, H. A.; Fu, G. C. J. Am. Chem. Soc. 1997, 119, 1492. (b) 
Tu, Y.; Wang, Z.; Shi, Y. J. Am. Chem. Soc. 1996, 118, 9806. (c) Denmark, S. E.; 
Wu, Z.; Crudden, C.; Matsuhashi, H. J. Org. Chem. 1997, 62, 8288. (d) Yang, D.; 
Yip, Y. C.; Tang, M. W.; Wong, M. K.; Zheng, J. H.; Cheung, K. K. J. Am. Chem. 
Soc. 1996, 118, 491. (e) Sigman, M.; Jacobsen, E. N. J. Am. Chem. Soc. 1998, 
120, 4901. (f) Corey, E. J.; Grogan, M. Org. Lett. 1999, 1, 157. (g) Miller, S. J.; 
Copeland, J. T.; Papaioannou, N.; Horstmann, T. E.; Ruel, E. M. J. Am. Chem. 




10. List, B.; Lerner, R. A.; Barbas, C. F. Ⅲ. J. Am. Chem. Soc. 2000, 122, 2395. 
11. Ahrendt, K. A.; Borths, C. J.; MacMillan, D. W. C. J. Am. Chem. Soc. 2000, 122, 
4243. 
12. MacMillan, D. W. C. Nature 2008, 455, 304. 
13. (a) Mukherjee, S.; Yang, J. W.; Hoffmann, S.; List, B. Chem. Rev. 2007, 107, 
5471. (b) Erkkilä, A.; Majander, I.; Pihko, P. M. Chem. Rev. 2007, 107, 5416. (c) 
Wurz, R. P. Chem. Rev. 2007, 107, 5570. (d) Gaunt, M. J.; Johansson, C. C. C. 
Chem. Rev. 2007, 107, 5596. 
14. (a) Doyle, A. G.; Jacobsen Chem. Rev. 2007, 107, 5713. (b) Akiyama, T. Chem. 
Rev. 2007, 107, 5744. (c) Davie, E. A. C.; Mennen, S. M.; Xu, Y.; Miller, S. J. 
Chem. Rev. 2007, 107, 5759. (d) Hashimoto, T.; Maruoka, K. Chem. Rev. 2007, 
107, 5656. 
15. (a) Morita, K. Japan Patent 6803364, 1968; Chem. Abstr. 1968, 69, 58828s. (b) 
Morita, K.; Suzuki, Z.; Hirose, H. Bull. Chem. Soc. Jpn. 1968, 41, 2815. (c) 
Baylis, A. B.; Hillman, M. E. D.; German Patent 2155113, 1972; Chem. Abstr. 
1972, 77, 34174q.  
16. (a) Basavaiah, D.; Rao, A. J.; Satyanarayana, T. Chem. Rev. 2003, 103, 881. (b) 
Basavaiah, D.; Reddy, B. S.; Badsara, S. S. Chem. Rev. 2010, 110, 5447. 
17. Liu, T.-Y.; Xie, M.; Chen, Y.-C. Chem. Soc. Rev. 2012, 41, 4101. 
18. (a) Trost, B. M. Chem. Rev. 1996, 96, 395. (b) Trost, B. M.; Crawley, M. L. 
Chem. Rev. 2003, 103, 3921. (c) Alexakis, A.; Bäckvall, J. E.; Krause N.; 
Diéguez, M., Pámies, O. Chem. Rev. 2008, 108, 2796 
19. (a) Trost, B. M.; Thiel, O. R.; Tsui, H.-C. J. Am. Chem. Soc. 2002, 124, 11616. (b) 
Thiel, O. R.; Trost, B. M.; Tsui, H.-C. J. Am. Chem. Soc. 2003, 125, 13155. (c) 




20. Du, Y.; Han, X.; Lu, X. Tetrahedron Lett. 2004, 45, 4967.  
21. Cho, C.-W.; Kong, J. R.; Krische, M. J. Org. Lett. 2004, 6, 1337.  
22. Zhang. T.-Z., Dai, L.-X.; Hou, X.-L. Tetrahedron Asymmmetry 2007, 18, 1990.  
23. Steenis, D. J. V. C., Marcelli, T., Lutz, M., Spek, A. L., Maarseveen, J. H., 
Hiemstra, H. Adv. Synth. 2007, 349, 281-286. 
24.  Jiang, Y.-Q.; Shi, Y. L.; Shi, M. J. Am. Chem. Soc. 2008, 130, 7202. 
25. Selected reviews on the synthesis of γ-butenolides: (a) Langer, P. Synlett 2006, 
3369. (b) Romeo, G.; Iannazzo, D.; Piperno, A.; Romeo, R.; Corsaro, A.; 
Rescifina, A.; Chiacchio, U. Mini-Rev. Org. Chem. 2005, 2, 59. (c) Ito, M. Pure 
Appl. Chem. 1991, 63, 13. (d) Bruckner, R. Curr. Org. Chem. 2001, 5, 679. (e) 
Jacobi, P. A. Adv. Heterocycl. Nat. Prod. Synth. 1992, 2, 251. 
26. (a) Chuit, C.; Corriu, R. J. P.; Reye, C.; Young, J. C. Chem. Rev. 1993, 93, 1371. 
(b) Kira, M.; Sato, K.; Sakurai, H. J. Am. Chem. Soc. 1990, 112, 257. 
27. Zhang, S.-J; Cui, H.-L; Jiang, K.; Li, R.; Ding, Z.-Y.; Chen, Y.-C. Eur. J. Org. 
Chem. 2009, 5804. 
28. (a) Trost, B. M.; Krische, M. J.; Berl, V.; Grenzer, E. M. Org. Lett. 2002, 4, 2005. 
(b)  Bandini, M.; Eichholzer, A.; Tragni, M.; Umani-Ronchi, A. Angew. Chem., 
Int. Ed. 2008, 47, 3238. 
29. Cui, H.-L., Feng, X., Peng, J., Lei, J., Jiang, K., Chen, Y.-C. Angew. Chem., Int. 
Ed. 2009, 48, 5737. 
30. Feng, X.; Yuan, Y.-Q.; Cui. H.-L.; Jiang, K.; Chen, Y.-C. Org. Biomol. Chem. 
2009, 7, 3660. 
31. For examples: (a) Poulsen, T. B.; Bell, M.; Jøgensen, K. A. Org. Biomol. Chem. 
2006, 4, 63. (b) Niess, B.; Jøgensen, K. A. Chem. Commun. 2007, 1620. (c) 
Alemán, J.; Jacobsen, C. B.; Frisch, K.; Overgaard, J.; Jøgensen, K. A. Chem. 
Commun. 2008, 632. (d) Jiang, L.; Zheng, H.-T.; Liu, T.-Y,; Yue, L.; Chen, Y.-C. 
Tetrahedron 2007, 63, 5123. 





33. Jiang, K.; Peng, J.; Cui, H.-L.; Chen, Y.-C. Chem. Commun. 2009, 3955. 
34. (a) Ishimaru, T.; Shibata, N.; Nagai, J.; Nakamura, S.; Toru, T.; Kanemas, S. J. 
Am. Chem. Soc. 2006, 128, 16488. (b) Sano, D.; Nagata, K.; Itoh, T. Org. Lett. 
2008, 10, 1593. (c) Shaw, S. A.; Aleman, A. P.; Vedejs, E. J. Am. Chem. Soc. 2003, 
125, 13368. (d) Shaw, S. A.; Aleman, A. P.; Christ, J.; Kampf, J. W.; Va, P.; 
Vedejs, E. J. Am. Chem. Soc. 2006, 128, 925. (e) Hill, I. D.; Fu, G. C. Angew. 
Chem. Int. Ed. 2003, 42, 3921. (f) Ogawa, S.; Shibata, N.; Inagaki, J.; Nakamura, 
S.; Toru, T.; Shiro, M. Angew. Chem., Int. Ed. 2007, 46, 5737. (g) Tian, X.; Jiang, 
K.; Peng, J.; Du, W.; Chen, Y.-C. Org. Lett. 2008, 10, 3583. 
35. Cui, H.-L.; Huang, J.-R.; Lei, J.; Wang, Z.-F.; Chen, S.; Wu, L.; Chen, Y.-C. Org. 
Lett. 2010, 12, 720. 
36. Peng, J.; Huang, X.; Cui, H.-L.; Chen, Y.-C. Org. Lett. 2010, 12, 4260. 
37. For selected examples, see: (a) Hamashima, Y.; Suzuki, T.; Takano, H.; Shimura, 
Y.; Sedeoka, M. J. Am. Chem. Soc. 2005, 127, 10164. (b) Ishimaru, T.; Shibata, 
N.; Horikawa, T.; Yasuda, N.; Nakamura, S.; Toru, T.; Shiro, M. Angew. Chem., 
Ed. Int. 2008, 47, 4157. (c) Ishimaru, T.; Shibata, N.; Nagai, J.; Nakamura, S.; 
Toru, T.; Kanemasa, S. J. Am. Chem. Soc. 2006, 128, 16488. (d) Shaw, S. A.; 
Aleman, P.; Christy, J.; Kampf, J. W.; Va, P.; Vedejs, E. J. Am. Chem. Soc. 2006, 
128, 925. (e) Ogawa, S.; Shibata, N.; Inagaki, J.; Nakamura, S.; Toru, T.; Shiro, 
M. Angew. Chem., Ed. Int. 2007, 46, 8666. (f) Trost, B. M.; Zhang, Y. J. Am. 
Chem. Soc. 2007, 129, 14548. (g) Tian, X.; Jiang, K.; Peng, J.; Du, W.; Chen, Y.-
C. Org. Lett. 2008, 10, 3583. (h) Galzerano, P.; Bencivenni, G.; Pesciaioli, F.; 
Mazzanti, A.; Giannichi, B.; Sambri, L.; Bartoli, G.; Melchiorre, P. Chem. Eur. J. 
2009, 15, 7846. (i) Kato, Y.; Furutachi, M.; Chen, Z.; Mitsunuma, H.; Matsunaga, 
S.; Shibasaki, M. J. Am. Chem. Soc. 2009, 131, 9168. (j) He, R.; Shirakawa, S.; 
Maruoka, K. J. Am. Chem. Soc. 2009, 131, 16620. (k) Bui, T.; Candeias, N. R.; 




38. (a) Ma, S.; Han, X.; Krishnan, S.; Virgil, S. C.; Stoltz, B. M. Angew. Chem., Int. 
Ed. 2009, 48, 8037. (b) Liu, L.; Wu, D.; Zheng, S.; Li, T.; Li, X.; Wang, S.; Li, J.; 
Li, H.; Wang, W. Org. Lett. 2012, 14, 134. 
39. (a) Hong, L.; Sun, W.; Liu, C.; Zhao, D.; Wang, R. Chem. Commun. 2010, 46, 
2856. (b) Sun, W.; Hong, L.; Liu, C.; Wang, R. Org. Lett. 2010, 12, 3914. 
40. For the selected examples, see: (a) Wang, J.; Heikkinen, L. D.; Li, H.; Zu, L.; 
Jiang, W.; Xie, H.; Wang, W. Adv. Synth. Catal. 2007, 349, 1052. (b) Terada, M.; 
Ikehara, T.; Ube, H. J. Am. Chem. Soc. 2007, 129, 14112. (c) Rai, V.; 
Namboothiri, I. N. N. Tetrahedron: Asymmetry 2008, 19, 2335. (d) Wang, F.; Liu, 
X.; Cui, X.; Xiong, Y.; Zhou, X.; Feng, X.  Chem.–Eur. J. 2009, 15, 589. (e) 
Maerten, E.; Cabrera, S.; Kjarsgaard, A.; Jøgensen, K. A. J. Org. Chem. 2007, 72, 
8893. (f) Zhao, D.; Yuan, Y.; Chan, A. S. C.;  Wang, R. Chem.–Eur. J. 2009, 15, 
2738. (g) Zhao, D.; Wang, Y.; Mao, L.; Wang, R. Chem.–Eur. J. 2009, 15, 10983. 
(h) Nakamura, S.; Hayashi, M.; Hiramatsu, Y.; Shibata, N.;  Funahashi, Y.; Toru, 
T. J. Am. Chem. Soc. 2009, 131, 18240. (i) Zhu, Y.; Malerich, J. P.; Rawal, V. H. 
Angew. Chem., Int. Ed. 2010, 49, 153. 
41. (a) Fu, X.; Loh, W.-T.; Zhang, Y.; Chen, T.; Ma, T.; Liu, H.; Wang, J.;  Tan, C.-
H. Angew. Chem., Int. Ed. 2009, 48, 7387. (b) Leow, D.; Lin, S.; Chittimalla, S. 
K.; Fu, X.; Tan, C.-H.  Angew. Chem., Int. Ed. 2008, 47, 5641. (c) Fu, X.; Jiang, 
Z.; Tan, C.-H. Chem. Commun. 2007, 5058. 
42. Jiang, L.; Lei, Q.; Huang, X.; Cui, H.-L.; Zhou, X.; Chen, Y.-C. Chem. Eur. J. 
2011, 17, 9489. 
43. For reviews, see: (a) Toru, T.; Bolm, C. Organosulfur Chemistry in Asymmetric 
Synthesis, Wiley-VCH, Weinheim, 2008. (b) El-Awa, A.;  Noshi, M. N.; Jourdin, 




Holub, N.;. Paixăo, M. W.; Jøgensen, K. A. Angew. Chem., Int. Ed. 2010, 49, 
2668. (d) Alba, A.-N.; Companyό, X.; Rios, R.  Chem. Soc. Rev. 2010, 39, 2018. 
44. Cui, H.-L.; Sun, X.-H.; Jiang, L.; Chen, Y. -C. Eur. J. Org. Chem. 2011, 7366. 
45. (a) Clegg, N. J.; Paruthiyil, S.; Leitman, D. C.; Scanlan, T. S. J. Med. Chem. 2005, 
48, 5989. (b) Felts, A. S.; Siegel, B. S.; Young, S. M.; Moth, C. W.; Lybrand, T. 
P.; Dannenberg, A. J.; Marnett, L. J.; Subbaramaiah, K. J. Med. Chem. 2008, 51, 
4911. (c) Handler, N.; Brunhofer, G.; Studenik, C.; Leisser, K.; Jaeger, W.; Parth, 
S.; Erker, T. Bioorg. Med. Chem. 2007, 15, 6109. (d) Korte, A.; Legros, J.; Bolm, 
C. Synlett 2004, 2397. (e) Alcalde, E.; Mesquida, N.; Frigola, J.; López-Pérez, S.; 
Mercè, R. Org. Biomol.Chem. 2008, 6, 3795. (f) Gao, H.; Katzenellenbogen, J. A.; 
Garg, R.; Hansch, C. Chem. Rev. 1999, 99, 723. (g) Alt, H. G.; Köppl, A. Chem. 
Rev. 2000, 100, 1205. (h) Leino, R.; Lehmus, P.; Lehtonen, A. Eur. J. Inorg. 
Chem. 2004, 3201. (i) Yang, J.; Lakshmikantham, M. V.; Cava, M. P.; Lorcy, D.; 
Bethelot, J. R.  J. Org. Chem. 2000, 65, 6739. (j) Barberá, J.; Rakitin, O. A.; Ros, 
M. B; Torroba, T. Angew. Chem., Int. Ed. 1998, 37, 296. (k) Levi, Z. U.; Tilley, T. 
D. J. Am. Chem. Soc. 2010, 132, 11012. 
46. Yang, Y.-L.; Pei, C.-K.; Shi, M. Org. Biomol. Chem. 2011, 9, 3349. 
47. (a) Cabrera, S.; Reyes, E.; Alemán, J.; Milelli, A.; Kobbelgaard, S.;  Jøgensen, K. 
J. Am. Chem. Soc. 2008, 130, 12031. (b) Liu, X.; Deng, L.; Jiang, X.; Yan, W.; 
Liu, C.; Wang, R. Org. Lett. 2010, 12, 876. (c) Weber, M.; Jautze, S.; Frey, W.; 
Peters, R. J. Am. Chem. Soc. 2010, 132, 12222. 
48. Liu, C.; Tan, B.-X.; Jin, J.-L.; Zhang, Y.-Y.; Dong, N.; Li, X.; Cheng, J.-P. J. Org. 




49. (a) Ramírez, M. L. G.; Trejo, A.; Navarro, V.; Bye, R.; Linares, E.; Delgado, G. J. 
Nat. Prod. 2001, 64, 432. (b) Inman, W. D.; Luo, J.; Jolad, S. D.; King, S. R.; 
Cooper, R. J. Nat. Prod. 1999, 62, 1088. (c) Baba, K.; Takeuchi, K.; Doi, M.; 
Inoue, M.; Kozawa, M. Chem. Pharm. Bull 1986, 34, 1540. (d) Su, B.-N.; 
Takaishi, Y.; Tori, M.; Takaoka, S.; Honda, G.; Itoh, M.; Takeda, Y.; 
Kodzhimatov, O. K.; Ashurmetov, O. Org. Lett. 2000, 2, 493. (e) Li, W.; Asada, 
Y.; Yoshikawa, T. Phytochemistry 2000, 55, 447. (f) Wandji, J.; Awanchiri, S. S.; 
Fomum, Z. T.; Tillequin, F.; Daniwicz, S. M. Phytochemistry 1995, 38, 1309. (g) 
Ge, H. M.; Zhu, C. H.; Shi, D. H.; Zhang, L. D.; Xie, D. Q.; Yang, J.; Ng, S. W.; 
Tan, R. X. Chem.Eur. J. 2008, 14, 376. (h) Pérez-Fons, L.; Garzόn, M. T.; 
Micol, V. J. Agric. Food Chem. 2010, 58, 161. (i) Pertino, M. W.; Theoduloz, C.; 
Rodríguez, J. A.; Lazo, V. J. Nat. Prod. 2010, 73, 639. 
50. (a) Kirsch, P. Modern Fluoroorganic Chemistry, Wiley-VCH, Weinheim, 2004. 
(b) Uneyama, K. Organofluorine Chemistry, Blackwell Publishing, Oxford, 2006. 
(c) Ojima, I.  Fluorine in Medicinal Chemistry and Chemical Biology, Blackwell, 
Oxford, 2009. 
51. (a) Furukawa, T.; Kawazoe, J.; Zhang, W.; Nishimine, T.; Tokunaga, E.; 
Matsumoto, T.; Shiro, M.; Shibata, N. Angew. Chem. Int. Ed. 2011, 50, 9684. (b) 
Yang, W.; Wei, X.; Pan, Y.; Lee, R.; Zhu, B.; Liu, H.; Yan, L.; Huang, K.-W.; 
Jiang, Z.; Tan, C.-H. Chem.Eur. J. 2011, 17, 7986. 
52. (a) Fukuzumi, T.; Shibata, N.; Sugiura, M.; Yasui, H.; Nakamura, S.; Toru, T. 
Angew. Chem., Int. Ed. 2006, 45, 4973. (b) Ni, C.; Li, Y.; Hu, J. J. Org. Chem. 
2006, 71, 6829. (c) Cahard, D.; Xu, X.; Bonnaire, S. C.; Pannecoucke, X. Chem. 




2011, 17, 2018. (e) Jiang, B.; Huang, Z. G.; Cheng, K. J. Tetrahedron: 
Asymmetry 2006, 17, 942. (f) Beare, N. A.; Hartwig, J. F. J. Org. Chem. 2002, 67, 
541. (g) Ding, C.; Maruoka, K. Synlett 2009, 664. (h) Ishikawa, N.; Takaoka, A.; 
Ibrahim, M. K. J. Fluorine Chem. 1984, 25, 203. 
53. (a) Furukawa, T.; Nishimine, T.; Tokunaga, E.; Hasegawa, K.; Shiro, M.; Shibata, 
N. Org. Lett. 2011, 13, 3972. (b) Li, Y.; Liang, F.; Li, Q.; Xu, Y.-C.; Wang, Q.-R.; 
Jiang, L. Org. Lett. 2011, 13, 6082. 
54. a) Ruppert, I.; Shlich, K; Volbach, W. Tetrahedron Lett. 1984, 24, 2195. (b) 
Pawelke, G. J. J. Fluorine Chem. 1989, 42, 429. (c) Prakash, G. K. S.; Yudin, A. 
K. Chem. Rev. 1997, 97, 757. (d) Billard, T.; Langlois, B. R. Eur. J. Org. Chem. 
2007, 891. (e) Shibata, N.; Mizuta, S.; Kawai, H. Tetrahedron: Asymmetry 2008, 
19, 2633. (f) Gritsenko, R. T.; Levin, V. V.; Dilman, A. D.; Belyakov, P. 
A.;Struchkova, M. I.; Tartakovsky, V. A. Tetrahedron Lett. 2009, 50, 2994. (g) 
Levin, V. V.; Kozlov, M. A.; Song, Y. H.; Dilman, A. D.; Belyakov, P. A.; 
Struchkova, M. I.; Tartakovsky, V. A. Tetrahedron Lett. 2008, 49, 3108. (h) 
Eisenberger, P.; Gischig, S.; Togni, A. Chem.Eur. J. 2006, 12, 2597. (i) Allen, 
A. E.; MacMillan, D. W. C. J. Am. Chem. Soc. 2010, 132, 4986. (j) Shimizu, R.; 
Egami, H.; Nagi, T.; Chae, J.; Hamashima, Y.; Sodeoka, M. Tetrahedron Lett. 
2010, 51, 5947. (k) Prakash, G. K. S.; Mandal, M. J. Am. Chem. Soc. 2002, 124, 
6538. 
55. Lin, A.; Mao, H.; Zhu, X.; Ge, H.; Tan, R.; Zhu, C.; Cheng, Y. Chem.Eur. J. 
2011, 17, 13676. 
56. (a) Yet, L. Chem. Rev. 2003, 103, 4283. (b) Vidal, J. P.; Escale, R.; Girard, J. P.; 




K.; Kobinata, K.; Osada, H. Tetrahedron Lett. 1997, 38, 1223; (d) Toske, S. G.; 
Jensen, P. R.; Kauffman, C. A.; Fencial, W.  Tetrahedron 1998, 54, 13459. 
57. (a) Terada, M.; Sorimachi, K. J. Am. Chem. Soc. 2007, 129, 292. (b) Jia, Y.; 
Zhong, J.; Zhu, S.; Zhang, C.; Zhou, Q.  Angew. Chem., Int. Ed. 2007, 46, 5565. 
(c) Matsubara, R.; Nakamura, Y.; Kobayashi, S. Angew. Chem., Int. Ed. 2004, 43, 
1679. (d) Matsubara, R.; Kawai, N.; Kobayashi, S. Angew. Chem., Int. Ed. 2006, 
45, 3814. (e) Berthiol, F.; Matsubara, R.; Kawai, N.; Kobayashi, S. Angew.Chem., 
Int. Ed. 2007, 46, 7803. (f) Matsubara, R.; Doko, T.; Uetake, R.; Kobayashi, S.  
Angew. Chem. Int. Ed. 2007, 46, 3047. (g) Matsubara, R.; Kobayashi, S. Acc. 
Chem. Res. 2008, 41, 292. (h) Terada, M.; Machioka, K.; Sorimachi, K. Angew. 
Chem., Int. Ed. 2006, 45, 2254. (i) Terada, M.; Machioka, K.; Sorimachi, K. J. 
Am. Chem. Soc. 2007, 129, 10336. (j) Hayashi, Y.; Gotoh, H.; Masui R.; 
Ishikawa, H. Angew. Chem. Int. Ed. 2008, 47, 4012. (k) Zu, L.; Xie, H.; Li, H.;  
Wang, J.; Yu, X.; Wang, W. Chem. Eur. J. 2008, 14, 6333. (l) Guo, Q.-X.; Peng, 
Y.-G.; Zhang, J.-W.; Song, L.; Feng, Z.; Gong, L.-Z.  Org. Lett., 2009, 11, 4620. 
(m) Chang, L.; Kuang, Y.; Qin, B.; Zhou, X.; Liu, X.; Lin, L.; Feng, X. Org. Lett., 
2010, 12, 2214. (n) Lu, M.; Lu, Y.; Zhu, D.; Zeng, X.; Li, X.; Zhong, G. Angew. 
Chem., Int Ed. 2010, 49, 8588. 
58. Huang, J.-R.; Cui, H.-L.; Lei, J.; Sun, X.-H.; Chen, Y.-C. Chem. Commun. 2011, 
47, 4784. 
59. Sun, W.; Ma, X.; Hong, L.; Wang. R. J. Org. Chem. 2011, 76, 7826. 
60. (a)Nguyen, U. T. T.; Guo, Z.; Delon, C.; Wu, Y.; Deraeve, C.; Franzel, B.; Bon, 
R. S; Blankenfeldt, W.; Goody, R. S; Waldmann, H.; Wolters, D.; Alexandrov, K. 
Nature Chem. Biol. 2009, 5, 227. (b) Castellano, S.; Fiji, H. D. G.; Kinderman, S. 




129, 5843. (c) Valentekovich, R. J.; Schreiber, S. L. J. Am. Chem. Soc. 1995, 117, 
9069. (d) Zhang, B.; He, Z.; Xu, S.; Wu, G.; He, Z. Tetrahedron 2008, 64, 9471. 
(e) Balan, D.; Adolfsson, H. Tetrahedron Lett. 2004, 45, 3089. (f) Kim, J. M.; 
Lee, K. Y.; Lee, S.; Kim, J. N. Tetrahedron Lett. 2004, 45, 2805. 
61. Zhu, B.; Yan, L.; Pan, Y.; Lee, R.; Liu, H.; Han, Z.; Huang, K.-W.; Tan, C.-H.; 
Jiang, Z.  J. Org. Chem. 2011, 76, 6894. 
62. Lin, A.; Mao, H.; Zhu, X.; Ge, H.; Tan, R.; Zhu, C.; Cheng, Y.  Adv. Synth. Catal. 
2011, 353, 3301. 
63. (a) Nishimura, K.; Ono, M.; Nagaoka, Y.; Tomioka, K. J. Am. Chem. Soc. 1997, 
119, 12974. (b) Kondo, T.; Mitsudo, T.; Chem. Rev. 2000, 100, 3205. (c) Enders, 
D.; Lüttgen, K.; Narine, A. A. Synthesis 2007, 959. (d) Enders, D.; Hoffman, K. 
Eur. J. Org. Chem. 2009, 1665. (e) Kimmel, K. L.; Robak, M. T.; Ellman, J. A. J. 
Am. Chem. Soc. 2009, 131, 8754. (f) Lu, H. H.; Zhang, F. G.; Meng, X. G.; Duan, 
S. W.; Xiao, W. J. Org. Lett. 2009, 11, 3946. (g) Sun, J. W.;  Fu, G. C. J. Am. 
Chem. Soc. 2010, 132, 4568. 
64. Huang, X.; Peng, J.; Dong, L.; Chen, Y.-C. Chem. Commun. 2012, 48, 2439. 
65. Zhong, F.; Luo, J.; Chen, G,-Y; Dow, X.; Lu, Y. J. Am. Chem. Soc. 2012, 134, 
10222. 
66. (a) Beck, J. J.; Chou, S.-C. J. Nat. Prod. 2007, 70, 891. (b) Xiong, M. J.; Li, Z. H. 
Curr. Org. Chem. 2007, 11, 833. (c) Tayone, W. C.; Honma, M.; Kanamaru, S.; 
Noguchi, S.; Tanaka, K.; Nehira, T.; Hashimoto, M.; J. Nat. Prod. 2011, 74, 425. 
(d) Tymiak, A. A.; Aklonis, C.; Bolgar, M. S.; Kahle, A. D.; Kirsch, D. R.; 
O’Sullivan, J.; Porubcan, M. A.; Principe, P.; Trejo, W. H.; Ax, H. A.; Wells, J. 
S.; Andersen, N. H.; Devasthale, P. V.; Telikepalli, H.; Vander Velde, D.; Zou, 




Hirai, G.; Yanagisawa, T.; Nagamatsu, K.; Mayumi,S.; Hashimoto, Y.; Sodeoka, 
M.; Bioorg. Med. Chem. Lett. 2004, 14, 2963. (f) Williams, D. J.; Thoms, R. 
Tetrahedron Lett. 1973, 9, 639. (g) Ogino, Y.; Ohtake, N.; Nagae, Y.; Matsuda, 
K.; Ishikawa, M.; Moriya, M.; Kanesaka, M.; Mitobe, Y.; Ito, J.; Kanno, T.; 
Ishihara, A.; Iwaasa, H.; Ohe, T.; Kanatani, A.; Fukami, T. Bioorg. Med. Chem. 
Lett. 2008, 18, 4997. (h) Abdel-Mageed W. M.; Milne B. F.; Wagner, M.; 
Schumacher, M.; Sandor, P.; Pathom-aree, W.; Goodfellow, M.; Bull, A. T.; 
Horikoshi, K.; Ebel, R.; Diederich, M.; Fiedler, H.-P.; Jaspars, M. Org. Biomol. 
Chem., 2010, 8, 2352. 
67. Du, Y.; Lu, X.; Zhang, C. Angew. Chem., Int. Ed. 2003, 42, 1035. 
68. (a) Büchi, G.; Wüest, H. Helv. Chim. Acta 1971, 54, 1767. (b) Bohlmann, F.; 
Zdero, C. Chem. Ber. 1973, 106, 3779. (c) Dauben, W. G.; Ipaktschi, J. J.Am. 
Chem. Soc. 1973, 95, 5088. (d) Padwa, A.; Brodsky, L. J. Org. Chem. 1974, 39, 
1318. (e) Schneider, D. F.; Venter, A. C.  Synth. Commun. 1999, 29, 1303. (f) 
Dauben, W. G.; Hart, D. J.; Ipaktschi, J.; Kozikowski, A. P. Tetrahedron Lett. 
1973, 4425. (g) Dauben, W. G.; Kozikowski, A. P.  Tetrahedron Lett. 1973, 3711. 
69. Ye, L.-W.; Sun, X.-L.; Wang, Q.-G.; Tang, Y. Angew. Chem., Int. Ed. 2007, 46, 
5951. 
70. Wang, Q.-G.; Zhu, S.-F.; Ye, L.-W.; Zhou, C. Y.; Sun, X.-L.; Tang, Y; Zhou, Q.-
L.  Adv. Synth. Catal. 2010, 352, 1914. 
71. Tan, B.; Candeias, N. R.; Barbas III, C. F.  J. Am. Chem. Soc. 2011, 133, 4672. 
72. Zhong, F.; Han, X.; Wang Y.; Lu, Y.  Angew. Chem., Int. Ed. 2011, 50, 7837. 
73. (a) Han, X.;  Wang, Y.; Zhong, F.; Lu, Y. J. Am. Chem. Soc. 2011, 133, 1726. (b) 
Zhong, F.; Wang, Y.; Han, X.; Huang, K.-W.; Lu, Y.  Org. Lett. 2011, 13, 1310. 




75.  Wang, Y.; Liu, L.; Zhang, T.; Zhong, N.-J.; Wang. D.; Chen, Y.-J. J. Org. Chem. 
2012, 77, 4134. 
76. (a) Tsukamoto, S.; Kato, H.; Samizo, M.; Nojiri, Y.; Onuki, H.; Hirota, H.; Ohta, 
T. J. Nat. Prod. 2008, 71, 2064. (b) Fensome, A.; Adams, W. R.; Adams, A. L.; 
Berrodin, T. J.; Cohen, J.; Huselton, C.; Illenberger, A.; Kern, J. C.; Hudak, V. A.; 
Marella, M. A.; Melenski, E. G.; McComas, C. C.; Mugford, C. A.; Slayden, O. 
D.; Yudt, M.; Zhang, Z. M.; Zhang, P. W.; Zhu, Y.; Winneker, R. C.; Wrobel, J. 
E. J. Med. Chem. 2008, 51, 1861. (c) Finefield, J. M.; Kato, H.; Greshock, T. J.; 
Sherman, D. H.; Tsukamoto, S.; Williams, R. M. Org. Lett. 2011, 13, 3802. (d) 
Greshock, T. J.; Grubbs, A. W.; Jiao, P.; Wicklow, D. T.; Gloer, J. B.; Williams, 
R. M. Angew. Chem. Int. Ed. 2008, 47, 3573. (e) Kato, H.; Yoshida, T.; Tokue, T.; 
Nojiri, Y.; Hirota, H.; Ohta, T.; Williams, R. M.; Tsukamoto, S. Angew. Chem., 
Int. Ed. 2007, 46, 2254. (f) Tsukamoto, S.; Kato, H.; Greshock, T. J.; Hirota, H.; 
Ohta, T.; Williams, R. M. J. Am. Chem. Soc. 2009, 131, 3834. (g) Tsukamoto, S.; 
Kawabata, T.; Kato, H.; Greshock, T. J.; Hirota, H.; Ohta, T.; Williams, R. M. 
Org. Lett. 2009, 11, 1297. 
77. Peng, J.; Huang, X.; Jiang, L.; Cui, H.-L. Org. Lett. 2011, 13, 4584. 
78. Ramachandran, P. V.; Madhi, S.; Bland-Berry, L; Reddy, M. V. R.; Donnell, M. J. 
J. Am. Chem. Soc. 2005, 127, 13450. 
79. Lee, K. N.; Lee, Y. J.; Kim, J. N. Bull. Korean Chem. Soc. 2008, 28, 147. 
80. Maki, M.; Kanai, M.; Shibasaki, M. Tetrahedron 2007, 63, 4250. 
81. (a) Uraguchi, D.; Ueki, Y.; Ooi, T. Science 2009, 326, 120. (b) Uraguchi, D.; 
Ueki, Y.; Ooi, T. Chem. Sci. 2012, 3, 842. 
82. Noboru, O. The nitro group in organic synthesis VCH, New York,  2001. 




M.; Kim, T. H.; Kim, J. N. Bull. Korean Chem. Soc. 2002, 23, 657. 
84. Basavaiah, D.; Rao, J. S. Tetrahedron. Lett. 2004, 45, 1621 
85. (a) Janecki,T.;Blaszczyk,E.; Studzian,K.; Janecka,A.;Krajewska, U.; Rozalski, M. 
J. Med. Chem. 2005, 48, 3516. (b) Choudhury, P. K.; Foubelo, F.; Yus, M. J. Org. 
Chem. 1999, 64, 3376. (c)Kornet, M. J.; Crider, A. M.; Magarian, E. O. J. Med. 
Chem. 1977, 20, 1210. (d) Hoffmann, H. M. R.; Rabe, J. Angew. Chem., Int. Ed. 
1985, 24, 94. (e) Lee, K. Y.; Lee, Y. J.;Kim, J. N. Bull. Korean Chem. Soc. 2007, 
28, 143. 
86. For examples: (a) Okino, T.; Nakamura, S.; Furukawa, T.; Takemoto, Y. Org. 
Lett. 2004, 6, 625. (b) Marcelli, T.; van der Hass, R. N. S.; van Maarseveen, J.; 
Hiemstra, H. Angew. Chem., Int. Ed. 2006, 45, 929. (c) Dalko, P. L.; Moisan, L. 
Angew. Chem., Int. Ed. 2004, 43, 5138. 
87. Wang, B.; Wu, F.; Wang, Y.; Liu, X.; Deng, L. J. Am. Chem. Soc. 2007, 129, 768. 
88. (a) Galeazzi,R.;  Martelli, G.; Mobbili, G.; Orena, M.; Rinaldi, S. Org. Lett. 2004, 
6, 2571. (b) Du, Y.; Han, X.; Lu, X. Tetrahedron 2007, 63, 6035. 
89. Vakulya, B.; Varga, S.; Csámpai, A.; Soós, T. Org. Lett. 2005, 7, 1976. 
90. (a) Anderton, N.; Cockrum,P. A.; Colegate, S. M.; Edgar, J. A.; Flower, K.; Vit, 
I.; Willing R. I. Phytochemistry  1998, 48, 437. (b) Pellegrini, C.; Strässler, C.; 
Weber, M.; Borschberg, H. Tetrahedron: Asymmetry 1994, 5, 1979. (c) Pellegrini, 
C.; Weber, M.; Borschberg, H. Helvetica Chimica Acta 1996, 79, 151. 
91. Zhu, Q.; Lu, Y. Angew. Chem., Int. Ed. 2010, 49, 7753. 
92. Zhong, F.; Chen, G.-Y.; Lu, Y. Org. Lett. 2011, 13, 82. 
93. (a) Trost, B. M.; Zhang, Y. J. Am. Chem. Soc. 2007, 129, 14558. (b) Chung, Y. 
M.; Im, Y. J.; Kim, J. N. Bull. Korean Chem. Soc. 2002, 23, 1651. (c) Du, Y.; 




94. Iwabuchi, Y.; Nakatani, M.; Yokoyama, N.; Hatakeyama, S. J. Am. Chem. Soc. 
1999, 121, 10219 
95. Barco, A.; Benetti, S.; Risi, C. D.; Pollini, G. P.; Spalluto, G.; Zanirato, V. 
Tetrahedron 1996, 52, 4719. 
96.  (a) Dydio, P.; Rubay, c.; Gadzikwa, T.; Lutz, M.; Reek, J. N. H. J. Am. Chem. 
Soc. 2011, 1331, 17176. (b) Barco, A.; Benetti, S.; Risi, C. D.; Pollini, G. P.; 
Spalluto, G.; Zanirato, V. Tetrahedron 1996, 52, 4719. 
 
